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Dedication 
 
 
 
 
 
To my parents 
 
 
 
“Enigmatici si cuminţi 
Terminîndu-şi rostul lor 
Lîngă noi se sting şi mor 
Dragii noştri, dragi părinţi. 
Cheamă-i Doamne, înapoi 
Că şi-aşa au dus-o prost 
Şi fă-i tineri cum au fost  
Fă-i mai tineri decît noi. 
 
Pentru cei ce ne-au făcut  
Dă un ordin, dă ceva 
Sa-i mai poţi întîrzia 
Să o ia de la-nceput. 
Au plătit cu viaţa lor  
Ale fiilor erori 
Doamne, fă-i nemuritori  
Pe părinţii care mor. 
 
Ia priviţi-i cum se duc 
Ia priviţi-i cum se sting 
Lumînări în cuib de cuc 
Parcă tac şi parcă ning. 
Plini de boli şi suferinţi  
Ne întoarcem în pămînt 
Cît mai sîntem, cît mai sînt, 
Mîngîiaţi-i pe părinţi. 
 
E pǎmantul tot mai greu, 
Desparţirea-i tot mai grea, 
Sǎrut-mana, tatǎl meu, 
Sǎrut-mana, mama mea.” 
 
                        A.  Pǎunescu, Ruga pentru pǎrinţi 
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1 Introduction 
 
 
 
 
Sulfonamides are very important compounds due to their wide range of 
biological activities, being also the first synthetic compounds to have had 
utility in human therapy as antimicrobial drugs, thus opening the route for 
the antibiotic revolution in medicine.  
Prontosil was the first sulfonamide drug synthesized and tested as  
antimicrobial by Gerhard Domagk (in the picture), who then received the 
1939 Nobel Prize in Medicine.  
 
 The first official communication about the breakthrough discovery was not published until 1935, 
more than two years after the drug was patented. Experiments with Prontosil began in 1932 in the 
laboratories of Bayer AG and showed that it was the first medicine ever discovered that could 
effectively treat a range of bacterial infections. Prontosil had a strong protective action against 
streptococcal infections, including blood infections, 
childbed fever, and erysipelas, and a lesser effect on 
infections caused by other cocci. Few people today 
would deny that 1936 was the turning point in the 
history of puerperal infection, one of the most 
common cause of death during childbirth, and that the 
arrival of Prontosil brought about the  change. 
 
In 1935 Tréfouël and his colleagues at the Pasteur Institute 
observed that Prontosil had no effect at all in the test tube, exerting 
its antibacterial action only in live animals; they soon surprised the 
scientific world by the suggestion that the red dye was probably a 
prodrug and that was metabolized into two pieces inside the body, 
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to a much simpler compound, p-aminobenzene sulfonamide. The discovery helped to establish 
the concept of "bioactivation".  
The active sulfanilamide had been known for many years being synthesized in 1906 and was 
widely used in the dye-making industry. These findings naturally led to a change-over in human 
therapy from red Prontosil to the simpler and cheaper compound which we soon came to know by 
the name Sulfanilide, the first of the ‘‘sulfa drugs’’. 
Furthermore, among the numerous other applications, the ability to serve as amide surrogates 
have made sulfonamide an ideal functional group for the development of novel 
peptidomimetics.
1,2  
 
Recently, enormous interest has also been directed to bioactive sultams,
3,4
 cyclic analogues of the 
open-chain sulfonamides, which have shown promising activities as antiviral, anticancer, 
antimicrobial, antimalarial, antileukemic, and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor modulatory properties, with potential for treating disorders of the brain, 
novel serine inhibitors, zinc enzyme carbonic anhydrase inhibitors, etc.
5,6
 
In particular, a number of fused sultams have recently been reported to exhibit broad inhibitory 
properties against a variety of enzymes including COX-2,4 HIV integrase,
7
 lipoxygenase,
8
 
Calpain I,
9
 and MMP-2.
10
  
Fused sultams have found many important applications in organic synthesis including use as 
protecting groups, chiral auxiliaries, and directed metalation groups (DMGs). For example, 
Oppolzer’s sultam 111 (Figure 1) are relevant in asymmetric synthesis as chiral auxiliaries in 
many stereoselective transformations. 
 
 
                                                 
1 Gennari, C.; Salom, B.; Potenza, D.; Williams, A. Angew. Chem. Int. Ed. 1994, 33, 2067. 
2 Carson, K. G.; Schwender, C. F.; Gallant, D. L.; Briskin, M. J. Bioorg. Med. Chem. Lett. 1997, 7, 711. 
3 Zhuang, L.; Wai, J. S.; Embrey, M.; Fisher, T. E.; Michelson, S. R.; Young, S. S. J. Med. Chem. 2003, 46, 453. 
4 Inagaki, M.; Tsuri, T.; Kakudo, S.; Koizumi, K.; Suzuki, R.; Kato, M.; Kawai, S.; Matsumoto, S. J. Med. Chem. 2000, 43, 2040. 
5 Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C. T. Curr. Med. Chem. 2003, 10, 925. 
6 Supuran, C. T. Nature Rev. Drug Discovery 2008, 7, 168. 
7 Brzozowski, F.; Saczewski, F.; Neamati, N. Bioorg. Med. Chem. Lett. 2006, 16, 5298. 
8 Misu, Y.; Togo, H. Org. Biomol. Chem. 2003, 1, 1342. 
9 Wells, G. J.; Tao, M.; Josef, K. A.; Bihovsky, R. J. Med. Chem. 2001, 44, 3488. 
10 Cherney, R. J.; Mo, R.; Meyer, D. T.; Hardman, K. D.; Liu, R. Q.; Covington, M. B.; Qian, M.; Wasserman, Z. R.; Christ, D. 
D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P. J. Med. Chem. 2004, 47, 2981. 
11 Kumaraswamy, G.; Padmaja, M.; Markondaiah, B.; Jena, N.; Sridhar, B.; Kiran, M. U. J. Org. Chem. 2006, 71, 337. 
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Figure 1. Oppolzer’s camphorsultam used as chiral auxiliary in asymmetric synthesis. 
 
Many protocols have been developed for the synthesis of sultams, e.g., Pictet-Spengler 
reactions,
12 
Friedel-Crafts reactions,
13,14 
sulfonamide dianion alkylation,
15
 cyclization of 
aminosulfonyl chlorides,
16 
[3+2]-cycloadditions,
17
 Diels_Alder reactions,
18
 and a number of 
transition-metal catalyzed cyclizations.
19,20
 Some review articles highlighting their biological 
activities, synthesis, and important uses have also appeared.
21,22 
 
 
                                                 
12 Silvestri, R.; Marfe, G.; Artico, M.; La Regina, G.; Ciriolo, M. R.; Russo, M. A.; Cirilli, R.. J. Med. Chem. 2006, 49, 5840. 
13 Bravo, R. D.; Canepa, A. S. Synth. Commun. 2002, 32, 3675. 
14 Katritzky, A. R.; Wu, J.; Rachwal, S.; Rachwal, B.; Macomber, D. W.; Smith, T. P. Org. Prep. Proced. Int. 1992, 24, 463. 
15 Lee, J.; Zhong, Y. L.; Reamer, R. A.; Askin, D. Org. Lett. 2003, 5, 4175. 
16 Enders, D.; Moll, A.; Bats, J. W. Eur. J. Org. Chem. 2006, 5, 1271. 
17 Chiacchio, U.; Corsaro, A.; Rescifina, A.; Bkaithan, M.; Piperno, A.; Privitera, T.; Romeo, G. Tetrahedron 2001, 57, 3425. 
18 Plietker, B.; Seng, D.; Frohlich, R.; Metz, P. Tetrahedron 2000, 56, 873. 
19 Zajac, M.; Peters, R. Chem.—Eur. J. 2009, 15, 8204. 
20 Vasudevan, A.; Tseng, P.-S.; Djuric, S. W. Tetrahedron Lett. 2006, 47, 8591. 
21 (a) Majumdar, K. C.; Mondal, S. Chem. Rev. 2011, 111, 7749-7773. (b) McReynolds, M. D.; Dougherty, J. M.; Hanson, P. R. 
Chem. Rev. 2004, 104, 2239. 
22 Liu, Z.; Takeuchi, Y. Heterocycles 2009, 78, 1387. 
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2 Benzosultams  
 
 
 
 
 
The powerful biological activities found for several categories of benzosultams make these 
compunds important targets for drug discovery. For example, benzothiadiazin-3-one-1,1-dioxides 
and their derivatives have shown promising activities as hypoglycemic,
23
 anti-HIV,
24
 etc.  
  
1,2-Benzisothiazoline 1,1-dioxide (saccharin) is the most famous member of this family, but 
other benzosultam have a high impact on contemporary life because are widely used drugs, such 
as trichloromethiazide, a benzothiazine diuretic.
25
 
 
Other benzosultams significantly inhibit carbonic anhydrases (CAs). The newly found binding 
modes of these diuretics may be exploited for designing better CA II inhibitors as well as 
compounds with selectivity/affinity for various isoforms with medicinal applications. Because of 
the important biological activities of benzisothiazoline 1,1-dioxides, much efforts have been 
devoted to develop novel methods for the sythesis of analogues of the saccharin derivatives.
26
 
Recently, Snieckus and co-workers developed
27
 the synthesis of 7- and 4,7-substituted saccharins 
                                                 
23 Wales, J. K.; Krees, S. V.; Grant, A. M.; Vikroa, J. K.; Wolff, F.W. J. Pharm. Exp. Ther. 1968, 164, 421. 
24 Arranz, E. M.; Diaz, J. A.; Ingate, S. T.; Balzarini, J.; Clercq, E. D.; Vega, S. Bioorg. Med. Chem. 1999, 7, 2811. 
25 Temperini, C.; Cecchi, A.; Scozzafava, A.; Supuran, C. T. Bioorg. Med. Chem. 2009, 17, 1214. 
26 Liu, Z.; Takeuchi, Y. Heterocycles 2009, 78, 1387. 
27 Blanchet, J.; Macklin, T.; Ang, P.; Metallinos, C.; Snieckus, V. J. Org. Chem. 2007, 72, 3199. 
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from N-cumyl arylsulfonamides by combining directed ortho-metalation (DoM) and Suzuki 
cross-coupling reactions (Scheme 1). Treatment of sulfonamide 1.1 with BuLi in the presence of 
TMEDA, followed by reaction with iodine, gave the 2-iodo derivatives 1.2 in good yields. Suzuki 
cross-coupling of the 2-iodo arylsulfonamides 1.2 led to the formation of biaryl N-
cumylsulfonamides 1.3. BuLi/TMEDA ortho-metalation of 1.3, followed by quenching with N,N-
diethylcarbamoyl chloride gave the amido-sulfonamides 1.4. The N-cumyl function was removed 
from these latter compounds with TFA and the resulting sulfonamide was cyclized in situ to the 
7-arylated saccharins 1.5.  
 
 
 
Scheme 1. Synthesis of 7-arylated saccharins 
 
 
In 2000, Dauban and Dodd (Scheme 2) described a new methodology for the preparation of 
benzosultams based on copper- or bromine-catalyzed aziridination.
28
 Olefinic primary 
sulfonamide 2.1 was treated with iodobenzene diacetate and potassium hydroxide in methanol to 
give the intermediate iminoiodinane 2.2, which was immediately treated with a catalytic amount 
of copper triflate to give the aziridine 2.3. Moreover, application of the bromine-catalyzed 
aziridination procedure
29
 to 2.5 led to the formation of aziridine 2.6. Aziridines 2.3 and 2.6 were 
then opened by various nucleophiles to give the corresponding sultams (2.4 and 2.7). 
 
                                                 
28 Dauban, P.; Dodd, R. H. Org. Lett. 2000, 2, 2327. 
29 Jeong, J. U.; Tao, B.; Sagasser, I.; Henniges, H.; Sharpless, K. B. J. Am. Chem. Soc. 1998, 120, 6844. 
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Scheme 2. Synthesis of benzosultams via aziridine formation 
 
In a subsequent report,
30
 sulfonamide 2.5 was treated with tert-butyl hypochlorite and aqueous 
sodium hydroxide to give the corresponding N-chloramine salt 2.8, which was reacted with a 
catalytic amount of phenyltrimethylammonium tribromide (PTAB) to afford the aziridine 2.6.  
Che
31
 reported the alternative dirhodium-complexes-catalyzed asymmetric intramolecular 
aziridation of unsaturated sulfonamides.  
In another paper,
32
 is described the synthesis of 3,3-disubstituted benzosultams 3.3 by ortho-
lithiation of N-tert-butylbenzenesulfonamide 3.1 and subsequent reaction with ketones followed 
by TMSCl-NaI mediated cyclization (Scheme 3). 
 
                                                 
30 Dauban, P.; Dodd, R. H. Tetrahedron Lett. 2001, 42, 1037. 
31 Liang, J. L.; Yuan, S. X.; Chan, P. W. H.; Che, C. M. Tetrahedron Lett. 2003, 44, 5917. 
32 Liu, Z.; Shibata, N.; Takeuchi, Y. J. Chem. Soc., Perkin Trans. 1 2002, 3, 302. 
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Scheme 3. synthesis of benzosultams mediated by TMSCl–NaI–MeCN reagent 
 
Saczewski
33
 demonstrated that 1,4,2-benzodithiazines constitute a novel class of nontoxic HIV-1 
integrase (IN) inhibitors. Benzodithiazines 4.3 were synthesized by cyclization of derivatives 4.2, 
which were obtained from the reactions of 4-chloro-2-mercaptobenzenesulfonamides 4.1 with 
bromomethyl ketones (Scheme 4). 
 
 
Scheme 4. Synthesis of benzodithiazines 
 
Au(PPh3)OTf catalyzed cycloisomerization of terminal alkenes 5.1, under microwave irradiation, 
gives benzosultams 5.2 in nearly quantitative yields (Scheme 5).
34
  
                                                 
33 Brzozowski, Z.; Saczewski, F.; Sanchez, T.; Kuo, C. L.; Gdaniec, M.; Neamati, N. Bioorg. Med. Chem. Lett. 2004, 12, 3663. 
34 Liu, X. Y.; Li, C. H.; Che, C. M. Org. Lett. 2006, 8, 2707. 
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Scheme 5. Synthesis of benzosultams by phosphine gold(I)-catalyzed intramolecular 
hydroamination 
 
 
Hanson and co-workers reported
35
 a new route to benzosultams 6.2 (Scheme 6) by a one-pot 
HeckazaMichael domino process, for a sequential three-component reaction of α-
bromobenzenesulfonyl chlorides 6.1, amines, and Michael acceptors. 
 
 
Scheme 6. Synthesis of benzosultams by domino HeckazaMichael reactions 
 
 
Recent studies have demonstrated the facile formation of bicyclic sultams by an intramolecular 
cyclodialkylation reaction (Scheme7).
36
 The N-alkenylanilines 7.3a-k reacted smoothly with 
methyl (chlorosulfonyl)acetate to give the corresponding sulfonamides 7.7 in good yields. 
Addition of bromine to the C=C double bonds in sulfonamides 7.7 occurred quantitatively to give 
the corresponding dibromoalkyl derivatives 7.8. Upon treatment with potassium carbonate in 
DMF, the (dibromoalkyl)- sulfonamides 7.8 under went intramolecular cyclodialkylation at their 
C,H-acidic positions to yield the bicyclic sultams 7.9 (n = 1 and 2). Under the established 
                                                 
35 Rolfe, A.; Young, K.; Hanson, P. R. Eur. J. Org. Chem. 2008, 31, 5254. 
36 Rassadin, V. A.; Tomashevskiy, A. A.; Sokolov, V. V.; Ringe, A.; Magull, J.; de Meijere, A. Eur. J. Org. Chem. 2009, 16, 
2635. 
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conditions, the dibromoalkyl derivative 7.8 with n = 3 gave an inseparable complex mixture. 
 
 
 
Scheme 7. Synthesis of benzosultams by intramolecular cyclodialkylation 
 
 
 
A two-step, one-pot protocol was developed by Hanson for the synthesis of benzosultams 
(Scheme 8).
37
 The first step is a copper-catalyzed N-arylation of (2-bromobenzene)sulfonamides 
8.1 with different amines to generate the corresponding (2-aminobenzene)sulfonamides 8.2, 
which then undergo cyclization to the desired sultams 8.3 upon treatment with 
carbonyldiimidazole (CDI). 
 
                                                 
37 Rolfe, A.; Hanson, P. R. Tetrahedron Lett. 2009, 50, 6935. 
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Scheme 8. Sequential one-pot synthesis of benzothiadiazin-3-one-1,1-dioxides 
 
Hanson
38
 reported a reagent-based, ‘diversity-oriented synthetic’ (DOS) strategy termed “Click, 
Click, Cyclize” en route to structurally diverse sultams 9.3, 9.6, 9.9, and 9.10 from the common 
sulfonamides 9.2, 9.5, and 9.8 (Scheme 9). The yield (96%) reported in the conversion of 9.1 to 
9.2 over two steps is notable. 
 
 
Scheme 9. Synthesis of benzosultams by “Click, Click, Cyclize” protocol 
                                                 
38 Rolfe, A.; Lushington, G. H.; Hanson, P. R. Org. Biomol. Chem. 2010, 8, 2198. 
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The 3-substituted γ-benzo[d]sultams have received much attention because of their excellent 
stereofacial discrimination when used as chiral auxiliaries: however, their usefulness has not been 
explored fully, probably owing to its tedious preparation involving, for example for the 3-tert-
butyl substituted sultam, a necessary chemical resolution of the racemic mixture via N-(S)-
camphorsulfonylated compound (Scheme 10). 
 
 
Scheme 10 
 
The 3-alkyl γ-benzo[d]sultams became more accessible in 90’s, because of the development of a 
more efficient synthesis via the asymmetric hydrogenation of the sulfonylimine (a synthetic route 
just exploited by Oppolzer for R = Me, Scheme 11); anyway the requirement of an asymmetric 
reduction step made with an expansive and hazardous catalyst like Ru-BINAP, make the whole 
approach not much achievable especially for a large-scale synthesis. 
 
 
Scheme 11 
 
The most important work appeared in 2000 and described for the first time the attempt of the 
synthesis of 3-carboxy γ-benzo[d]sultam;39 although the direct nucleophilic addition approaches 
                                                 
39 Ahn, K. H.; Baek, H-H; Lee, S. J.; Cho, C-W. J. Org. Chem. 2000, Vol. 65, No. 22, 7690-7696. 
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are useful for the synthesis of  3-alkyl- or 3-arylsubstituted derivatives, all the attempt to 
introduce directly a functional moiety such as cyano group were unsuccessful. To synthesize 3- 
carboxy analogues Ahn has studied both an asymmetric approach and a racemic synthesis 
followed by chemical resolution.  
The asymmetric route uses (Scheme 12), as starting material, sodium o-formylbenzenesulfonate 
and pass through an aqueous Wittig-Horner-Emmons reaction followed by the conversion of the 
resulting cinnamate derivative into a sulfonamide. Reduction of the ester group leads to the o-
(aminosulfonyl)-trans-cinnamyl alcohol employed in the key steps, the Sharpless asymmetric 
epoxidation and a subsequent intramolecular epoxide opening by the sulfonamido group. The 
final step, an oxidative conversion of the diol functionality into the carboxy group, was found to 
be difficult due to the instability of the reaction intermediate. 
 
 
 
Scheme 12 
 
Treatment of diol with sodium periodate produced the corresponding aldehyde, and subsequent in 
situ oxidation with potassium permanganate produced decomposed products instead of the 
desired 3-carboxysultam. Treatment with sodium periodate followed by sodium borohydride 
leads to the corresponding alcohol, compound impossible to oxidize with PDC, KMnO4, or 
Ru(IV) reagents. 
Again when N-protected diol was subjected to the RuCl3-NaIO4 oxidation (Scheme 13), the 
major product was not the desired carboxylic acid but saccharine: these results indicate that 3- 
formylsultam and its N-protected derivatives have limited stability and may undergo 
deformylation and pushes the authors to turn their attention to a racemic route. 
15 
 
 
 
 
Scheme 13 
 
 
This one starts from the N-protected saccharin, and proceed through conversion to the semi 
aminal by treatement with DIBALH and subsequent conversion of the hydroxy group into the 
cyano group with TMSCN in the presence of  BF3.OEt2 ; after hydrolyzation to the corresponding 
methyl ester, deprotection of the MPM group and hydrolysis of the ester group, racemic 3- 
carboxysultam was obtained (Scheme 14) and the two single enantiomers were prepared by 
coupling with (S)-(-)-α-methylbenzylamine and chromatographic separation of the mixture of 
diastereomeric amide. 
 
 
Scheme 14 
 
16 
 
 
In the past years were reported a range of nonconventionally fused β-lactams.  Metz40 developed 
β-lactams fused to a sultam from low cost, commercially available starting materials, always 
using ring closing metathesis as the key operation. Lactams were synthesized by cycloaddition of 
chlorosulfonyl isocyanate with 1,3-butadiene or isoprene and the resulting compounds were 
converted to N-sulfonyl derivatives with olefinic sulfonyl chlorides, readily derived from 
commercially available 2-chloroethanesulfonyl chloride or from the corresponding olefinic 
bromides; finally RCM strategy allowed the formation of unsaturated sultams with different ring 
size (from 5 to 8 members, Scheme 15). 
 
 
Scheme 15 
 
Even β-sultams themselves can be seen as a building blocks for the synthesis of new synthetic 
drugs, for example corresponding to β-lactam antibiotics In general, β-sultams can be synthesized 
by [2+2] cycloaddition of sulfene intermediates with imines,
41
 of alkenes with N-
sulfonylamines
42
 or by intramolecular cyclization
43
. 
Kataoka et al., for example, described the diastereoselective [2+2] cycloaddition using mesyl 
chloride and chiral imines.
44
 However, the adaptable substrates are not only restricted in the 
choice of substituents, the cycloaddition also yields unsatisfactory stereoselectivities. Another 
access to enantiomerically pure β-sultams is the synthesis starting from natural amino acids. 
Initially Otto et al. utilized cysteine derivatives
45
 as precursors, but recently also embarked on 
other amino acids followed by introduction of the sulfur moiety.
46
 
 
 
                                                 
40 Freitag, D.; Schwab, P.; Metz, P. Tetrahedron Lett. 2004, 45, 3589-3592. 
41 (a) Szymonifka, M. J.; Heck, J. V. Tetrahedron Lett. 1989, 30, 2869. (b) Grunder, E.; Leclerc, G. Synthesis, 1989, 135. (c) 
Grunder-Klotz, E.; Ehrhardt, J.-D. Tetrahedron Lett. 1990, 32, 751. (d) Gordeev, M. F.; Gordon, E. M.; Patel, D. V. J. Org. Chem. 
1997, 62, 8177. 
42 (a) Atkins, G. M. Jr.; Burgess, E. M. J. Am. Chem. Soc. 1967, 89, 2502. (b) Burgess, E. M.; Williams, W. M. J. Am. Chem. 
Soc. 1972, 94, 4386. (c) Atkins, G. M. Jr.; Burgess, E. M. J. Am. Chem. Soc. 1972, 94, 6135. 
43 (a) Schwenkkraus, P.; Otto, H.-H. Arch. Pharm. (Weinheim, Ger.) 1993, 326, 519. (b) Schwenkkraus, P.; Otto, H.-H. Liebigs 
Ann. Chem. 1994, 251. 
44 Iwama, T.; Kataoka, T.; Muraoka, O.; Tanabe, G. J. Org. Chem. 1998, 63, 8355. 
45 Schwenkkraus, P.; Merkle, S.; Otto, H.-H. Liebigs Ann./ Recl. 1997, 1261. 
46 Meinzer, A.; Breckel, A.; Thaler, B. A.; Manicone, N.; Otto, H.-H. Helv. Chim. Acta, 2004, 87,90. 
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Among all these protocols, quite interesting is the asymmetric synthesis of cis-3,4-disubstituted  
β-sultams reported by Enders and Moll47. The protocol is based on the initial synthesis of the 
anti-1,2-benzylsulfanyl amines previously reported by the same author
48
: key steps are the 
diastereoselective α-alkylation of α-sulfanylated acetaldehyde-SAMP-hydrazone, reaction 
conducted with various electrophiles and subsequent nucleophilic 1,2-addition of organocerium 
compounds to the hydrazone C=N double bond. The resulting hydrazines were converted to the 
corresponding protected amines by reductive N–N bond cleavage-oxidation of 1,2-aminothiols 
with H2O2 and ammonium heptamolybdate. The obtained anti-1,2-benzylsulfanyl amines has 
been cleaved to the deprotected thiol and sequently oxidized; chlorination of the resulting β-
amino sulfonic acids was achieved with phosgene and the β-aminosulfonyl chlorides obtained 
were cyclized to the title compounds under basic conditions without epimerisation and good 
overall yields (Scheme 16). 
 
 
 
 
 
 
 
 
 
Scheme 16 
 
  
                                                 
47 Enders, D.; Moll, A. Synthesis 2005, No. 11, 1807-1816. 
48 Enders, D.; Moll, A.; Schaadt, A.; Runsink, J.; Raabe, G. Eur. J. Org. Chem. 2003, 3923. 
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3 Chiral and Enantiomerically 
Pure Sultams 
 
 
 
 
 
Chiral sultams have been widely exploited as chiral auxiliaries in asymmetric synthesis. For 
example, the application of the Oppolzer’s sultam for carbon-carbon bond formation has been 
well documented.
49,50 
  
The chiral bicyclic sultams can be subdivided into the following categories: (i) simply chiral 
(which can be racemic) and (ii) enantiopure sultams. 
 
3.1  Chiral Sultams 
 
 
In 2000, Tozer
51
 synthesized chiral bicyclic sultams by intramolecular Diels-Alder reactions of 
suitable trienes. The intramolecular Diels-Alder reactions of compounds 1.1 and 1.2 were carried 
out at 145 °C in toluene, in a sealed screw-cap vessel under argon. Under these conditions, 
racemic mixtures of the diastereomeric [4.3.0]-bicyclic products 1.3 and 1.4 and the [4.4.0]-
bicyclic products 1.5 and 1.6 were obtained in good yields (Scheme 1). Notably, the sultams 1.3 
and 1.4 are closely similar to the compound 1.7 (Figure 1), which is a histamine H3 antagonist. 
 
 
Figure 1 Histamine H3 antagonist. 
                                                 
49 Evans, D. A.; Chapman, K. T.; Bisaha, J. J. Am. Chem. Soc. 1988, 110, 1238. 
50 Oppolzer, W. Pure Appl. Chem. 1990, 62, 1241. 
51 Greig, I. R.; Tozer, M. J.; Wright, P. T. Org. Lett. 2001, 3, 369. 
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Scheme 1 Synthesis of chiral sultams by intramolecular Diels-Alder reactions 
 
 
Chan
52
 also reported the synthesis of a number of bicyclic chiral sultams for use as chiral 
auxiliaries in asymmetric Diels-Alder reactions based on 1,3-dipolar cycloadditions of nitrile 
oxides and nitrones with prop-1-ene-1,3-sultone. Nucleophilic ring-opening of the racemic 
sultone adducts 2.3a,b obtained from 1,3-dipolar cycloaddition of 2.1 and nitrile oxides 2.2a,b 
with (S)-(-)-α-methylbenzylamine in refluxing THF afforded a mixture of diastereomeric internal 
ammonium sulfonate salts. POCl3 mediated cyclization of the internal salts gave 1:1 mixtures of 
the diastereomers 2.4a,b and 2.5a,b. 
Treatment of 2.4a,b and 2.5a,b with concentrated formic acid at 70-80 °C for 5 h followed by 
subsequent hydrolysis under basic conditions afforded 2.6a,b and 2.7a,b, respectively. For the 
use of these chiral sultams as chiral auxiliaries in asymmetric Diels-Alder reactions, N-acylation 
                                                 
52 Zhang, H. K.; Chan, W. H.; Lee, A. W. M.; Wong, W. Y.; Xia, P. F. Tetrahedron: Asymm. 2005, 16, 761. 
entry triene R1 R2 product (ratio) yield (%) 
1 1.1a H 4-Cl-C6H4CH2 1.3a, 1.4a (6:1) 76 
2 1.1b Me 4-Cl-C6H4CH2 1.3b, 1.4b (6:1) 71 
3 1.1c Ph 4-Cl-C6H4CH2 1.3c, 1.4c (3:1) 92 
4 1.1d Ph n-Bu 1.3d, 1.4d (3:1) 87 
5 1.2a H 4-Cl-C6H4CH2 1.5a, 1.6a (5:1) 66 
6 1.2b Me 4-Cl-C6H4CH2 1.5b, 1.6b (6:1) 74 
7 1.2c Ph 4-Cl-C6H4CH2 1.5c, 1.6c (4:1) 92 
8 1.2d Ph n-Bu 1.5d, 1.6d (4:1) 80 
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by successive treatment with n-butyllithium and acid chlorides were carried out to give the 
corresponding N-acryloyl sultams 2.8c, and N-crotonyl sultams 2.8a,b,d (Scheme 2). 
 
 
 
Scheme 2 Preparation of bicyclic chiral sultams based on 1,3-dipolar cycloadditions 
 
 
Using the “Click, Click, Cyclize” protocol, Hanson and coworkers synthesized a number of chiral 
sultams from vinyl sulfonamides (Scheme 3).
53
 The vinyl sulfonamide 3.3 was prepared from 
vinyl sulfonylation of valine methyl ester 3.1 with 2-chloro ethanesulfonyl chloride 3.2. 
Subsequent alkylation with propargyl bromide followed by intramolecular cyclization afforded 
sultam 3.5. 
 
 
Scheme 3 “Click, Click, Cyclize” protocol for sultams 
 
                                                 
53 Zhou, A.; Rayabarapu, D.; Hanson, P. R. Org. Lett. 2009, 11, 531. 
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3.2  Enantiopure Sultams 
 
In an effort to synthesize novel enantiopure chiral bicyclic sultams, Chiacchio
45a 
exploited the 
intramolecular 1,3-dipolar cycloaddition of different dipoles, in which the sulfonamide group is 
located at the α-position with respect to the reactive center. The aminoalcohols 4.1 were treated 
with trans-2-phenylethenesulfonyl chloride to give the corresponding sulfonamide alcohols 4.2, 
which were then converted into the α-sulfonamido aldehydes 4.3 by oxidation with Dess-Martin 
periodinane (DMP). Subsequent treatment with different nucleophilic reagents followed by 
intramolecular cycloaddition gave the corresponding sultams 4.4-4.8 in enantiomerically pure 
form and good yields (Scheme 4). 
 
 
 
Scheme 4 Stereoselective synthesis of chiral sultams by intramolecular cycloadditions  
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In a subsequent report,
54b 
the work was extended using the same methodology (Scheme 5). The 
major compounds 5.6a,b were isolated enantiomerically pure by flash chromatography. Here it is 
important to note that they have used the chiral bicyclic sultams as chiral auxiliaries in 
asymmetric conjugate additions of the Grignard reagents. 
 
 
 
Scheme 5 Synthesis of chiral sultams by intramolecular cycloaddition reactions 
 
 
 
 
Metz
55 
 described the synthesis of enantiopure bicyclic bridged sultams by intramolecular Diels-
Alder (Scheme 6). By refluxing ethenylsulfonamide 6.4 in toluene, sultams 6.5 and 6.6 were 
formed in 80% yield with diastereomeric ratio 62:38.  
                                                 
54 (a) Chiacchio, U.; Corsaro, A.; Rescifina, A.; Bkaithan, M.; Grassi, G.; Piperno, A.; Privitera, T.; Romeo, G. Tetrahedron 
2001, 57, 3425.(b) Chiacchio, U.; Corsaro, A.; Gambera, G.; Rescifina, A.; Piperno, A.; Romeo, R.; Romeo, G. Tetrahedron: 
Asymmetry 2002, 13, 1915. 
55 Rogatchov, V. O.; Bernsmann, H.; Schwab, P.; Frohlich, R.; Wibbeling, B.; Metz, P. Tetrahedron Lett. 2002, 43, 4753. 
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Scheme 6 Preparation of enantiopure sultams by intramolecular Diels-Alder reaction 
 
 
An application of ring-closing metathesis (RCM) in the synthesis of enantiopure bicyclic sultams 
was reported by Hanessian in 2003.
56
 The 4-cis-(2-propenyl)-N-Boc-L-proline benzyl ester 7.1 
was deprotected with trifluoroacetic acid. The product 7.2 was then sulfonated with 
ethenesulfonyl chloride, to give 7.3 that, by treatment with the Grubbs catalyst A and through  
RCM, produces the bicyclic sulfonamide 7.4 in low yield. Analogously, the N-sulfonyl 
derivatives 7.5 and 7.7 gave the sultams 7.6 and 7.8, respectively (Scheme 7).  
 
 
 
Scheme 7 Synthesis of bicyclic enantiopure sultams by ring-closure metathesis  
 
                                                 
56 Hanessian, S.; Sailes, H.; Therrien, E. Tetrahedron, 2003, 59, 7047. 
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The synthesis of bicyclic sultams by Heck cyclization was described Metz (Scheme 8).
57
 The α-
bromovinylsulfonamides 8.4, 8.8, and 8.11 were prepared in good yields by treatment of 1-
bromoethenesulfonyl chloride 8.3 with the amines 8.2, 8.7, and 8.10. The Heck cyclizations of 
the sulfonamides under established standard conditions afforded the desired sultams 8.5, 8.9, and 
8.12 along with the undesired products arising from a double-bond migration due to readdition of 
the hydridopalladium bromide and a complementary regioselectivity of carbopalladation (“6-
endo” cyclization instead of the desired “5-exo” cyclization). To avoid these undesired features, 
silver and thallium additives were used to enhance the selectivity. The optimized conditions for 
the Heck cyclizations of the precursors 8.4 and 8.8 for the formation of the corresponding sultams 
8.5 and 8.9 were 10 mol % Pd(OAc)2, 11 mol%P(o-Tol)3, 2 equiv TlOAc, MeCN, reflux.  
 
 
 
 
 
Scheme 8 Synthesis of enantiopure sultams by intramolecular Heck reaction  
 
 
Recently, Hanson explored the synthesis of chiral benzothiaoxazepine-1,1-dioxides containing a 
secondary sulfonamide in enantiomerically pure form via an intramolecular SNAr ortho-
                                                 
57 Merten, S.; Frohlich, R.; Kataeva, O.; Metz, P. Adv. Synth. Catal. 2005, 347, 754. 
25 
 
 
arylation.58 β-Hydroxy α-fluorobenzene sulfonamides 9.3, prepared from the corresponding 
amino alcohols 9.1, were subjected to microwave irradiation at 140 °C for 30 min in DMF and in 
the presence of Cs2CO3. Under these conditions, a variety of chiral benzothiaoxazepine-1,1-
dioxides 9.4 were isolated in 83-95% yields (Scheme 9). 
 
 
 
 
Scheme 9 Click-cyclize protocol to diverse benzothiaoxazepine-1,1-dioxides 
 
 
 
Hanson also described59 an alternative route for the synthesis of benzothiaoxazepine-1,1’-dioxides 
10.3 through a formal [4+3]-epoxide cascade protocol (Scheme 10). 
 
 
 
Scheme 10 One-pot epoxide, SNAr cascade protocol to benzothiaoxazepine-1,1’-dioxides 
 
 
Zhou and Hanson developed the intramolecular oxa-Michael and Baylis-Hillman approaches for 
the synthesis of enantiopure sultams (Scheme 11).
60
 The tert-butyldimethylsilyl protected 
prolinol-derived vinyl sulfonamide 11.2 was treated with TBAF and the bicyclic sultam 11.3 is 
produced in excellent yields via an oxa-Michael pathway. In contrast, treatment of 11.2 underr 
                                                 
58 Ullah, F.; Samarakoon, T.; Rolfe, A.; Kurtz, R. D.; Hanson, P. R.; Organ, M. G. Chem. Eur. J. 2010, 16, 10959. 
59 Rolfe, A.; Samarakoon, T. B.; Hanson, P. R. Org. Lett. 2010, 12, 1216. 
60 Zhou, A.; Hanson, P. R. Org. Lett. 2008, 10, 2951.  
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the orthogonal Baylis-Hillman conditions, involving acidic deprotection, oxidation, and addition 
of DABCO, gave the bicyclic sultam 11.5 with good yield and excellent diastereoselectivity. 
 
 
Scheme 11 Oxa-Michael and Baylis-Hillman approaches to sultams 
 
 
 
Chen
61
 synthesized a number of bicyclic chiral sultams 11.6, the sultam moiety of which is a part 
of the compounds 11.7, novel potent inhibitors of hepatitis C virus (HCV) (Figure 1). 
 
 
 
Figure 1 Potent inhibitors of hepatitis C virus   
                                                 
61 Chen, K. X.; Vibulbhan, B.; Yang, W.; Tong, X. Cheng, K. C.; Njoroge, F. G. Bioorg. Med. Chem. Lett. 2009, 19, 1105. 
27 
 
 
4 Memory of Chirality 
(MOC) 
 
 
 
4.1 Introduction 
 
 
The term “Memory Of Chirality” (MOC) was coined by Fuji,62 who was the first to successfully 
design a reaction to capitalize on this principle. The proposal that MOC could underlay reaction 
enantioselectivity was actually first offered by Seebach.
63
 A MOC reaction “....can be defined as a 
formal substitution at a sp
3
-stereogenic center that proceeds stereospecifically, even though the 
reaction proceeds by trigonalization of that center, and despite the fact that no other permanently 
chiral elements are present in the system”.64 
 
4.2 Requirements for Memory of Chirality 
 
Beginning students of organic chemistry learn that if a enantiopure sp
3
-hybridized stereogenic 
center is trigonalized, any chiral products resulting from that intermediate will be largely racemic 
(Scheme 1). In some SN1 reactions a slight preference of retentive substitution is seen, due to 
shielding of backside attack by the leaving group. However, these low stereoselectivities are not 
synthetically useful. 
 
 
 
Scheme 1 Racemic products resulting from a planar achiral intermediate 
 
                                                 
62 Kawabata, T.; Yahiro, K.; Fuji, K. J. Am. Chem. Soc. 1991, 113, 9694. 
63 Seebach, D.; Wasmuth, D. Angew. Chem. Int. Ed. 1981, 20, 971. 
64 Zhao, H.; Hsu, D. C.; Carlier, P. R. Synthesis 2005, 1. 
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In the absence of any other chiral controllers, a substantially non-racemic outcome would only be 
possible if the intermediate possesses some form of conformational chirality.
 
By its very nature, this conformational chirality will be short-lived; Fuji and Kawabata have 
termed this phenomenon “dynamic chirality”,65  since the enantiopurity of this intermediate is 
dependent on time and temperature. 
However, formation of a conformationally chiral intermediate is not a sufficient condition for 
MOC: this intermediate must be formed enantioselectively. The essential requirements for a MOC 
reaction are illustrated for a hypothetical deprotonation/methylation in Scheme 2. 
 
 
 
 
Scheme 2 Essential requirements for a MOC reaction of hypothetical depronation/methylation 
 
 
Firstly, deprotonation of the stereogenic center in the enantiopure reactant (S)-A-H must generate a 
conformationally chiral reactive intermediate (M)-A with high enantioselectivity. We use the 
helical descriptors (M)- and (P)- to describe the chirality of the intermediates; the choice of (M)-
helicity in this example is arbitrary. Next, this conformationally chiral intermediate (M)-A must 
not readily racemize, at least not on the time scale of the desired subsequent reaction. Finally, the 
conformationally chiral intermediate must react with MeI with high stereopecificity to produce 
(S)-A-Me (again, the choice of (S)-configuration is arbitrary). Failure to meet all three of these 
requirements will result in zero or low enantioselectivity.  
Note that both steps of the MOC process involve transfer of chirality: from static, central chirality 
to transient, conformational chirality (1), and then back again (2). How to ensure efficient chirality 
transfer in both steps is not immediately clear, and represents the essential challenge of the MOC 
strategy. 
  
                                                 
65 Fuji, K.; Kawabata, T. Chem.-Eur. J. 1998, 4, 373. 
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4.3 Memory of Chirality in Enolate Chemistry 
 
The MOC phenomenon was first demonstrated in the field of enolate chemistry by Fuji,
53
 and to 
date enolates have proven the most fertile ground for the application of the MOC principle. His 
key insight
53
 was that deprotonation of a stereogenic center α to a carbonyl in 1 need not always 
lead to an achiral enolate intermediate 2 (Scheme 3). 
 
 
Scheme 3 Intentional design of conformationally chiral enolates 
 
 
The enantiomeric forms A and ent-A, and B and ent-B, under normal conditions are not 
differentiated because of the rapid equilibrium between them. They may be differentiated from 
each other at an extremely low temperature or by the introduction of specific structural constraints 
into the molecule (such as changing 2,2'-dihydroxybiphenyl to the corresponding binaphthalene). 
Thus, this is a phenomenon in which the information on chirality in the original system is kept in a 
reactive intermediate for a limited period of time. 
Kawabata and Fuji have introduced this concept in 1991
53
  in the below mentioned example, the 
authors showed that treatment of the -alkoxy naphtyl ketone 3 (93% enantiomeric excess) with 
potassium hydride and methyl iodide in the presence of 18-crown-6 afforded 5 in 66% 
enantiomeric excess without any additional chiral source (Scheme 4).  
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Scheme 4 First MOC reaction 
 
 
The obtained results suggested the formation of a chiral enolate intermediate in a nonracemic 
form.  
The authors proposed that the reaction occurs via the enolate 4, whose structure is reminiscent of 
the atropisomeric 1,1-binaphthyls. In accord with this hypothesis, the O-alkylated product 6 was 
also detected in the reaction mixture with 65% enantiomeric excess. At room temperature, 6 was 
found to racemize with half-life time of 53 minutes, corresponding to a rotation barrier of 22.6 
kcal/mol; the phenyl analogue of 3 subjected to the same reaction conditions, gave the racemic 
product. 
 
 
 
4.4 Enantioselective α-Alkylation of Amino Acid Esters Without 
External Chiral Sources  
 
 
In order to extend this strategy, Kawabata studied the -alkylation of the enolates generated from 
-amino acids. In fact, an enolate derived from an optically active amino acid derivative, may not 
racemize under basic conditions. Here are reported (Scheme 5) three different species of enolates 
which could furnish an optically active product: 
- enolate C, which has axial chirality across the carbon- nitrogen bond. This kind of enolates is 
expected if R
3
 is different from R
4
;  
- enolate D, which has planar chirality due to the enolate plane and the metal cation, stabilized by 
coordination with a substituent on the nitrogen;  
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- enolate E where tight coordination of the nitrogen atom to a metal cation creates a stereogenic 
nitrogen atom, not allowing the pyramidal inversion.  
 
 
 
Scheme 5 Three types of enolate chirality 
 
Kawabata proposed a study on the chirality transfer using as a starting amino acid the N-Boc-
phenylalanine 6 ethyl ester.
66 
Non-racemic products were obtained, the best enantiomeric excess 
being obtained by using LiTMP as a base. Even more interestingly, KHMDS gave a predominance 
of the inversion product (20% ee), suggesting the existence of two pseudo-enantiomeric transition 
states (Scheme 6 ). 
 
Scheme 6 Asymmetric methylation of (S)-7 
                                                 
66 Kawabata, T.; Wirth, T.; Yahiro, K.; H. Suzuk; Fuji, K. J. Am. Chem. Soc. 1994, 116, 10809-10807;  
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In order to improve the yields and enantioselectivity of this process, the authors screened a serie of 
substituents on the nitrogen moiety of phenylalanine derivative 9a.
67
 They found that substrates 
bearing tert-butoxycarbonyl (Boc) and methoxymethyl (MOM) groups gave the best results (Table 
1, enrty 1). 
 
Table 1 Asymmetric α-methylation of N-MOM-N-Boc α-amino acid derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
Kawabata et al. have also applied the best reaction conditions to amino acid derivatives different 
from phenylalanine 9 (Table 1). In each case, they obtained quite good yields and 
enantioselectivity; moreover, differently from the N-methyl derivative 8 (Scheme 6), Boc and 
MOM protective groups are simply removed by treatment with aqueous HCl, affording the 
corresponding -methyl--amino acids in 51–86% yields. The degree of asymmetric induction in 
                                                 
67 Kawabata, T.; H. Suzuki; Wirth, T.; Nagae, Y.; Fuji, K. Angew. Chem. Int. Ed. 2000, 12, 2155- 2158 
entry R yield (%) ee (%) 
1 a 96 81 
2 b 83 93 
3 c 94 79 
4 d 95 80 
5 e 88 76 
6 f 81 87 
7 g 78 78 
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the -methylation indicates that MOM and Boc groups on the nitrogen atom have a decisive effect 
on the stereochemical course of the reaction. 
Fuji and Kawabata addressed their study to the -alkylation of L-isoleucine and D-allo-isoleucine 
derivatives 11 and 14 to investigate the influence of an additional chiral center (Scheme 7).
68
 
Amino esters 11 and 14 have the same absolute configuration at C3 and opposite configurations at 
C2. When the N-MOM ethyl esters 11 and the N-Boc ethyl esters 14 were subjected to the standard 
alkylation condition, both the corresponding methylated compounds 13 and 16 were obtained in 
excellent diastereoselectivities (93% and 86% diastereoisomeric excess respectively). Thus, the 
stereochemical course of deprotonation/methylation of 11 and 14 appears to be controlled by the 
chirality at C2: in fact, if the chiral information at C2 had been lost during enolate formation, -
methylation would have given products with identical diastereomeric composition via a common 
enolate intemediate. These results suggest the formation of diastereomeric enolate intermediates 
such as 12 and 15. 
 
 
 
 
Scheme 7 MOC α-alkylation of isoleucine derivatives 
 
 
As regards the reaction mechanism, during the years, Fuji and Kawabata have carried out a 
number of mechanistic investigations. For the deprotonation/alkylation of N-Boc, N-Me amino 
acid esters 16, the authors considered several mechanistic scenarios (Scheme 8): 
 
                                                 
68 Kawabata, T.; H. Suzuki; Wirth, T.; Nagae, Y.; Fuji, K. Org. Lett. 2000, 2, 3883- 3885 
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Scheme 8 Three possible intermediates during asymmetric induction 
 
 
Asymmetric induction could arise from: a chiral enolate/ starting material aggregate 17; a species 
18 with a chiral nitrogen atom; an axially chiral enolate 19.  
To rule out the presence of an aggregate such as 16, the authors conducted a crossover experiment 
(Scheme 9).
69 
 
 
 
Scheme 9 Crossover experiment to investigate the origin of chirality 
 
 
A mixture of optically pure 1 and racemic 20 were subjected to deprotonation with LiTMP at -78 
°C followed by addition of methyl iodide, to afford optically active 2 (74% ee, 26% yield) and 
                                                 
69 Kawabata, T.; Wirth, T.; Yahiro, K.; H. Suzuk; Fuji, K. J. Am. Chem. Soc. 1994, 116, 10809-10807 
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racemic 20 (30% yield). The same treatment of a 1:1 mixture of racemic 1 and optically active 20 
afforded the racemic 2 (17% yield) and optically active 20 (71% ee, 24% yield). These 
observations indicate that 17 (Scheme 8) does not make a significant contribution to the 
asymmetric induction. 
In their opinion, the most suitable intermediate is compound 19 (Scheme 8). As a confirmation, 
Fuji and Kawabata reported the isolation of the (Z)- and (E)-TBS ketene acetals 21 (Figure 1).
70
 
 
 
Figure 1 (Z)- and (E)-TBS ketene acetals  
 
The methylene protons of the MOM groups are diastereotopic in both isomers of 21, indicating 
restricted rotation of the C2–N bond. The rotational barrier of the C2–N bond in the major isomer 
Z-21 was determined to be 16.8 kcal/mol and it corresponds to a racemization half-life of seven 
days at -78 °C. 
For this reason the authors proposed that deprotonation of 9a occurs through the most stable 
conformer 25 (Scheme 10). 
 
 
Scheme 10 Proposed mechanism of retentive methylation of (S)-9a 
 
 
Kawabata found support for the presence of an axially chiral enolate in both 
deprotonation/alkylation of both substrates 22 and 23 (Figure 2). 
                                                 
70 Kawabata, T.; Suzuki, H.; Nagae, Y.; Fuji, K. Angew. Chem. Int. Ed. 2000, 39, 2155. 
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Figure 2 Examination of the intermediacy of axially chiral enolate in deprotonation/alkylation 
 
Deprotonation/methylation of enantiopure 22 and enantiopure 23 gave racemic 24 and 25, because 
of the formation of an achiral enolate: in fact, the presence of two identical Boc protecting groups 
in compound 22 rule out the possibility of chirality on the N–C2 axis. In the case of 23 the five-
membered ring prevents the N substituents from rotating out of the enolate plane to attain axial 
dissymmetry. 
In the last few years, Kawabata et al. have also applied the concept of autoinduction of chirality to 
the synthesis of cyclic amino acids.
71
  
 
Table 2 Synthesis of cyclic amino acids 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
71 a) Kawabata, T.; Kawakami, S.; Majumdar, S. J. Am. Chem. Soc. 2003, 125, 13012; b) Kawabata, T.; Moriyama, K; 
Kawakami, S.; Tsubaki, K. J. Am. Chem. Soc. 2008, 130, 4153- 4157 
entry  n R yield (%) ee (%) 
1 a 3 Bn 94 98 
2 b 3 4-EtO(C6H4)CH2 95 97 
3 c 3 MeSCH2CH2 92 97 
4 d 3 iPr 78 94 
5 e 3 Me 91 95 
6 f 2 Bn 61 95 
7 g 4 Bn 84 97 
8 h 5 Bn 31 83 
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They designed a series of N-Boc-N--bromoalkyl- -amino acid derivatives 26a–h for 
asymmetric intramolecular cyclization (Table 2). Compounds 27 were obtained in quite good 
enantiomeric excess and fairly yields. The chirality of the starting amino acids 26a-h was 
preserved during enolate formation and subsequent cyclization, giving enantiomerically enriched 
azacyclic quaternary amino acids, with retention of configuration, as found for the acyclic 
quaternary amino acids. For this reason, Fuji and Kawabata proposed a similar mechanism to that 
of 9a (Scheme 10). In this case, a conformational study identified two stable conformers of 
compound 26a of similar energy: A and B. Deprotonation of B is disfavored because of a steric 
interaction between KHMDS and the N-Boc group. On the other hand, deprotonation of A is 
favored and gives axially chiral nonracemic enolate X, which then cyclizes to give the retention 
product 27A. With the aim of shifting the equilibrium, making dominant the transition state Y, 
thus extending this procedure to the synthesis of inversion compounds, the authors investigated the 
asymmetric cyclization of 26 changing the cation of the employed base.
72
 The best result of 27B ( 
93%, 91% enantiomeric excess) was obtained using as a cation Li
+
, which is the smallest metal 
cation. 
 
 
 
 
Scheme 11 Proposed mechanism of MOC cyclization of (S)-26a  
 
                                                 
72 Kawabata, T.; Matsuda, S.; Kawakami, S.; Monguchi, D. ; Moriyama, K. J. Am. Chem. Soc. 2006, 128, 15394. 
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The protocol for enantio-divergent cyclization was applied to intramolecular conjugate addition of 
chiral enolates. Treatment of the alanine derivative 28 with KHMDS in DMF-THF (1:1) at -78 °C 
gave 29 as a single diastereoisomer in 95% ee (Scheme 12, (path A). The absolute configuration 
assignment of 29 was based on the stereochemical course of asymmetric intramolecuar conjugate 
addition via memory of chirality. Treatment  of 28 with LTMP in THF at 0 °C gave ent-29 as a 
single diastereoisomer in 91% ee.  
 
 
Scheme 12 Stereochemical diversity in MOC cyclization of 28 
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5 Application of MOC to the Synthesis of α-
Quaternary α-Amino Acids 
 
 
 
Non-natural amino acids have attracted considerable attention in biological and medicinal 
chemistry,
73 
because they are powerful tools for the design of new oligopeptidic fragments, 
capable of influencing the secondary structure of proteins. In particular, -quaternary -amino 
acids are of great interest for their potential intrinsic bioactivity.
74
 In addition, new foldamers are 
formed by the introduction of quaternary -amino acids into peptidomimetics. This procedure 
increases the lipophilicity of the oligomeric chain, and restricts its conformational flexibility, thus 
making the peptide more resistant to metabolic and chemical degradation.
75
 
A number of strategies
56
 and, among them, those that adopt the well-known Kawabata’s 
principles of “memory of chirality” (MOC)43,44 and of “chiral non-racemic enolate”76 emerge as 
the most appealing-have been proposed for the stereoselective synthesis of quaternary -amino 
acids. In particular, the synthetic methods for quaternary prolines
77
 involve the enantioselective 
functionalization of L-proline derivatives, for example, through self-reproduction of chirality, 
diastereoselective alkylation, or transfer of stereochemical information via cyclic ammonium 
ylides. 
In the past few decades, a variety of synthetic strategies for such important building blocks have 
been developed.
78
 In the field of carbon-carbon bond formation, synthetic strategies based on 
sigmatropic rearrangements are one of the most interesting method to obtain -quaternary 
prolines.  
                                                 
73 (a) S. Hunt, Chemistry and Biochemistry of the Amino Acids, ed. G. C. Barrett, Chapman and Hall, London, 1985, p. 55; (b) Y. 
Ohfune, Acc. Chem. Res., 1992, 25, 360. 
74 (a) T. Kan, Y. Kawamoto, T. Asakawa, T. Furuta and T. Fukuyama, Org. Lett., 2008, 10, 169; (b) S. Pizzarello, Acc. Chem. 
Res., 2006, 39, 231; (c) Y. Ohfune and T. Shinada, Eur. J. Org. Chem., 2005, 5127. 
75 (a) M. Tanaka, Chem. Pharm. Bull., 2007, 55, 349; (b) C. Toniolo, F. Formaggio, Q. B. Broxterman, Synlett, 2006, 1295; (c) S. 
J. O’Connor and Z. Liu, Synlett, 2003, 2135; 
76 a) T. Kawabata, S. Majumdar, K. Tsubaki, D. Monguchi, Org. Biomol. Chem. 2005, 3, 1609 –1611; b) T. Kawabata, S. 
Kawakami, K. Fuji, Tetrahedron Lett. 2002, 43, 1465 –1467; c) T. Kawabata, H. Suzuki, Y. Nagae, K. Fuji, Angew. Chem. 2000, 
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West and Glaeske reported a study on chirality transfer in [1,2]-Stevens rearrangement of the 
diastereomerically pure cyclic ammonium salt methyl ester 1 (Table 1, entry 1).
79
 Using 
tetrahydrofuran as solvent under the action of potassium tert-butylate, the quaternary proline ester 
2 was isolated with fairly good enantioselectivity. 
 
 Table 1 
 
 
 
 
 
 
 
 
 
 
 
This technique was further improved by Tayama et al. by employing solid-liquid biphasic 
reaction conditions (entry 2,5); the best yield and enantioselectivity were reached by using 
caesium hydroxide in dichloroethane (entry 6).
80
 It has also been noticed that the level of N-C 
chirality transfer depends not only on the reaction conditions but also on the N-benzyl moiety 
(Table 2).  
  
                                                 
79 Glaeske, K. W.; West, F. G. Org. Lett. 1999, 31-33. 
80 Tayama, E.; Orihara, E.; Kimura, H. Org. Biomol. Chem. 2008, 3673-3680. 
 
entry R base solvent T(°C) t (h) yield (%)
 
ee (%) 
1 Me tBuOK THF rt 1.5 73 54 
2 tBu tBuOK DCM
 
rt 3 80 72 
3 tBu 50% KOH DCM
 
-10 24 45 86 
4 tBu KOH DCM -10 24 52 94 
5 tBu CsOH DCM -10 24 88 84 
6 tBu CsOH DCE -10 24 73 92 
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 Table 2 
 
 
 
 
 
 
 
 
This rearrangement is assumed to proceed by a radical cleavage-recombination mechanism. 
Tayama et al. suggested that the stability of the benzylic radicals involved and the solid–liquid 
biphasic reaction conditions employed determine the stereochemical course of the reaction 
(Scheme 1). The recombination of the radical pair initially formed from the N-ylide occurs more 
rapidly in a solvent cage and hence more preferentially in a retentive fashion. 
 
 
 
Scheme 1 
 
The main drawback of this methodology is accessing the pure diastereomer of the ammonium 
salt, which requires stereoselective quaternization with methyl iodide followed by several 
recrystallizations and ultimately yielding the pure diastereomer in low yields. 
Tayama has also observed that, when the rearrangement is performed in THF at -40°C using 
potassium tert-butoxide as a base, the Sommelet–Hauser rearrangement (concerted 
[2,3]sigmatropic process) proceeded exclusively to give the corresponding -aryl proline 
derivative 3 in 96% yield and 99% enantiomeric excess (Scheme 2).
81
 
 
                                                 
81 Tayama, E.; Kimura, H. Anghew. Chem.Int. Ed. 2007, 8869-8871. 
 
Ar 2 yield (%)
 
ee (%) 
4-Me-Ph 2b 77 84 
4-MeO-Ph 2c 56 86 
4-F-Ph 2d 69 90 
4-tBuOCOPh 2e 42 99 
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Scheme 2 
 
Another example of Stevens rearrangement was described by Somfai.
82
 He performed an 
asymmetric Lewis acid mediated [1,2]-shift of proline derivatives; he found that complexation of 
proline amide derivatives 4 with BBr3, followed by addition of Et3N, gave the corresponding 
products 5 in good yield and excellent enantiomeric excess. 
 
Table 3 
 
 
 
 
 
 
 
 
 
The high enantiomeric excess can be explained by an in situ formation of the rigid bicyclic 
complex 6 (Scheme 3). Treatment of amide 4a with BBr3 results in coordination of the Lewis 
acid cis to the amide moiety, which is followed by formation of structure 6. Subsequent 
deprotonation of 6 with Et3N provides ylide 7, which suffers a homolytic cleavage of the C-N 
bond (structure 8) and then a radical recombination to form complex 9. An efficient N-C chirality 
transfer is secured by selective migration of the benzyl radical on the Re-face. Finally, hydrolysis 
of 9 gives 5a, the absolute stereochemistry of which is identical to the starting material 4a. 
                                                 
82 Pavel, T.; Somfai, P. Org. Lett. 2009, 919-921. 
 
entry 4 Ar t (h) 5 (%)
 
ee (%) 
1 4a Ph 1
 
5a 85 96 
2 4b 4-tBu-Ph 1
 
5b 82 96 
3 4c 4-Br-Ph 1 5c 76 96 
4 4d 4-CF3-Ph 1 5d 82 96 
5 4e 2-Me-Ph 2 5e 81 96 
6 4f 2-Tyophene 1 5f 79 96 
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Scheme 3 
 
An exclusive [2,3]-shifts of a prenyl group for substrate 10 has been reported by Coldham,
83
 
(Scheme 4). In this case, the rearrangement is stereospecific because the [2,3]-migration is 
restricted to the same face. 
 
Scheme 4 
 
The ester-enolate Claisen rearrangement is a powerful method for enantioselective C–C bond 
formation from an original chiral ester. Recently this type of reaction was applied to and α-
acyloxy-α-vinylsilane possessing a proline as the acyloxy group (Scheme 5).84 The enolate 
generated from 12 underwent the Claisen rearrangement, through a chair-like transition state with 
a Z-enolate in the presence of HMPA, to give the α-substituted proline derivative 13 with transfer 
of the original chirality of the ester counterpart. 
                                                 
83 Arboré, A. P. A.; Cane-Honeysett, D. J.; Coldham, I.; Middleton, M. L. Synlett 2000, 236–238 
84 Sakaguchi, K.; Yamamoto, M.; Watanabe, Y.; Ohfune, Y. Tetrahedron Lett. 2007, 48, 4821–4824. 
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Scheme 5 
 
Recently, our group reported on the enantioselective synthesis of quaternary N-alkyl--4-
nitrophenyl--amino tert-butyl esters, through N-alkylation of the corresponding α-N-(4-
nitrophenyl)sulfonamido esters, followed by degradative rearrangement, with loss of SO2 (Table 
4)
85
 
 
Table 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
85 Foschi, F.; Landini, D.;  Lupi, V.; Mihali, V. ; Penso, M.; Pilati, T.; Tagliabue A. Chem. Eur. J. 2010, 16, 10667. 
Entry Base Solvent t (h) 15(%) ee (%) 
1 NaNH2 DMA 0.25 90 94 
2 NaNH2 DMA 1.5 89 96 
3 NaNH2 DMF 1 68 94 
4 NaNH2 NMP 24 – – 
5 NaNH2 DMSO 24 – – 
6 LiNH2 DMA 24 – – 
7 LDA DMA 0.25 – – 
8 LDA THF 24 – – 
9 LDA DMF 96 40 77 
10 tBuOK DMA 48 15 92 
11 DBU DMA 48 – – 
12 MeONa DMA 48 – – 
13 NaH DMA 26 79 94 
14 NaH/NH3 DMA 1 97 94 
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The elevated reaction rates, together with the high yields and ee’s, highlight the paramount 
efficiency of NaNH2: in fact, the reaction is 10
2 
times faster than with NaH. Sodium amide was 
used, because ammonia produced in the process solvates the sodium ion associated to the 
carbanion derived from 14, forming a loose ion-pair that is much more reactive than the 
unsolvated tight ion pair generated by deprotonation with sodium hydride. Deprotonation of the 
less crowded conformer of the substrate 14A, in which the arylsulfonyl group is far from the tert-
butyl ester, gives the non-racemic enolate A. This intermediate, through a Re-face attack, evolves 
into a chiral spiro-Meisenheimer complex B that, in turn, undergoes the S-C migration of the 
aryl group, with an overall configuration retention (Scheme 6). 
 
 
 
Scheme 6 
 
Tayama et al. recently described the straightforward application of the Stevens and Sommelet–
Hauser (S.–H.) rearrangements in the preparation of non-natural amino acid derivatives.86 In 
                                                 
86 (a) E. Tayama, K. Orihara and H. Kimura, Org. Biomol. Chem., 2008, 6, 3673; (b) E. Tayama, S. Nanbara and T. Nakai, 
Chem. Lett., 2006, 35, 478. 
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particular, the S.–H. rearrangement of N-benzylic -ammonium acid esters gave quaternary -
aryl--amino esters, through a [2,3]-sigmatropic shift of an aromatic ring, bearing an electron-
withdrawing group. However, in order to display stereoselectivity, this process required the 
presence of the expensive (-)-8-phenylmenthyl ester that acts as a chiral auxiliary (Scheme 7). 
 
 
 
Scheme 7 Diastereoselective Sommelet-Hauser rearrangement 
 
Wilson,
87
 with the aim to deprotect a series of optically pure N-alkyl-N-
(nitrobenzenesulfonyl)amino acid tert-butyl esters, found that the reaction between the tertiary 
protected amino acid and the basic ion exchange resin (Amberlite 120) gave a large amount of a 
by-product. As an example, in the reaction of valine derivative 19 (Scheme 8), the analyses of by-
product 21 (
1
H NMR and Mass spectral analyses) were consistent with the absence of sulfur 
dioxide. 
 
 
Scheme 8 
 
 
                                                 
87 M. W. Wilson, S. E. Ault-Justus, J. C. Hodges and J. R. Rubin, Tetrahedron 1999, 55, 1647. 
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The X-ray crystallographic analysis of the 21 hydrochloride salt confirmed both his structure and 
racemic nature. 
Further investigations revealed that quaternary amino ester 23 could be obtained as the main 
product as a racemic mixture, when 50% aqueous Bu4N
+
OH
-
 solution was used as a base 
(Scheme 9). 
 
 
Scheme 9 
 
 
The migration of the 4-nitrophenyl moiety is due to the intramolecular nucleophilic attack of the 
enolate A toward the aromatic ring, which affords the Meisenheimer intermediate B (Scheme 10). 
 
 
 
Scheme 10 
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Subsequent S-C migration of the p-nitrophenyl group is promoted by loss of sulfur dioxide, 
whom gaseous nature act as a strong driving force shifting the equilibrium toward the product 23. 
An analogous rearrangement has been reported for a 9-(N-4-nitrobenzenesulfonyl-N-
methylamino) fluorene system
88 
and 2-cyano-(N-4-ntirobenzenesulfonyl)- acetamide.
89
 
Recently, we have reported
90 
 on a powerful method for enantioselective C–C bond formation in a 
synthesis of quaternary -aryl--amino acids, starting from optically pure phenylalanine 
derivative (Table 7). 
 
Table 7 Rearrangement of sulfonamido tert-butyl ester 24a with several alkylating agents R
2
X 
 
                                                 
88 Meng, Q.; Thibblin, A. J. Am. Chem. Soc. 1997, 119, 1224-1229. 
89 Naito, T.; Dohmori, R.; Nagase, O. J. Pharm. Soc. Japan. 1954, 74, 593-595. 
90 Lupi V.; Penso M.; Foschi F.; Gassa F.; Mihali V.; Tagliabue A. Chem. Commun., 2009, 5012–5014. 
 at 0 °C  at -20 °C 
entry R
2
X t (h) yield (%) ee (%)  t (h) 
ayield(
%) 
ee (%) 
1 a AllBr 5 25a 87 62  48 25a 85 74 
2 b MeI
 
2 25b 96 82  24 25b 90 91 
3 c EtI 7 25c 99 57  – – – 
4 d nPrI 16 25d 80 57  – – – 
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This methodology was extended using allyl bromide and propargyl bromide as alkylating agents 
to study the reactivity of several representative -(p-nosylamido)acid tert-butyl esters (Table 8). 
Quantitative yields and very high ee’s of the corresponding rearranged products (>95%) were 
reached with strongly hindered valine (26d) and isoleucine (26e) derivatives (entries 4, 5, 8, 9). 
The phenylglycine derivative 26b is very sensitive to basic conditions and reacted with poor 
enantioselectivity (entry 2). Due to the ready N-deallylation, the N-allyl derivatives 27a and 28 
are useful intermediates for the preparation of the N-unsubstituted -quaternary-amino acids. 
 
 
 
Table 8 Alkylation–rearrangement of tert-butyl esters 26a–e with allyl and propargyl bromide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 e nBuI 4 25e 86 62  – – – 
6 f C8H17I 16 25f 73
 
61  – – – 
7 g BnBr 4 25g 75 51  48 25g 84 61 
8 h PrgBr 8 25h 88 80  – – – 
   N-Allyl Derivative 
 Substrate  At 0 °C  At -20 °C 
Entry  R
1
  t (h) Yield (%) ee (%)  t (h) Yield (%) ee (%) 
1 26a PhCH2  5 27a 87 62  48 27a 85 74 
2 26b Ph  28 28b 92 50  48 28b 65
b 
58 
3 26c Me  6 28c 89 59  16 28c 89 68 
4 26d iPr  24 28d 99 95  – – – 
5 26e sBu  26 28e 99 96  – – – 
     
    N-Propargyl Derivative 
    t (h) Yield (%) ee (%) 
6 26a PhCH2  8 27h 88 80 
7 26c Me  5 29c 93 68 
8 26d iPr  20 29d 98  96 
9 26e sBu  26 29e 97 98 
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Regarding the reaction mechanism, we hypothesized that the stereochemical information is 
transferred from the N-alkylated sulfonamide 24 to the final rearranged product 25 via a non-
racemic enolate B. This intermediate, through a Re-face attack, evolves into a chiral spiro-
Meisenheimer complex that, in turn, undergoes the stereoselective S-C migration of the aryl 
group. The enolate B is probably formed by deprotonation of the less crowded conformer A, in 
which the arylsulfonyl group is far from the tert-butyl ester. (Scheme 11). 
 
 
Scheme 11 Proposed mechanism and stereochemical course. 
 
 
 
In order to generate a reactive intermediate (enol/enolate) in which the rotation along the C-N 
bond was minimum, we have chosen the N-allyl phenylalaninate 25a as model compound for an 
extensive study devoted to find the optimal reaction conditions able to stabilize a chiral non 
racemic species. 
Compound 25a was reacted in the presence of several basic systems (Table 9). A support for our 
hypotheses was obtained from the reaction, in the presence of a strong organic base likes DBU 
(1,8-diazabicyclo[5.4.0]undec-7-ene), under mild homogenous conditions. Using DMA as 
solvent, at 25 °C, the target compound 27a was obtained in 95% ee (Table 9, entry 2). Also in 
these cases the retention product was the major enantiomer isolated. 
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Table 9 Rearrengement of N-allyl phenylalanine 25a with different bases 
 
 
 
 
 
 
 
 
 
We carried out several experiments using DBU as a base and varying the nature of the solvent 
(Table 10): in each reaction compound 27a has been isolated in good yields, and the best ee was 
obtained using dimethoxyethane (DME) or DMA (Table 10, Entry 1-3). Eventually, our choice 
fell on DME, because of its higher vapor pressure thus easier removal. 
 
Table 10 Rearrengement of N-allyl phenylalanine 25a with different solvents 
 
 
 
 
 
 
 
entry base T (°C) t (h) 27a (%) ee (%) 
1 NaH 0 1 90 28 
2 NaNH2 0 0.5 78 35 
3 DBU 25 14 89 95 
4 TMG 25 - - - 
5 BTMG 25 - - - 
entry Solvent T (°C) t (h) yield (%) ee (%) 
1 DMA 25 14 89 95 
2 DME 25 12 94 95 
3 DME/ DMA 25 10 94 94 
4 THF 25 12 88 83 
5 CH2Cl2 25 12 85 81 
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We have also studied the reactivity of a representative number of - (p-nosylamido)acid tert-
butyl esters 25 using DBU as organic soluble base and DME as a solvent (Table 11).  
 
Table 11 Rearrengement of N-allyl -amino-acids 25a-e 
 
 
 
 
 
 
 
 
 
 
While a low ee was detected using alanine (entry 3), very poor yields were obtained with strongly 
hindered valine and isoleucine derivatives (entries 4,5). The obtained data indicate a strong 
reactivity dependence on the increasing dimension of the side chain on the amino acid: the 
smaller the steric hindrance near the reacting centre, the greater the reaction reactivity. 
Thus, the steric hindrance was decreased by using the methyl ester instead of tert-butyl ester. The 
methyl N-allyl-phenylalaninate 31a was treated with DBU in DME (Table 12, entry 1). 
Besides nearly quantitative yields, a very high ee of the corresponding rearranged products 32a, 
c-g (entries 1, 4-8) and excellent diastereoselectivities of quaternary derivatives 32h-i (entries 9-
10) were reached. 
 
 
 
 
entry R T(°C) t (h) yield (%) ee (%) 
1 Phe  0 36 85 95 
2 Phe 25 36 94 91 
3 Ala 0 20 92 43 
4 Leu 25 60 25 96 
5 Val 25 60 30 95 
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Table 12 Rearrangement of N-allyl α-amino acid methyl esters 30a-h 
 
 
 
 
In particular, under homogeneus conditions, we synthesized derivatives 32c,h bearing a 
hydroxylic function like threonine or tyrosine (entries 4-9).  On the contrary, unsatisfying ee were 
obtained with the alaninate derivative 32b (entry 2), even operating at -50 °C (Table 12, entry 3) 
Finally, we evaluated the reactivity of a series of alkyl halides RX using the phenylalanine 
derivative 30a as model compound (Table 13). The use of SL-PTC for the synthesis of N-alkyl 
derivatives was the best choice because the reaction condition did not interest the stereocentre of 
the amino acid and the reaction proceeds with quantitative yields under mild condition. 
The application of the homogeneus transposition conditions furnished the corresponding N-
alkylated--quaternary esters 32a, i-n in excellent yields, and ee’s major of 90%.  
 
 
 
entry  R  T(°C) t (h) 32 (%) ee (%) 
1 a Bn Phe 0 14 95 95 
2 b Me Ala -50 16 90 55 
3 c 4-HOC6H4CH2 Tyr 0 16 88 88 
4 d  DHPhG 0 48 94 79 
5 e iPr Val 25 48 93 95 
6 f MeSCH2 Met 0 8 60 60 
7 g Me2CHCH2 Leu 25 36 78 90 
8 h (2S,3R)-MeCH(OH) Thr 25 24 90 99 (de) 
9 i MeCH2CH(Me) i Leu 25 48 84 99(de) 
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Table 13 Alkylation/Rearrangement of sulfonamide 30a with several alkylating agents RX 
 
 
 
 
 
 
 
  
entry  R yield 31% yield 32 (%) 32 ee (%) 
1 a All 98 95 95 
2 i Prg 95 84 92 
3 l Bn 96 84 90 
4 m Me 98 97 93 
5 n Bu 94 82 95 
56 
 
 
6 Results  
 
 
6.1 Synthesis of Racemic Benzosultams 
 
 
 
 
Scheme 1 
 
 
In the screening of various sulfonamido esters activated to this transposition, we tested the N-
(pentafluorobenzene)sulfonyl derivative. In fact, we supposed that this compound, bearing the 
strongly electronegative five fluorine atoms, could easily give the bicyclic Meisenheimer 
activated structure, through the aromatic intramolecular substitution. 
Preliminary tests showed a particularly interesting behavior of 3: the molecule, after the initial N-
alkylation with an alkyl halide, cyclizes by displacement of the fluorine atom in the ortho position 
to the sulfonyl group furnishing the N-alkyl benzo[d]isothiazole-1,1-dioxide 4 (Scheme 2). 
 
 
 
Scheme 2 
 
 
Starting materials are racemic (pentafluorobenzene)sulfonamides 3 prepared, in turn, from the 
corresponding α-amino esters. 
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Sulfonamide 3a has been prepared by condensation of the commercially available 
(pentafluorobenzene)sulfonyl chloride 5a and phenylglycine methyl ester hydrochloride 6a. 
The reaction, conducted at 0−25°C, in dichloromethane with di-(iso-propyl)ethylamine (DIEA) as 
a base, to neutralize the hydrogen chloride formed during the condensation, gave the desired 
product 3a in good yield after crystallization of the crude (Scheme 3). 
 
 
Scheme 3 
 
Sulfonamide 3a was the starting point for an extensive study devoted to find the best reaction 
conditions for the cyclization. In a preliminary step, we studied the alkylation of 3a with an 
activated alkylating agent, such as BnBr, MeI, etc. Analogously to that obtained with (4-
nitrobenzene)sulfonamides, we found that solid-liquid phase transfer catalysis (SL-PTC) 
conditions provide good reactivity. The reaction was carried out in highly polar solvents, at room 
temperature, using a solid, anhydrous alkaline metal carbonate as a base, and in the presence of a 
catalytic amount (10% molar) of triethylbenzylammonium chloride (TEBA) as PTC agent. The 
initial step of the optimized SL-PTC procedure (Scheme 4) was the reaction of sulfonamide 3a 
with methyl iodide in MeCN, in the presence of anhydrous K2CO3 (0.1 mol equiv.). The resulting 
N-methyl sulfonamide 7a was transformed into the corresponding N-
methyl(tetrafluorobenzo)[d]sultam 4a by generating, under SL-PTC in DMSO, the enolate A, 
which rapidly cyclizes through an intramolecular nucleophilic displacement of the aromatic ortho 
fluorine atom.  
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Scheme 4 
 
 
The role of the solvent is particularly crucial for the selectivity of both N-alkylation and ring-
closing step (Table 1). Actually, rapid cyclization rate of 7a and high yield of sultam 4a were 
reached by operating in pure DMSO (entry 1) or in MeCN containing at least 1 mol equiv. of 
DMSO as an additive (entry 3). On the contrary, a low 7a yield was obtained with a catalytic 
amount of DMSO (entry 4), indicating the formation of an equimolar adduct (enolate A : 
DMSO) as the plausible activated species. In pure MeCN, under analogous conditions, the 
starting material was recovered unchanged (entry 5), whereas at 50 °C only a minor yield of 4a 
was obtained (entry 6). 
 
Table 1 
entry solvent  DMSO (mol equiv.) t (min) 4a (%) 
1 DMSO  15 91 
2 MeCN 5 90 89 
3 MeCN 1 90 86 
4 MeCN 0.1 90 68 
5 MeCN  90  
6 MeCN  90 5 
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In the screening for the best reaction solvent, the use of DMSO resulted in an increased yield of 
4a operating at 25°C in 20 h. As indicated by these preliminary data, DMSO shows the better 
solvent ability toward the cyclization process. In summary, an excess of potassium carbonate, in 
DMSO, at room temperature represent the best reaction conditions for the cyclization reaction. 
With these results in hand, we focused our attention on the SL-PTC “one-pot” N-
methylation/cyclization process (Table 2). Several experiments were performed by reacting 
sulfonamide 3a with methyl iodide in DMSO, in the presence of different bases. Using anhydrous 
cesium carbonate, 4a was isolated after 75 min in 94% yield (entry 1), whereas the reaction with 
potassium carbonate required longer reaction times (entries 2, 3). All the other tested bases gave 
lower yields of 4a, but n-BuLi produced only byproducts, derived from nucleophilic substitution 
of aromatic fluorine atom(s) by n-butyl anion. Finally, the non-catalyzed process (i.e. entry 4, 
without PTC agent) was not complete even after prolonged reaction times and 4a yield was 
moderate, thus confirming the effectiveness of the PTC agent. 
 
Table 2 
 
entry base (mol equiv) t (h) 4a (%) 
1 Cs2CO3 (2) 1.25 94 
2 K2CO3 (2) 2 88 
3 K2CO3 (2) 20 92 
4 K2CO3 (2) 20 61 
5 Na2CO3 (2) 48 75 
6 NaHCO3 (5) 48 70 
7 NaH  (2.5) 26 28 
 
The “one-pot” procedure was applied to the synthesis of different sultams, using several alkyl 
halides (Table 3). Good to acceptable yields of 4 were reached with ethyl, propyl, and butyl 
iodide, in DMSO at room temperature (entries 2‒5). In the reaction with BuI, other non-
hydrogen-bonding donor (non-HBD) solvents were tested, but only DMPU (entry 7) and NMP 
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(entry 8) gave comparable yields. In the reaction with benzyl bromide, an unexpected behavior 
was observed, both in DMSO and in MeCN. In fact, after a rapid conversion of 3a to the N-
benzylsulfonamide 7e, only minor amounts of 4e were isolated (entries 10-13). The reaction with 
allyl bromide gave a similar result (entry 14) indicating, most likely, that the introduction of the 
benzyl or allyl group increases the steric hindrance of both the intermediate open-chain 
sulfonamides 7e and 7f, reducing the cyclization rate, as confirmed by the scarce efficiency of the 
PTC ring-closing of N-benzyl sulfonamide 7e (4e in 45% yield) prepared, in turn, by N-
benzylation of 3a in 88% yield. 
 
Table 3 
 
entry RX solvent base (mol equiv) t (h) yield (%) 
1 MeI DMSO Cs2CO3 (2) 1.25 4a 94 
2 EtI DMSO K2CO3 (2) 20 4b 83 
3 EtI DMSO Cs2CO3 (4) 12 4b 81 
4 n-PrI DMSO K2CO3 (2) 24 4c 51 
5 n-PrI DMSO Cs2CO3 (4) 16 4c 50 
6 n-BuI DMSO K2CO3 (4) 48 4d 61 
7 n-BuI DMPU K2CO3 (2) 48 4d 58 
8 n-BuI NMP K2CO3 (2) 20 4d 62 
9 n-BuBr DMSO K2CO3 (2) 48 4d 37 
10 BnBr DMSO Na2CO3 (4) 20 4e 32 
11 BnBr DMSO Cs2CO3 (4) 12 4e 20 
12 BnBr MeCN Na2CO3 (4) 20 4e 15 
13 BnBr MeCN Na2CO3 (4) 20 4e 12 
14 AllylBr MeCN Na2CO3 (4) 24 4f 46 
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In order to solve this problem, we thought that the ring closure of the sulfonamide 3a without the 
alkylating agent, would lead to the non-alkylated sultam 8, a much more interesting compound. 
This molecule, in fact, is the single scaffold which could eventually be N-alkylated in a 
subsequent step, therefore this way represents a valid alternative to the “one-pot” cyclization. A 
screening of reaction conditions showed that PTC technique failed (Table 4, entry 1) even when 
drastic conditions were applied (entry 2); a change in the anhydrous alkaline carbonate indicates a 
decreasing yield along the series Na > K > Cs (entries 2-4), while any attempt to change the 
reaction solvent (entries 5,6) was unsuccesful. 
 
Table 4 
 
entry solvent base T(°C) t (h) Yield 8 (%) 
1 DMSO Na2CO3 25 90 - 
2 DMSO Na2CO3 80 90 28 
3 DMSO K2CO3 50 90 10 
4 DMSO Cs2CO3 50 90 8 
5 DMF Na2CO3 80 60 - 
6 MeCN Na2CO3 80 60 - 
 
 
After these negative results obtained under PTC conditions, we turned our attention to the 
cyclization of the N-unsubsituted sultams under homogeneous conditions, considering that it is 
well known that many organic soluble bases are able to enolize carboxylic derivatives. Among 
the bases employed  DBU gave the best yields (Table 5, entries 4,5); 1,4-
diazabycyclo[2.2.2]octane (DABCO, entry 3) gave low yields, while tetramethylguanidine 
(TMG, entry 2) gave good yields but in very long times. Also in this case, the choice of the 
solvent is important as demonstrated by the different yields obtained passing from DMSO (entry 
1) to the less polar DME (entries 4). 
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Table 5 
entry solvent base t (h) yield 8 (%) 
1 DMSO DBU 48 62 
2 MeCN TMG 80 96 
3 MeCN DABCO 24 54 
4 DME DBU 16 96 
5 MeCN DBU 20 98 
 
 
The application of the homogeneous methodology to the “one-pot” synthesis of the N-methyl 
benzosultam 4a starting from sulfonamide 3a with excess MeI, gave only low yields of the non-
alkylated benzosultam 8. Analogously, the cyclization of the N-methyl sulfonamide 7a failed, 
producing the correspondent sultam 4a only in modest yield (Scheme 5). 
 
 
 
 
Scheme 5 
 
To complete the synthetic procedure, the NH sultam 8 has been reacted under SL-PTC conditions 
with a series of alkyl halides RX (Table 6), and the desired N-alkyl tetrafluorobenzo sultams 4a-f 
were obtained in very good overall yields (74-90%), starting from sulfonamide 3a. 
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Table 6 
entry RX t(h) yield (%) 
1 MeI 18 4a 99 
2 EtI 48 4b 95 
3 n-PrI 48 4c 88 
4 n-BuI 48 4d 82 
5 BnBr 20 4e 85 
6 AllBr 20 4f 82 
 
These results clearly show that homogeneous cyclization followed by N-alkylation emerges as 
the best protocol to produce N-alkyl benzo[d]sultams, and preferred alternative to the “one-pot” 
cyclization, especially in the case of the bulky benzyl and allyl derivatives 4e and 4f. 
In summary, sulfonamides 3a have been cyclized to the corresponding benzo[d]sultams through 
two different and complementary synthetic pathways: N-Alkylation of open-chain sulfonamides 
3a with an alkyl halide, then cyclization of the intermediate N-alkylsulfonamide 7a-f under solid-
liquid phase transfer catalysis (SL-PTC) conditions, gave the corresponding N-alkylbenzosultams 
4a-f. Alternatively, using DBU as organic soluble base under homogeneous conditions, 
sulfonamides 3a were transformed into the unsubstituted benzosultams 8 that, in turn, can be N-
alkylated to sultams 4a-f (Scheme 6). 
 
Scheme 6 
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6.2 Enantiodivergent Synthesis of Chiral Benzo[d]sultams 
 
 
 
After having defined the optimal conditions to reach the highest yields for the cyclization step, 
we turned our attention to the stereoselective synthesis of our sultams: in fact, as we have seen in 
the previous chapter, the synthesis of optically pure benzo[d]sultams is a subject of great interest, 
even in the light of the very small number of synthetic methods available in literature. 
When we performed the SL-PTC “one pot” reaction on the optically pure sulfonamide S-3a, we 
found small but encouraging enantiomeric excess of benzosultams (Scheme 7) with the 
prevalence of the (-) isomer. 
 
Scheme 7 
 
Moreover, the variation of the alkylating agent led to a continuous, even if low, increase of ee’s 
with the increasing dimension of the alkyl chain, along with decreasing yields (Table 7). 
 
Table 7 
 
entry solvent RX t (h) yield (%) ee (%) 
1 DMSO EtI 20 83 16 
2 DMSO n-PrI 24 50 25 
3 DMF MeI 48 47 13 
 
The complete absence of an external source of stereochemical information, suggested to 
investigate the nature of the auto-induced stereoselectivity and the influence of the single reaction 
parameters of the cyclization process. 
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In the light of the very scarce results obtained under heterogeneous conditions, we turned our 
attention to the cyclization under homogeneous conditions. Since the ring-closing of sulfonamide 
S-3a with DBU as a base in CH3CN, as described before, leads to the racemic benzosultam, we 
decided to evaluate the use of an additive in the system sulfonamide-DBU, looking for additive-
base-substrate interactions capable of inducing the formation of a chiral adduct, which can evolve 
enantioselectively toward the desired benzosultam. 
Preliminary positive results have been obtained by reacting S-3a with DBU, in acetonitrile at 
25°C in the presence of 0.2 molar equivalents of a diamine: the choice fell both on simple 
diamines (Table 8, entries 1-4) and on more complex chiral diamines (entries 5-8). All these 
reactions gave an almost quantitative yield of 8a and the ee ranging from 19 to 23%. The results 
show that the added base induces a general effect, probably due to a modulation of the DBU basic 
strength, rather than to the formation of a chiral complex.  
 
Table 8 
 
entry diamine yield (%) ee (%) 
1 
 
98 21 
2 
 
98 20 
3 
 
98 19 
4 
 
98 23 
5 
 
98 21 
6 (RR)-1,2-diamino cyclohexane 97 23 
7 (SS)- 1,2-diamino cyclohexane 98 22 
8 rac-1,2-diamino cyclohexane 98 22 
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This  hypothesis is confirmed by the reaction of the achiral bases (entries 1-4) and by the use of 
both the enantiomer of 1,2-diaminocyclohexane (entries 6-7), and of their racemic mixture (entry 
8). All these reactions, in fact, lead to nearly identical ee values, with prevalence of the same 
enantiomer (-)-8a. 
Similar results were obtained by addition of both a chiral amino alcohol (Scheme 8) and cinchona 
alkaloid derivatives, compounds that are often used in asymmetric synthesis. 
 
 
Scheme 8 
 
Several experiments were then conducted with (1R,2S)-N-methylephedrine as additive and by 
varying the solvent (Table 9): the best ee’s were obtained in ethereal solvents like THF (entry 2) 
and DME (entry 3). In DCM (entry 4) both ee’s and yields were very low, while in 
chlorobenzene and toluene quantitative yields and, conversely, poor ee values were obtained 
(entries 5-6). 
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Table 9 
 
entry solvent yield (%) ee (%) 
1 MeCN 98 22 
2 THF 98 24 
3 DME 98 33 
4 DCM 85 14 
5 PhCl 98 18 
6 toluene 95 18 
 
An improved result was reached by using DME as a solvent and DBU alone and (-)-8a was 
isolated in quantitative yield and with 35 % ee in favor of the (−) isomer (Scheme 9). 
 
 
 
Scheme 9 
 
 
 
With the aim of  screening the effects of both the strength and the structure of the base/additive, 
we carried out experiments (Table 10)  in DME with a series of bases (Figure 1) similar to DBU 
regarding structural characteristics and/or basicity. 
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Figure 1. Organic bases used in the sultam 8a synthesis. In parentheses, pka value of the 
conjugate acid in acetonitrile. 
 
 
Among bicyclic bases, only MTBD (entry 4) was partially effective, giving a ee comparable to 
that obtained with DBU, but in a longer reaction time. Surprisingly, BTMG completely reversed 
the enantioselectivity in favor of the (+) isomer with the highest ee found until now (entry 6). 
 
Table 10 
 
 
 
 
 
 
 
 
 
 
 The influence of the ester group bulkiness was also analyzed (Table 11): as expected, the larger 
the alkyl group, the higher the ee, but the longer the reaction time and, when BTMG was used, 
only partial conversion was reached (entry 5). By decreasing the reaction temperature to 0 °C 
better ee’s were reached, but the reaction rate drastically dropped, especially in the case of tert-
butyl ester (entry 6). Considering these results, we decided to conduct the following experiments 
on methyl ester (S-3a) by operating at 25 °C.  
 
entry base solvent t (h) yield (%) ee (%) 
1 DBU DME 8 98 (-) 35 
2 DBN DME 16 94 (-) 14 
3 TBD DME 16 98 < 5 
4 MTBD DME 20 56 (-) 38 
5 TMG DME 16 90 < 5 
6 BTMG DME 90 95 (+) 80 
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Table 11 
 
 
 
 
In the light of the possibility to choose between chiral and achiral base/additive, we focused our 
attention on the good results obtained with BTMG (entry 5).  
Interesting results were achieved using the system BTMG/DBU in variable molar ratios (Table 
12): the use of a large molar excess of BTMG (entries 1−3) with decreasing quantity of DBU led 
to prolonged reaction times, but gave good ee’s. The best ee of the methyl ester (-)-8a was 
obtained using equimolar amount of the two bases (entry 5). A similar behavior was found with 
the tert-butyl ester S-3d, which gave the desired sultam (-)-8d in 54% ee in longer reaction times 
(entry 6). 
  
entry R
1
  base T (°C) t (h) product yield (%) ee (%) 
1 Me 3a DBU 25 8 8a 96 (-) 35 
2 Et 3b DBU 25 16 8b 94 (-) 44 
3 iPr 3c DBU 25 20 8c 93 (-) 48 
4 tBu 3d DBU 25 20 8d 91 (-) 52 
5 tBu
 
3d BTMG 25 140 8d 37 (+) 88 
6 tBu 3d DBU 0 160 8d 66 (-) 68 
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Table 12 
 
entry R BTMG (mol) DBU (mol) t (h) product (%) ee (%) 
1 Me 4 2 20 (-)-8a 96 50 
2 Me 4 0.5 20 (-)-8a 96 48 
3 Me 4 0.25 30 (-)-8a 93 47 
4 Me 2 1 20 (-)-8a 95 48 
5 Me 1 1 20 (-)-8a 91 53 
6 tBu 1 1 144 (-)-8d 90 54 
 
To better understand the outcome of the cyclization reaction, it was then conducted by using 
molar amounts of DBU as a base in association with variable quantities of BTMG. In fact, the 
runs carried out by varying the ratio of the basic system DBU/BTMG (Figure 3) evidenced a 
strong synergistic effect between the two bases on the enantioselectivity, i.e. the ee value 
increased in favour of the retention product  by increasing the amount of BTMG, up to a 
maximum (ee 67%) with a 7:93 DBU/BTMG molar ratio; as reported before, by using only 
BTMG as a base (Table 13, entry 7), the enantioselectivity drastically changed in favour of  the 
inverted configuration (Figure 2, right side of the graphic). 
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Table 13 
 
 
 
 
 
 
Figure 3. Synthesis of sultam 8a under homogeneous conditions using the basic system 
DBU/BTMG (2 mol equiv.): influence of the bases ratio variation on the er. On the abscissas is 
the molar percentage of BTMG; on the ordinates is the percentage of the main enantiomer. 
entry BTMG (×mol %) t (h) yield (%) ee (%) er (%) 
1 0 8 98 (-)35 (-)68 
2 25 16 95 (-)44 (-)73 
3 50 20 96 (-)53 (-)77 
4 75 24 95 (-)63 (-)82 
5 93 24 94 (-)67 (-)83 
6 95 24 97 (-)64 (-)84 
7 100 90 95 (+)80 (+)90 
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We have also observed that the use of DME as the reaction solvent is essential for the 
enantiodivergent  course of this process. In fact, by operating in more polar solvents (Table 14), 
such as DMSO or MeCN (entries 3-6), longer reaction times and very low ee’s were found. 
Table 14 
 
entry solvent base t (h) yield  (%) ee (%) 
1 DME BTMG/DBU 24 (-)-8a 94 67 
2 DME BTMG 90 (+)-8a 95 80 
3 DMSO BTMG/DBU 1 week (+)-8a 70 < 5 
4 DMSO BTMG 1 week (-)-8a 30 < 5 
5 MeCN BTMG/DBU 48 (+)-8a 38 13 
6 MeCN BTMG 48 (+)-8a 76 10 
 
Interestingly, the application of the best cyclization conditions (BTMG/DBU basic system or 
BTMG alone in DME) to S-3a, in the presence of an alkylating agent such as allyl bromide, gave 
the non alkylated sultam. On the contrary, by operating in DMSO we isolated the racemic N-
allylated  sultam 4f (Table 15). 
Table 15 
 
entry solvent base t (h) yield  (%) ee (%) 
1 DME BTMG/DBU 24 (-)-8a 94 67 
2 DME BTMG 90 (+)-8a 95 80 
3 DMSO BTMG/DBU 2 4f  60 ‒ 
4 DMSO BTMG 2 4f  85 ‒ 
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Furthermore, the optically pure N-alkylated tertiary sulfonamide 22, prepared under SL-PTC 
conditions,  gave in a short reaction time the corresponding N-allyl sultam (-)-4f  in good yields, 
but with very low ee’s, in the presence of both BTMG and DBU/BTMG (Table 16). 
 
Table 16 
 
In order to analyze the effect of the Hα acidity on the stereoselectivity of the process, we 
modulated the mesomeric (M) and inductive (I) effects on the aryl moiety of the starting 
phenylglycine. Several  sulfonamides were synthesized: sulfonamide 9a (Scheme 10) bearing a 
para-nitro group (-M, -I);  9b having an orto-chlorine atom (+M, -I); the para-biphenyl (+I) 
derivative 9c (Scheme 12); sulfonamides 9d,e containing strong para-PhCH2O (Scheme 13) and 
para-MeO (Scheme 14) electrondonating groups (+M).  
As regards the phenylglicine derivative 9a bearing the para-nitro group position, the direct 
nitration of the sulfonamide S-3a was the only synthetic strategy we found to isolate an 
enantiomerically enriched (ee 70%) product (Scheme 10). 
 
 
Scheme 10 
 
  
entry base t (min) yield  (%) ee (%) 
1 BTMG/DBU 15 (-)-4f  77 8 
2 BTMG 20 (-)-4f  86 21 
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The enantiopure (pentafluorobenzene)sulfonamide 9b was obtained by N-sulfonylation of the 
corresponding commercially available α-amino ester 6b (Scheme 11). 
 
 
Scheme 11 
 
Commercially available 4-hydroxy-D-phenylglycine 6c was used as starting material for the 
synthesis of sulfonamide 9c (Scheme 12). After esterification of the carboxylic function and 
protection of the amino group, the intermediate 10 was made to react with 
(trifluoromethane)sulfonic anhydride, to generate the corresponding triflate 11, that was isolated 
in good yield. Suzuki cross-coupling reaction with phenylboronic acid in toluene, using 
tetrakis(triphenylphosphine)palladium as catalyst, led to the desired N-tert-butyloxycarbonyl-4’-
biphenylglycine methyl ester 12 in 84% yield. The compound 12  was N-deprotected under acidic 
conditions to the hydrochloride of 13, which is obtained as free amino ester by washing  with 
aqueous saturated solution of NaHCO3; 13 was finally sulfonylated  as usual to the target 
compound 9c. 
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Scheme 12 
 
Sulfonamide 9d (Scheme 13) was obtained from (4-hydroxyphenyl)glycine 6c by alkylation  with 
benzyl bromide, in the presence of copper(II) sulfate, to the benzyloxy derivative 14 that, in turn, 
was converted into the target sulfonamide 9d by first esterification, followed by  N-
arylsulfonylation as usual.  
 
Scheme 13 
 
The sulfonamide 9e (Scheme 14) was prepared starting from the N-Boc amino acid 15 that is 
transformed into its methyl ester 16 by reaction with diazomethane. The ester was N-deprotected 
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under acidic conditions to the hydrochloride 17, which is sulfonylated  as usual to the target 
compound 9e. 
 
 
Scheme 14 
 
The results obtained in the cyclization reactions confirm that the presence of a substituent in para 
or ortho position effectively modulates the sulfonamide reactivity. In particular, the presence of 
an electron withdrawing group (EWG) on the aromatic ring was detrimental to the overall 
process, decreasing the reaction enantioselectivity. Actually, practical complete racemization was 
obtained starting from compounds 9a,b with both the base systems (Table 17, entries 1-4). On the 
contrary, the presence of an electron donating group (EDG) in compounds 9ce produced good 
ee, the stronger the EDG the higher the ee value (entries 5-10). Furthermore, as found for S-3a, 
the reactions promoted by BTMG are sensibly slower than those promoted by BTMG/DBU also 
in the case of substrates 9. 
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Table 17 
 
 
 
Finally an important progress toward the obtainment of enantiopure benzosultams, was the N-
alkylation of the enantio-enriched sultams here before. The non-racemic sultams were reacted 
under SL-PTC conditions with different alkyl halides and the N-alkyl derivatives 4 were isolated 
in good yields (Table 18). 
 
  
entry Ar sulfonamide base product yield (%) ee (%) 
1 4-NO2C6H4 9a A (+)-18a 94 <5 
2 4-NO2C6H4 9a B
 
()-18a 97 <5 
3 2-ClC6H4 9b A (+)-18b 18 5 
4 2-ClC6H4 9b B ()-18b 19 15 
5 4-PhC6H4 9c A (+)-18c 94 56 
6 4-PhC6H4 9c B ()-18c 98 64 
7 4-BnOC6H4 9d A (+)-18d 35 96 
8 4-BnOC6H4
 
9d B ()-18d 83 94 
9 4-MeOC6H4
 
9e A (+)-18e 70 94 
10 4-MeOC6H4 9e B (-)-18e 79 95 
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Table 18 
 
 
 
 
 
 
 
The N-alkylated benzosultams 4 were then subjected to preferential crystallization (Table 19). By 
this protocol, the optically pure enantiomers R-4f and S-4g were recovered from the mother 
liquor, after removal of the crystallized racemic mixture by filtration and evaporation of the 
solvent, whereas R-4c crystallized in an enantiopure form and the racemic mixture remained in 
the mother liquor. All these enantiomers were isolated in theoretical yields, i.e. equal to the 
enantiomeric excess values of the starting compounds. 
  
Table 19 
 
  Solution  Crystallized 
 R
2
 yield (%) ee (%)  yield (%) ee (%) 
R-4f (iPr2O/hexane) Allyl 67 > 99  30 0 
R-4c (iPrOH) Pr 30 0  68 > 99 
S-4g (iPrOH) Me 86 > 99  14 0 
 
The non-alkylated sultam (-)-8a was the unique compound that did not crystallize with this 
technique, but was obtained through deprotection of the N-allyl derivative (-)-21c with 
tetrakis(triphenylphosphine)palladium and dimedone (Scheme 15). 
 R
1
 ee (%)  R
2
X product yield (%) ee (%) 
(-)-8a Me 68  AllylBr 4f 94 68 
(-)-8a Me 68  PrI 4c 95 68 
(+)-8d tBu 87  MeI 4g 93 87 
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Scheme 15 
 
 
The single crystal X-ray analysis allowed us to assign the right configuration: for the cyclization 
with DBU/BTMG we observed (Figure 4) the retention product R-4c starting from S-3a (Scheme 
16); the descriptor change occurs only for a change in priority and the reaction, even if occurring 
with retention, formally goes through inversion of configuration. 
 
 
Scheme 16 
 
Figure 4 
 
Furthermore, retention of configuration it is also observed for the cyclization with DBU/BTMG 
starting from S-3a (Figure 5, Scheme 17) and using allyl bromide as the alkylating agent. 
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Scheme 17 
 
Figure 5 
 
On the other hand, cyclization with BTMG, led to the inversion product (S) (Figure 6). 
 
Scheme 18 
 
   
 
Figure 6 
81 
 
 
In order to synthesize new and more versatile compounds and to go deeper inside into the 
reaction mechanism, we decided to investigate the role of the fluorine substituent by preparing 
and reacting differently halogenated sulfonamides. We prepared a series of sulfonyl chlorides 
bearing different substituents on the aromatic fluorinated moiety. 
We choose, as starting compounds, the commercially available (polyfluoro)halobenzenes  that 
were sulfonated with 20% oleum, following a literature procedure applied on several chlorinated 
analogues,
91
 and good yields were obtained for all the sulfonic acids (Scheme 19). The sulfonic 
acids were subsequently chlorinated by reaction at 110-120 °C for 30 minutes with neat 
phosphorus pentachloride, followed by a rapid quench in ice and extraction. With this protocol, 
we do not observe any substitution at the aromatic ring by the chloride anion. 
 
 
Scheme 19 
 
The sulfonyl chlorides 5d-f were condensed with optically pure phenylglycine methyl ester to 
give the corresponding  sulfonamides S-26a-e in good yield, after crystallization or 
chromatographic purification (Scheme 20). 
 
Scheme 20 
                                                 
91 Medina, J. C., Roche, D., Shan, B., Learned, R. M., Frankmoelle, W. P., Clark, D. L. Bioorg. Med. Chem. Lett. 1999, 9, 1843-
1846. 
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The best base/additive conditions, i.e. the DBU/BTMG basic system, were applied to the 
cyclization of the differently halogenated sulfonamides S-26a-e (Scheme 21), reaching good 
yields and modest ee’s of the resulting benzosultams. 
 
 
Scheme 21 
 
 
As found in the case of the (pentafluorobenzene)sulfonamide S-3a, the cyclization of 
(polyhalobenzene)sulfonamides S-26a-c using BTMG alone, gave (+)-27a-c in very good yield 
and ee, that decreases with the decrease of the activation toward the aromatic nucleophilic 
substitution. Furthermore, analogously to that found for (+)-8a, the (polyhalobenzo)sultams (+)-
27a-c presented an inversion of configuration, respect to that observed with other bases (Scheme 
22). 
 
Scheme 22 
 
As regards the mechanism of the enantiodivergent ring-closing reactions (Scheme 23), we 
suppose that the stronger base (BTMG) first N-deprotonates the open-chain sulfonamide S-3a 
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forming the tight ion-pair A. In the presence of catalytic amounts of the less sterically hindered 
DBU (path a), this base coordinates the α-hydrogen atom through an intermolecular attack from 
the less crowded side (intermediate B) forming the α-enol that, in turn, cyclizes to the sultam with 
retention of the starting configuration, releasing DBU to the catalytic cycle. In the presence of 
BTMG alone (path b) the ion-pair, through an intramolecular hydrogen bond, is forced to  form 
the more crowded intermediate C, which evolves to the β-enol that forms the inversion sultam.  
To support our hypothesis, it is worth noting that the DBU/BTMG promoted process is 
kinetically controlled  and it is faster than the BTMG termodinamically controlled process. For 
this reason, in path a, the formation of the retention product is favoured, even if derives from an 
intermolecular attack by DBU ( Scheme 23). 
In conclusion, in this thesis I have described the MOC stereodivergent synthesis of a series of  
enantiomerically enriched polyfluorobenzo[d]sultams. The interest of  this protocol resides in the 
possibility of making use of the chirality of a starting sulfonamide single enantiomer to 
synthesize the target sultams in both absolute configurations. The choice of the organic base 
system is the determining factor to direct the cyclization toward either enantiomer. In fact, the 
steric hindrance of the base regulates its access to the α-hydrogen, that can be approached 
alternatively through an inter- or an intramolecular attack. A further peculiarity of this protocol is 
the use, as starting compound, of an α-amino acid derivative bearing a mono-substituted 
sulfonamidic NH function. 
Actually, in our knowledge, C-alkylation reactions under MOC conditions of such type of 
compounds have not been described until now. Furthermore, MOC conditions are ineffective on 
symmetrically N,N-disubstitued substrates, therefore all MOC reactions reported were carried out 
using compounds having two different substituents on the nitrogen atom (e.g., sulfonyl and 
carbamoyl, or two different carbamoyl, etc.). To explain the reactivity of our starting 
sulfonamides, we supposed that the very stable tight ion-pair formed by BTMG and the substrate 
(intermediate B in Scheme 23)  mimics an asymmetrically N,N-disubstitued sulfonamide hence, 
in an analogous way, it stabilizes a specific conformation of the formed enol. 
The behaviour of NH sulfonamides shown in the presence of hindered  organic bases, open the 
possibility to study the synthesis under MOC conditions of several amino acid derivatives, 
without the need of introducing two different N-activating groups, thus avoiding the cleavage step 
of one of them.  
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REMARKS:  
 The use of phenylglycine is essential for the formation of a chiral enol on a secondary 
solfonamide due to the high acidity of the Cα hydrogen atom. 
 The reaction with  the couple of bases BTMG/DBU is four times faster  than  the reaction 
with BTMG alone. 
 In DME, BTMG is more basic than DBU. 
 
 
Scheme 23 
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6.3 Chiral Benzo[d]sultams Derived from Other Optically Pure α-
Amino Acids 
 
 
 
In an effort to synthesize novel enantiopure chiral benzo[d]sultams bearing in the Cα position a 
substituent different from phenyl, thus having a less acidic Hα than  that of phenylglycine, we 
conducted several experiments on a number of optically pure amino acid derivatives, structurally 
different from. 
Differently from phenylglycine derivatives, N-unsubstituted (polifluoro)benzenesulfonamides 
derived from alkylglycine did not react under the action of any base (or basic system) that was 
used in our screening.  In fact, in all cases, the starting compounds S-18 (R
1
 = Me, Bn, 
CH2CH(CH3)2, MeSCH2CH2) were recovered unchanged from the crude. As we describe before 
exhaustively, we found that the benzosultams form only from the corresponding N-alkylated 
sulfonamides S-20 (Scheme 24). 
 
 
Scheme 24 
 
 
To identify the best reaction conditions for the enantioselective cyclization of these N-alkyl 
sulfonamides, we chose as model compound the N-metyl phenylalaninate sulfonamide S-19a. 
This compound was prepared in good overall yield by N-methylation under SL-PTC conditions 
of sulfonamide  S-18a (Scheme 25) that, in turn, was obtained by condensation, as usual,  of 
methyl phenylalaninate hydrochloride 6c with (pentafluorobenzene)sulfonyl chloride (5a). 
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Scheme 25 
 
Compound S-19a was then reacted in DME as solvent, by using several bases (Table 16). The 
best results were reached by using DBU, at -20 °C: the target benzosultam  R-20a, with retention 
of configuration, was obtained in moderate yield and 95% ee (entry 1). On the contrary, with 
BTMG (entry 2) S-19a was unreactive. Very poor yields were reached  with the bicyclic bases 
DBN and MTBD (entries 2 and 4), and also in these cases the retention R sultam was the major 
enantiomer isolated. 
 
Table 16 
entry base T (°C) t  yield (%)  ee (%) 
1 DBU -20 2 h 63 95 
2 BTMG -20 20 h - - 
3 DBN 25 7 d 5 93 
4 MTBD 25 7 d 13 87 
 
 
  
The cyclization reaction gave complete conversion of the starting sulfonamide by using these 
strong organic bases, but with low selectivity. In fact, together with the desired sultam, relevant 
amounts of by-products were isolated. After an accurate analysis of the reaction products of S-
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19a with DBU (Table 16, entry 1), we found that two derivatives of nucleophilic attack of DBU 
on the fluorinated aromatic ring were also formed: the -caprolactam containing para-substituted 
sulfonamide S-21a, and the analogously 4’-substituted sultam R-22a, in which the  4’-fluorine 
atom was replaced  by this novel DBU derived amino-lactame (Scheme 26). 
 
 
Scheme 26 
 
 
In a similar way, by using DBN (Scheme 27) the corresponding -butyrolactam S-21b was 
isolated in 82% yield, while very low amounts of the sultam R-20a were detected in the crude.  
 
 
 
Scheme 27 
 
In the literature, is reported that amidines - such as DBU and DBN
92
 - and guanidines - such as 
BTMG  and MTBD
93
 - are very strong organic nitrogen-bases (23.89 < pKa < 25.44, in MeCN)
94
, 
but very weak nucleophiles.
95
   
                                                 
92 (a) Gierczyk, B.; Schroeder, G.; Brzezinski, B. J. Org. Chem. 2003, 38, 3139-3144. (b) Leffek, K. T.. Pruszynski, P.; 
Thanapaalasingham, K. Can. J. Chem. 1989, 67, 590. 
93 Schwesinger, R.; Willaredt, J.; Schlemper, H.; Keller, M.; Schmitt, D.; Fritz, H. Chem. Ber. 1994, 127, 2435. 
94 Gais, H.-J. Vollhardt, J.; Kruger, C. Angew. Chem. 1988, 100, 108. 
95 (a) Schwesinger, R. Nachr. Chem. Technol. Lab. 1990, 38, 1214. b) Pietzonka, T.; Seebach, D. Chem. Ber. 1990, 124, 1837. 
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These tertiary amines are widely used in organic synthesis as bases, especially in 
dehydrohalogenation. Furthermore, DBU and  DBN are described to act as nucleophilic reagents. 
The nucleophilic behavior of DBU and DBN has also recently been reported in two other cases: 
Reed et al.
96
 described them in reactions with halogenated compounds of main group elements; 
Lammers et al.
97
 have also observed nucleophility in the reaction with 4-halo-3,5-dimethyl-1-
nitro-1H-pyrazoles, obtaining lactam-type products in which one of the bicyclic rings in DBU 
and DBN was opened by water.
 
 
 
 Regarding the reaction mechanism, e.g. in the case of DBU as nucleophile (Scheme 28), through 
7-N attack on the 4’-F of the sultam R-20a, the fluoride salt A is formed, which by hydrolysis via 
aminoacetal B gives the lactam R-22a. 
All these results indicate that the fluorine atoms present in the para position of the sulfonamide 
S-19a and sultam R-20a  are highly susceptible to nucleophilic aromatic substitution (SNAr). 
  
Scheme 28 
 
                                                 
96 Reed, R.; Reau, R.; Dahan, F.; Bertrand, G. Angew. Chem. Int. Ed. Engl. 1993, 32,399-401. 
97 (a) Lammers, H.; Cohen-Fernandes, P.; Habraken, C. L. Tetrahedron 1994, 50, 865. (b) Sutherland, J. K. J. Chem. Soc. Chem. 
Commun. 1997, 325. (c) Perbost, M.; Lucas, M.; Chavis, C.; Imbach, J.-L. J. Heterocycl. Chem. 1993, 30, 627. (d) Chambers, R. 
D.; Roche, A. J.; Batsanov, A. S.; Howard, J. A. K. Chem. Commun. 1994, 2055. 
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It is well known
 
that in SNAr on polyfluorinated substrates the nucleophile attack is governed by 
the relative fluorine atoms position, rather than by the activating effects of other functional 
groups possibly present in the aromatic ring. Furthermore, it has been determined that (Scheme 
29) for an aromatic a fluorine F leaving group, the F-meta is powerfully activating, while the 
ortho-fluorine is less activating, and the para-fluorine has an effect similar to a hydrogen 
substituent. The negatively charged primary addition product is stabilized best by fluorine in the 
ortho position, then by meta-F, and least in the para position. Only for attack of the nucleophile 
in the para position (right) the complex is stabilized by two ortho and two meta fluorines. 
Scheme 29 
 
To confirm our hypothesis  N-methyl (tetrafluorobenzo)sultam R-20a  has been reacted with 
DBU and the mono-substitution was obtained. The most labile position is the fluorine in 5-
position, probably due the activation both by fluorine in 7-position and by the sulfonyl group in 
1-position, and the 5(-caprolactam)-sultam derivative R-22a was isolated as sole product in 
quantitative yield (Scheme 30). 
 
Scheme 30 
 
On the contrary, treatment of  open chain 4’(-caprolactam)-sulfonamide S-21a  with DBU at 25 
°C in DME  did not give the cyclization reaction, and the starting compound  was recovered 
unchanged (Scheme 31). 
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Scheme 31 
 
To increase the selectivity of the cyclization step, we carried out several experiments using DBU 
as base, varying the nature of the solvent and the temperature (Table 17): all these reactions gave 
low yields of benzosultam R-20a, but with good enantioselectivity. The best result for this series 
of reactions was reached in DME at -50 °C (entry 1), where the by-products are reduced to the 
minimum, confirming once again that this is the solvent of choice. 
 
Table 17 
 
 
 
  
    R-20a   
entry solvent T (°C) t (h)  yield (%) ee  (%) S-21a(%) R-22a(%) 
1 DME -50 4  66 95 8 5 
2 DMF -50 12  40 92 14 10 
3 CH2Cl2 -50 120 39 94 10 7 
4 THF -20 7 50 95 13 8 
5 DIOX 25 0.25 - - 40 11 
6 Diglyme -20 2 50 93 9 6 
7 Et2O -20 7 37 94 10 8 
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In light of these results, the reactivity of S-19a in DME as the solvent and in the presence of  
variable quantities of DBU was investigated (Table 18). The best results were attained by using 4 
equivalents quantitative of DBU (entry 1). By reducing the amounts of DBU (entries 2-5) the 
benzosultam R-20a yield progressively decreased, the by-products amount increased, and the 
reaction time became longer. When a catalytic amount of DBU was used, the reaction rapidly 
stopped because this base is quenched from HF formed (entry 7).  
 
Table 18 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, we decided to investigate the cyclization reaction of the N-allyl-phenylalanine derivative 
S-19d, which gave the corresponding benzo[d]sultam in 70% yield end 96% ee (Scheme 32).  
 
 DBU    R-20a 
entry (mol equiv.) T (°C) t (h) yield (%) ee (%) 
1 4 -20 2 63 95 
2 2 -20 8 56 95 
3 1 -20 14 50 95 
4 1 0 6 38 91 
5 1 25 0.5 20 90 
6 2 25 0.25 31 90 
7 0.1 25 72    
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Scheme 32 
 
To eliminate in the cyclization process any interference from the SNAr, which reduces the amount 
of the target sultam, we decided to synthesize new and more versatile sulfonamides bearing in the 
4’ position a bromine or a hydrogen atom instead of the fluorine atom. We choose, as starting 
compounds of the synthetic plan, the commercially available 3-bromo-1,2,4,5-tetrafluorobenzene 
and 1,2,4,5-tetrafluorobenzene, which have been converted to the corresponding mono-sulfonyl 
chlorides 5b,c by chlorosulfonylation  with sulfuric chlorohydrin/thionyl chloride, as described in 
the literature
98
 (Scheme 33). 
 
Scheme 33 
 
 
The corresponding  sulfonamides 18b,c  derived from phenylalanine methyl ester, were 
synthesized in enantiopure form and in good yields (89-92%) (Scheme 31) by condensation with 
these sulfonyl chlorides at 0−25 °C, in dichloromethane with DIPEA, as usual. Finally the N-
alkylation with methyl iodide under SL-PTC conditions (Scheme 34) led the desired sulfonamide 
derivatives 19b,c in excellent  yields (see Experimentals). 
 
                                                 
98 Vullo, D.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T.;  Bioorg. Med. Chem. Lett. 2004, 14, 2351–2356 
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Scheme 34 
 
 
The best reaction conditions found, i.e. 4 mol equivalents of DBU and DME as solvent, were 
applied to the cyclization of this differently substituted sulfonamides S-19b,c (Table 19), 
reaching good yields and ee’s of the resulting benzosultams R-20b,c. 
 
Table 19 
 
 
 
 
 
 
 
 
This strategy has been successfully applied to different optically pure α-amino acid derivatives 
6d-g [alanine (6d), leucine (6e), methionine (6f) and tyrosine (6g)], thus performing the synthesis 
of  enantio enriched polyfluorobenzo[d]sultams in few steps.  
entry X T (°C) t (h) yield (%) ee 
1 Br -20 8 R-20b 87 96 
2 H 25 48 R-20c 82 95 
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The sulfonamide derivatives S-23ad were prepared in good yields (78-90 %) by condensation of 
the α-amino acid methyl ester hydrochlorides 6d-g and the arylsulfonyl chloride 5b,c (Table 20). 
The subsequent N-methylation of compounds S-23ad under SL-PTC conditions gave the N-
methyl open chain sulfonamides S-24ad in quantitative yields (95-96%) and in enantiopure 
form (Table 20). 
 
Table 20 
 
 
 
Sulfonamides S-24a-d were then cyclized by operating at -20 °C to the corresponding 
benzo[d]sultams R-25a-d  (Table 21) that were isolated in good yields in the case of alanine 
derivatives (entries 1,2), but in very modest yields when leucine derived sulfonamides  were 
made to react (entries 3,4). On the contrary, as regards the ee’s, the larger the amino acid side 
chain the higher the ee value found. 
  
entry R
1
 X yields (%)  yields (%) 
1 Me (6d) Br S-23a 90  S-24a 95 
2 Me (6d) H S-23b 81  S-24b 96 
3 Me2CHCH2 (6e) Br S-23c 83  S-24c 96 
4 Me2CHCH2 (6e) H S-23d 78  S-24d 96 
95 
 
 
Table 21 
 
 
 
 
 
 
 
This methodology was extended also to methionine and methionine derived sulfone and 
sulfoxide. The sulfonamides S-23e-f derived of methionine was obtained in good yields (84-89%, 
respectively) using the classical reaction conditions by condensation of L-methionine methyl 
ester 6f, with the arylsulfonyl chlorides 5b,c (Scheme 36). 
 
 
Scheme 36 
 
The successive N-methylation under SL-PTC conditions with excess MeI, gave the N-methyl 
open chain sulfonamides S-23e,f in lower yields, because alongside the N-alkylation is also 
present the S-alkylation compound (Scheme 37). To eliminate this by-product, we used 1 
equimolar amounts of substrate and alkylating agent. Under these conditions, we obtained the 
target N-alkyl sulfonamides S-24e,f in moderate yields (69-70%). 
 
entry  R1 X t (h) yield (%) ee (%) 
1 S-24a Me Br 24 R-25a  83 35 
2 S-24b Me H 5 day R-25b  75 27 
3 S-24c Me2CHCH2 Br 5 day R-25c  42 95 
4 S-24d Me2CHCH2 H 1 week R-25d  30 69 
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Scheme 37 
 
Proteins and peptides are susceptible to oxidative damage through reaction of certain amino acids 
with oxygen radicals present in their environment. Oxidation can alter protein physiochemical 
characteristics (e.g., folding and subunit association) and lead to aggregation or fragmentation. 
Methionine is an essential amino acid and is, together with cysteine, one of the two sulfur-
containing amino acids. Met is usually found buried within proteins because of its quite 
hydrophobic side chain. Met and Cys can be easily oxidized on their sulfur atoms to give the 
related sulfoxides and sulfones. 
With the aim of avoiding the parasitic S-methylation reaction and having a more stable Met 
derivative, we synthesized in quantitative yields (Scheme 38) the methionine derived sulfoxides  
26a,b by oxidation of N-alkyl sulfonamides S-24e,f with NaIO4. 
 
 
Scheme 38 
 
Methionine sulfone 27 was obtained in excellent yield by oxidation of S-24e at 25 °C with 2.1 
mol equivalents of meta-chloroperoxybenzoic acid (Scheme 39). 
 
 
Scheme 39 
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The sulfonamides of methionine (S-24e-f) and of its S-oxidized  derivatives (26e,f and 27) were 
made to react under the best cyclization conditions (DBU in DME), giving the corresponding 
benzosultams (Table 22) in good (entries 1 and 4) to moderate yields (entries 2,3 and 5). Low ee’s  
were reached from the sulfide and sulfone derivatives (entries 1,2 and 5), while unexpectedly the 
sulfoxides 26e,f gave only racemic mixtures of all the possible sultam diastereisomers (i.e. de 
0%).  At this point of the research, our knowledge of the reaction mechanism  it is not sufficient 
for the comprehension  of the stereochemical behavior of these sulfur-containing compounds, and 
further experiments should be done. 
 
Table 22 
 
 
 
 
 
 
 
 
The results obtained until now, indicate a strong reactivity dependence on the increasing 
dimension of starting α-amino acid side chain. As expected, the smaller the steric hindrance near 
the reacting center, the greater the reaction reactivity. 
Finally, we decided to investigate in the synthesis of benzosultams starting from tyrosine, 
structurally and sterically similar to phenylalanine, but bearing a para-hydroxy function that 
could act as activating element due to its electrodonating ability. 
The reaction of L-tyrosine methyl ester (6g) with (3-bromo-1,2,4,5-tetrafluorobenzene)sulfonyl 
chloride 5b, and (1,2,4,5-tetrafluorobenzene)sulfonyl chloride 5c, using the classical reaction 
entry sulfonamide R
1 
X t (h) yield (%) ee (%) 
1 S-24e MeSCH2CH2 Br 18 R-25e 70 57 
2 S-24f MeSCH2CH2 H 24 R-25f 52 35 
3 26e MeSOCH2CH2 Br 24 28e     54  
4 26bf MeSOCH2CH2 H 48 28f     82  
5 S-27 MeSO2CH2CH2 Br 48 R-29  49 43 
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conditions (DIPEA, CH2Cl2) gave poor yields of the corresponding N-sulfonamides S-23g,h  
(Scheme 36). The phenol hydroxy group, due to its acidity, was easily deprotonated and the 
derived phenoxide anion competed with the α-sulfonamido anion as a nucleophile, and significant 
amounts of N,O-bis(sulfonyl)tyrosine methyl esters S-23i,j were produced. Both mono- and bis-
sulfonylamides were made to react with DBU, but all these compounds resulted unreactive under 
the usual cyclization conditions (Scheme 40). 
 
 
Scheme 40 
 
Sulfonamides S-23g‒j were regioselectively N-methylated under SL-PTC conditions (Scheme 
41). The corresponding N-methyl open chain sulfonamides S-24g,h, having the free phenol 
hydroxy function, did not react under the action of DBU and were recovered unchanged. 
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Scheme 41 
On the contrary the sulfonamides S-24i,j have been cyclized with DBU in DME and the 
corresponding benzosultams were isolated in good yields end excellent ee’s (Table 23). These 
results are similar to that obtained with the phenylalanine derivatives. 
 
Table 23 
 
 
 
 
 
 
 
As regard the reaction mechanism (Scheme 42) of the cyclization of N-alkyl substituted 
sulfonamides, we can postulate the equilibration of sulfonamide between conformers A and B. 
Conformer A, which is less sterically hindered, evolves into the enol C that, in turn, gives the 
sultam with complete configuration retention. On the contrary, the less favored conformer B 
shows a strong steric interaction between the fluorinated aromatic ring and the α-amino acid side 
chain, as shown in Scheme 42. Intermediate B, through the enol D, could evolve into the 
inversion sultam that, actually, it is not formed or it is present in very minor amounts.  
Due to these final results, it would be very interesting a screening of several O-alkylsulfonyl, O-
arylsulfonyl, O-phosphoryl, or O-acyl substituted tyrosine sulfonamides. 
entry  X t (h) yield (%) ee 
1 S-24i Br 7 R-25i   87 > 99 
2 S-24j H 28 R-25j   75 > 99 
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Scheme 42 
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6.4 Conclusions 
In conclusion, in this research a series of chiral polyfluoro-polyfunctionalized benzosultams were 
prepared by stereoselective cyclization of enantiopure open-chain sulfonamides obtained, in turn, 
from natural and unnatural α-amino acids. Starting from the same optically pure arylglycine, it 
was realized the enantiodivergent synthesis of both the enantiomers of the corresponding 
benzosultam. The choice of the organic base system is the determining factor to direct the 
cyclization of the sulfonamide toward either enantiomer. 
This process represents the first example of ‘Memory Of Chirality’ (MOC) principle application 
to NH-unsubstituted sulfonamides and the unique synthesis of chiral benzosultams bearing a C-3 
carboxy function.  
Part of our researches was also devoted to the study of the cyclization of N-alkylsulfonamides 
derived from α-amino acids having an alkyl side chain. These compounds were transformed, 
under homogeneous mild conditions, into the corresponding benzosultams with retention of 
configuration, confirming once again the validity of the MOC rules. 
These new benzosultams could find application as chiral auxiliaries or catalysts in asymmetric 
synthesis, or they could be tested as biologically active compounds.  
Furthermore, through straightforward chemical manipulations of sultams, new and more 
functionalized products are easily accessible: actually, the fluorine atoms, due to their good 
aromatic leaving group aptitude, can be substituted by all the classes of nucleophiles, while the 
bromine-containing sultams can easily undergo a number of Pd-catalyzed coupling reactions 
(Suzuki, Stille, Sonogashira, Buchwald-Hartwig, Heck, Hiyama, Negishi, etc.).  
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7  Experimental section 
 
 
 
7.1 Materials and Methods 
 
 
 
All reactions were carried out in flame-dried glassware with magnetic stirring. Isolated yields 
refer to homogeneous materials (TLC, HPLC, NMR). Reagent-grade commercially available 
reagents and solvents were used; anhydrous solvents (MeOH, Et2O, DCM, DMSO, MeCN and 
DME) were used as purchased. TLC was performed using 0.25 mm silica-gel pre-coated plates 
and visualized by UV-254 light and CAM staining. Silica-gel (particle size 0.040–0.063 mm) 
was used for flash column chromatography (FCC) and medium pressure liquid 
chromatographic (MPLC). Melting points are corrected. HPLC analyses were performed using 
an EC 250/4.6 NUCLEOSIL 100-5 column and, for chiral HPLC analyses, a 250/4.6 Chiracel 
OD column, Chiralpak AD column, and Chiralcel OJ-H column; IR spectra are reported in 
frequency of absorption (cm
–1). [α]D’s were measured at 589 nm, using a 10 cm x 5 ml cell and 
c is in g/100 ml. NMR spectra were recorded at: 300.13 MHz for 
1
H; 75.00 MHz for 
13
C; 
282.407 MHz for 
19F. TMS was used as external reference; δ are in ppm and J are in Hz.  
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7.2 Synthesis of Sulfonyl Chlorides 5b-c: General Procedure. 
 
 
 
 
 
 
Chlorosulfonic acid of 5 equiv (9.7 g; 5.53 mL) were addedto 2.5 g of 3-bromo-1,2,4,5-
tetrafluorobenzeneor 1,2,4,5-tetrafluorobenzene and the obtainedsolution was heated at 150 °C. 
After 2h, the heating washalted in order to allow the solution to reach roomtemperature and 2 
equiv of thionyl chloride (3.99 g; 2.43 mL) were added. The obtained mixture was heatedfor 3 h 
at 150 °C. The brown solution obtained was thenadded dropwise under stirring to a mixture of 25 
g ice and 10 mL water. The obtained suspension was extracted three times with 15 mL of ethyl 
acetate. The organicfractions were collected and dried by solvent evaporationunder depression. 
The obtained brown oil was collected and stored at) - 20 °C.  
 
 
 
 4-bromo-2,3,5,6-tetrafluorobenzene-1-sulfonyl chloride(5b)(3,1 g, 86%); 
brawn solid, mp 48-49°C,
19
F NMR (282 MHz, CDCl3)  -127.9 (m, 2F), -
134.2 (m,2F). 
 
 
 
 
 
2,3,5,6-tetrafluorobenzene-1-sulfonyl chloride (5c)(3,5 g, 70%); white  solid, 
mp 50-52°C, 
19
F NMR (282 MHz, CDCl3)  -126.9 (m, 2F), -135.2 (m,2F). 
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7.3 Synthesis of (S)-Methyl 2-amino-2-(4-methoxyphenyl)acetate (17) 
 
 
 
 
To a solution of (S)-2-(tert-butoxycarbonylamino)-2-(4-hydroxyphenyl)acetic acid 15 (267 
mg, 1 mmol) and AlCl3 (13 mg, 0.1 mmol) in dry MeOH (3 ml) at 0 °C, CH2N2 in Et2O was 
added dropwise until the solution remains yellow.
99
 After evaporation under vacuum (RV) and 
filtration under silica (AcOEt/hexane  1 : 2) the pure (S)-Methyl 2-(tert-
butoxycarbonylamino)-2-(4-methoxyphenyl)acetate 16 (24h, 269 mg, 91%) was obtained. 
White solid, mp 77-78 °C; FCC - AcOEt/hexane (1 :2); []D
20
 +134.2 (c 1, CHCl3). 
1
H NMR 
(300 MHz, CDCl3)  7.29-7.26 (m, 2H), 6.89-6.86 (m, 2H), 5.49-5.45 (m, 1H), 5.26-5.24 (m, 
1H), 3.80 (s, 3H), 3.72 (s, 3H), 1.43 (s, 9H); 
13
C NMR (75 MHz, CDCl3)  171.7, 160.0, 155.0, 
128.3, 128.2, 114.1, 79.8, 56.9, 55.1, 25.3, 28.1. 
Compound 16(269 mg, 0.91 mmol) was then dissolved in CHCl3 (1.9 ml); TFA (0.1 ml) was 
added at 0 °C and this solution was warmed at room temperature and stirred over night. The 
crude was quenched with NaHCO3 and extracted with DCM (220 mL). The organic layer was 
dried over MgSO4, evaporated (RV) and the pureproduct 17 was obtained without any further 
purification. 17(176 mg, 99%). White wax; []D
20
 -121.0 (c 1, CHCl3). 
1
H NMR (300 MHz, 
CDCl3)  7.31-7.26 (m, 2H), 6.90-6.87 (m, 2H), 4.56 (s, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 1.70 
(bs, 2H); 
13
C NMR (75 MHz, CDCl3)  174.5, 159.2, 132.3, 127.9, 114.0, 57.9, 55.1, 52.2; IR 
(nujol) 3543, 3321, 1685, 1563,1243, 815 cm
-1
. 
 
  
                                                 
99The CH2N2 solution must be kept at -78 °C. 
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7.4 Synthesis of (S)-methyl 2-amino-2-(biphenyl-4-yl)acetate (13) 
 
 
 
Starting (S)-Methyl 2-amino-2-(biphenyl-4-yl)acetate11was synthesised following literature 
method.
100
 NMR spectra and physical data completely matched with the reported data. We 
used KHCO3 instead of K2CO3 in the Suzuky coupling since the Bello et al’s reaction 
conditions lead to the N-Boc phenyl glycinederivative9cin 34% enantiomeric excess. We were 
able to estimate the enantiomeric excess value only when we isolated the sulphonamide 
derivative 9c. 
 
 
[]D
20
 +115.1 (c 1, CHCl3), ee = 34% 
[]D
20
 +306.8 (c 1, CHCl3), ee> 99% 
 
 
 
 
[]D
20
 +50.2 (c 1, CHCl3), ee = 34% 
[]D
20
 +137.0 (c 1, CHCl3), ee> 99% 
[CHIRALCEL OD 
®
, Hexane – Isopropanol 9 : 1, Flow rate 1 
mL/min, P= 13 bar, t1 = 13.8 min, t2 = 15.8 min]. 
 
  
                                                 
100Bello, C. Bioorg. Med. Chem., 2010, 18,3320-3334 
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7.5 Synthesis of sulfonamides S-3a-d, 9a-e, S-18a-c, S-23a-j : General 
Procedure 
 
 
 
 
To a suspension of alkyl or 2-arylaminoacetate hydrochloride (10 mmol) in drydichloromethane 
(40 mL), DIPEA (21 mmol) was added at 25 °C in 10 min. Thereaction mixture was stirred for 
furhter 10 min, then cooled to 0°C and sulfonylchloride (10 mmol) was added dropwise. The 
resulting solution was allowed to reach25 °C and stirred until no starting material was not 
detectable by TLC, then wasdiluted with dichloromethane (20 mL), washed with 3% HCl (3×15 
mL), saturatedNaHCO3 solution (2×15 mL) and brine (20 mL), dried over MgSO4, filtered. 
Afterevaporation of the solvent under vacuum (RV), the crude recrystallized fromethanol/water 
(1 : 9), or purified by FCC or MPLC, gave the desired sulfonamides.Starting materials, product, 
yield, chromatographic eluant, physical and analyticaldata are as follows. 
 
 
 
 
 (S)-Methyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-
phenylacetate (S-3a). (3h, 356 mg, 90%). White solid, mp 120-121 
°C (EtOH/water – 9 : 1); []D
20
 +79.8 (c 1, CHCl3). 
1
H NMR (300 
MHz, CDCl3)  7.29-7.19 (m, 5H), 6.42 (d, 1H, J = 7.5 Hz,), 5.28 (d, 
1H, J = 7.5 Hz), 3.72 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -136.5 (m, 2F), -146.9 (m, 1F), -
159.8 (m, 2F); 
13
C NMR (75 MHz, CDCl3)  169.6, 143.9 (dm, J = 258.6 Hz), 143.6 (dm, J = 
261.6 Hz), 137.4 (dm, J = 258.4 Hz), 133.8, 129.2, 128.9, 127.3, 116.7, 59.9, 53.4; IR (nujol) 
3331, 1741, 1644, 1522, 1300, 1214, 1101, 985, 885 cm
-1
. Anal. Calcd. for C15H10F5NO4S: C, 
45.58; H, 2.55; N, 3.54. Found: C, 45.52; H, 2.58; N, 3.59. 
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(S)-Ethyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-
phenylacetate (S-3b) (20h, 302,9 mg, 74%); FCC - AcOEt/hexane (1 : 
6); white solid, mp 100-102°C, []D
20
+71.5 (c 1, CHCl3).
1
H NMR 
(300 MHz, CDCl3)  7.26-7.20 (m, 5H), 6.25 (d,1H, J = 7.5 Hz,), 5.24 
(d, 1H, J = 7.8 Hz), 4.27-4.06 (m, 2H),1.73 (t, 3H, J = 7.2 Hz); 
19
F NMR (282 MHz, CDCl3)  -
136.5 (m, 2F), -146.9 (m, 1F), -159.8 (m, 2F); IR (nujol) 3342, 1746, 1642, 1522, 1301, 1216, 
1110, 973cm
-1
.Anal. Calcd. for C16H12F5NO4S: C, 43.11; H, 2.94; N,3.14. Found: C, 43.08; H, 
2.92; N, 3.12. 
 
 
 
 
(S)-Isopropyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-
phenylacetate (S-3c).(20h, 317,5 mg, 75%);FCC - AcOEt/hexane (1 : 
8), white solid, mp 91-92°C, []D
20
+54.9 (c 1, CHCl3).
1
H NMR (300 
MHz, CDCl3) 7.25-7.17 (m, 5H), 6.27 (d,1H, J = 7.6 Hz), 5.21 (d, 
1H, J = 7.6 Hz), 5.05-4.97 (m, 1H),1.22 (d, 3H, J = 6.3 Hz), 1.04 (d, 3H, J = 6.3 Hz).
19
F NMR 
(282 MHz, CDCl3)  -136.6 (m, 2F), -147.0 (m,1F), -159.9 (m, 2F).13C NMR (75 MHz, CDCl3) 
 168.6, 144.1 (dm, J = 261.7Hz), 143.6 (dm, J = 259.5 Hz), 137.4 (dm, J = 257.3 Hz),134.1, 
129.0, 128.8, 127.2, 119.0, 70.9, 60.1, 21.5, 21.1.Anal. Calcd. for C17H14F5NO4S: C, 48.23; H, 
3.33; N,3.31. Found: C, 45.24; H, 2.34; N, 3.33. 
 
 
 
(R)-tert-butyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-
phenylacetate (S-3d).(24h, 389,3 mg, 89%);FCC - AcOEt/hexane (1 
: 12), white solid, mp 91-92°C, []D
20
+82.4 (c 1, CHCl3).
1
H NMR 
(300 MHz, CDCl3)  7.24-7.17 (m, 5H), 6.23 (d,1H, J = 7.6 Hz), 
5.14 (d, 1H, J = 7.7 Hz), 1.34 (s, 9H).
19
F NMR (282 MHz, CDCl3)  -136.5 (m, 2F), -147.3 
(m,1F), -160.1 (m, 2F).
13
C NMR (75 MHz, CDCl3)  168.5, 144.4 (dm, J = 266.0Hz), 144.0 (dm, 
J = 258.4 Hz), 138.0 (dm, J = 265.9Hz),134.8, 129.3, 129.2, 127.6, 119.3, 84.4, 60.8, 28.0. IR 
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(nujol) 3333, 1739, 1645, 1526, 1298, 1218, 1106, 981,888 cm
-1
.Anal. Calcd. for C18H16F5NO4S: 
C, 49.43; H, 3.69; N,3.20. Found: C, 49.40; H, 3.70; N, 3.21. 
 
 
(S)-Methyl 2-(4-nitrophenyl)-2-
(perfluorophenylsulfonamido)acetate (9a). Compound (S)-
Methyl 2-(perfluorophenylsulfonamido)-2-phenylacetateS-3a(395 
mg, 1 mmol) was dissolved in H2SO4conc (1 ml); HNO3 (95 mg, 1.5 
mmol, 70 l) was added dropwise and this solution was stirred at -
10 °C for 2 h. The crude was diluted with water (20 mL), extracted 
with AcOEt (220 mL) and dried over MgSO4. After evaporation of the solvent under vacuum 
(RV), the crude was purified by FCC (AcOEt/hexane 1 : 3). 9a (431 mg, 98%). White solid, 
mp 111-112 °C; []D
20
 +76.8 (c 1.1 CHCl3) ee 70% [CHIRALPAK OD 
®
, Hexane – 
Isopropanol 8 : 2 + 0.2% TFA, Flow rate 0.7 mL/min, P= 15 bar, t1 = 4.9 min, t2 = 6.3 min]. 
1
H 
NMR (300 MHz, CDCl3)  8.20-8.17 (m, 2H), 7.54-7.51 (m, 2H), 6.60 (d, 1H, J = 6.3 Hz), 
5.40 (d, 1H, J = 6.3 Hz), 3.74 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -136.8 (m, 2F), -145.3 
(m, 1F), -158.9 (m, 2F); 
13
C NMR (75 MHz, CDCl3)  168.8, 148.2, 144.2 (dm, J = 255.5 Hz), 
144.1 (dm, J = 243.6 Hz), 141.7, 141.4, 137.7 (dm, J = 262.2 Hz), 128.3, 124.1, 59.1, 53.9 IR 
(nujol) 3310, 1741, 1644, 1575, 1278, 1214, 1101 cm
-1
. Anal. Calcd. for C15H9F5N2O6S: C, 
40.92; H, 2.06; N, 6.36. Found: C, 45.21; H, 2.89; N, 3.31.  
 
 
(S)-Methyl 2-(2-chlorophenyl)-2-
(perfluorophenylsulfonamido)acetate (9b). (S)-Methyl 2-
amino-2-(2-chlorophenyl)acetate hydrochloride 6b, 236 mg. 
9b(4h, 313 mg, 73%). White solid, mp 110-110 °C; FCC - 
AcOEt/hexane (1 : 4); []D
20
 +75.6 (c 1.1 CHCl3). 
1
H NMR (300 
MHz, CDCl3)  7.29-7.24 (m, 4H), 6.35 (d, 1H, J = 7.5 Hz), 5.58 (d, 1H, J = 7.5 Hz), 3.74 (s, 
3H); 
19
F NMR (282 MHz, CDCl3)  -136.5 (m, 2F), -146.0 (m, 1F), -159.2 (m, 2F); 
13
C NMR 
(75 MHz, CDCl3)  168.6, 143.7 (dm, J = 260.9 Hz), 143.2 (dm, J = 260.1 Hz), 137.0 (dm, J = 
252.8 Hz),132.8, 132.1, 132.0, 130.1, 129.9, 129.5, 126.8, 57.7, 53.0; IR (nujol) 3274, 1745, 
1634, 1510, 1294, 1160, 1100, 990 cm
-1
. Anal. Calcd. for C15H9ClF5NO4S: C, 41.92; H, 2.11; 
N, 3.26. Found: C, 45.21; H, 2.89; N, 3.31. 
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(S)-Methyl 2-(biphenyl-4-yl)-2-
(perfluorophenylsulfonamido)acetate (9c). (S)-Methyl 2-
(biphenyl-4-yl) acetate13, 308 mg. 9c (212 mg, 45%). White solid, 
mp 103-104 °C; FCC - AcOEt/hexane (1 : 4); []D
20
+137.0 (c 1, 
CHCl3).
 1
H NMR (300MHz, DMSO)  7.47-7.39 (m, 7H), 7.30-
7.26 (m, 2H), 6.30 (d, 1H, J = 7.5 Hz), 5.33 (d, 1H, J = 7.5 Hz), 
3.76 (s, 3H); 
19
F NMR (282 MHz, DMSO)  -136.5 (m, 2F), -147.7 
(m, 1F), -160.2 (m, 2F); 
13
C NMR (75 MHz, DMSO)  169.3, 143.6 (dm, J = 256.0 Hz), 143.0 
(dm, J = 251.8 Hz), 137.1 (dm, J = 253.9 Hz), 140.3, 139.3, 134.0, 130.0, 128.8, 128.2, 127.6, 
126.6, 121.6, 59.2, 52.6; IR (nujol) 3275, 1741, 1627, 1518, 1310, 1176, 1100, 996, 884 cm
-1
. 
Anal. Calcd. for C21H14F5NO4S: C, 53.51; H, 2.99; N, 2.97. Found: C, 52.74; H, 3.19; N, 2.83. 
 
 
 
(S)-Methyl 2-[4-(benzyloxy)phenyl]-2-(2,3,4,5,6-
pentafluorophenylsulfonamido)acetate (9d). (S)-Methyl 2-
amino-2-[4-(benzyloxy)phenyl]acetate hydrochloride, 308 mg. 
9d(416 mg, 83%). White solid, mp 103-104 °C; FCC - 
AcOEt/hexane (1 : 12); []D
20
 +48.4 (c 0.9 CHCl3). 
1
H NMR 
(300MHz, CDCl3)  7.40-7.33 (m, 5H), 7.13-7.10 (m, 2H), 6.83-
6.79 (m, 2H), 6.20 (d, 1H, J = 7.1 Hz), 5.22 (d, 1H, J = 7.1 Hz), 4.97 (s, 2H), 3.71 (s, 3H); 
19
F 
NMR (282 MHz, CDCl3)  -136.5 (m, 2F), -147.0 (m, 1F), -159.8 (m, 2F); 
13
C NMR (75 
MHz, CDCl3)  169.8, 159.5, 144.0 (dm, J = 263.0 Hz), 143.8 (dm, J = 260.0 Hz), 137.4 (dm, 
J = 257.9 Hz), 136.3, 126.1, 126.0, 128.7, 127.4, 126.1, 116.9 (t, J = 13.0 Hz), 115.0, 70.2, 
59.4, 53.3; IR (nujol) 3275, 1741, 1627, 1518, 1310, 1176, 1100, 996, 884 cm
-1
. Anal. Calcd. 
for C22H16F5NO5S: C, 52.70; H, 3.22; N, 2.79. Found: C, 52.74; H, 3.19; N, 2.83. 
 
 
(S)-Methyl 2-(4-methoxyphenyl)-2-(2,3,4,5,6-
pentafluorophenylsulfonamido)acetate (9e). (S)-Methyl 2-
amino-2-(4-methoxyphenyl)acetate hydrochloride17, 232 mg. 
9e(16h, 340 mg, 80%). White solid, mp 115-116 °C; FCC - 
AcOEt/hexane (1 : 9); []D
20
 +84.7 (c 1.1 CHCl3). 
1
H NMR (300 
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MHz, CDCl3)  7.13-7.10 (m, 2H), 6.74-6.71 (m, 2H), 6.27 (d, 1H, J = 7.5 Hz), 5.22 (d, 1H, J 
= 7.5 Hz), 3.74 (s, 3H), 3.71 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -136.5 (m, 2F), -147.2 (m, 
1F), -160.0 (m, 2F); 
13
C NMR (75 MHz, CDCl3)  170.5, 160.9, 144.6 (dm, J = 262.1 Hz), 
144.2 (dm, J = 258.6 Hz), 138.4 (dm, J = 267.2 Hz), 129.3, 126.5, 114.8, 60.8, 55.9, 53.9; IR 
(nujol) 3263, 1748, 1610, 1518, 1303, 1174, 1091, 990 cm
-1
. Anal. Calcd. for C16H12F5NO5S: 
C, 45.18; H, 2.84; N, 3.29. Found: C, 45.21; H, 2.89; N, 3.31. 
 
 
 
(S)-methyl 2-(perfluorophenylsulfonamido)-3-
phenylpropanoate(S-18a). (1,5 h, 286,5 mg, 70%). White solid, mp 
130-131 °C; FCC - AcOEt/hexane (1 : 7). 
1
H NMR (300MHz, 
CDCl3)  7.22-7.19 (m, 3H), 7.11-7.07 (m, 2H), 5.60 (d, 1H, J = 9.2 
Hz), 4.54-4.47 (m, 1H),3.73 (s, 3H), 3.19 (dd, 1H, J = 13.9, 4.8 Hz), 
2.97 (dd, 1H, J= 13.9, 8.1 Hz); 
19
F NMR (282 MHz, CDCl3)  -136.6 (m, 2F), -147.2 (m,1F), -
159.7 (m, 2F);
 13
C NMR (75 MHz, CDCl3)  170.7, 145.2 (dm, J = 260.1 Hz), 141.7 (dm, J = 
257.3 Hz), 138.7 (dm, J = 264.6 Hz), 134.6, 128.0, 126.7, 57.2, 52.4, 38.4;IR (nujol) 3225, 1722, 
160’, 1501, 1342, 1171, 1110, 1096,998 cm-1.Anal. Calcd. for C16H12F5NO4S: C, 46.95; H, 2.95; 
N,3.42. Found: C, 46.96; H, 2.98; N, 3.44. 
 
 
 
(S)-methyl 2-(4-bromo-2,3,5,6-tetrafluorophenylsulfonamido)-3-
phenylpropanoate (S-18b). (4 h, 300,5 mg, 80%). White solid, mp 
117-118 °C; FCC - AcOEt/hexane (1 : 9); []D
20
 -22.3 (c 0.3 
CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow 
rate 0.8 mL/min, P= 48 bar, t1 = 17.4 min]. 
1
H NMR (300MHz, 
CDCl3) δ 7.21-7.18 (m, 3H), 7.10-7.07 (m, 2H), 5.61 (d, 1H, J = 9.0 Hz), 4.56-4.49 (m, 1H),3.74 
(s, 3H), 3.20 (dd, 1H, J = 13.7, 4.5 Hz), 2.95 (dd, 1H, J= 13.8, 8.1 Hz); 
19
F NMR (282 MHz, 
CDCl3)  -130.9 (m, 2F), -136.2 (m,2F); 13C NMR (75 MHz, CDCl3)  171.2, 146.6 (dm, J = 
245.5 Hz), 144.9 (dm, J = 261.7 Hz), 143.3 (dm, J = 242.2 Hz), 141.5 (dm, J = 261.7 Hz), 136,3, 
129.1, 128.4, 127.0, 109.5, 105.2, 57.9, 52.9, 38.7;IR (nujol) 3226, 1724, 160’, 1501, 1345, 1169, 
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1109, 1092,994 cm
-1
.Anal. Calcd. for C16H12BrF4NO4S: C, 40.87; H, 2.57; N, 2.98. Found: C, 
41.23; H, 2.72; N, 3.20. 
 
 
 
(S)-methyl 2-(4-bromo-2,3,5,6-
tetrafluorophenylsulfonamido)propanoate (S-23a). (4 h, 322,5 
mg, 82%). Brown wax,  FCC - AcOEt/hexane (1 : 9); []D
20
 -38.4 (c 
1.3 CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, 
Flow rate 0.8 mL/min, P= 48 bar, t1 = 9.3 min]. 
1H NMR (300MHz, CDCl3) δ 5.78 (d, 1H, J = 
8.1 Hz), 4.33-4.28 (m, 1H),3.68 (s, 3H), 1.50 (d, 3H, J = 7.2 Hz); 
19
F NMR (282 MHz, CDCl3) δ 
-128.4 (m, 2F), -134.6 (m, 2F);
 13
C NMR (75 MHz, CDCl3)  171.0, 146.9 (dd, J = 251.2,19.5 
Hz), 145.5 (dd, J = 258.0, 15.0 Hz), 143.6, 142.0,120.4 (t, J = 14.5 Hz), 105.3 (t, J = 21.9 Hz), 
52.9, 52.22, 19.38;IR (nujol) 3224, 1750, 156, 1495, 1330, 1068,993 cm
-1
.Anal. Calcd. for  
C10H8BrF4NO4S: C, 30.47; H, 2.05; N, 3.55;. Found: C, 30.63; H, 2.25; N, 3.69. 
 
 
 (S)-methyl 2-(2,3,5,6-tetrafluorophenylsulfonamido)propanoate 
(S-23b)(4,5h, 267.7 mg, 83%). White solid,  FCC - AcOEt/hexane (1 
: 9); []D
20
 -23.0 (c 1.3 CHCl3). [CHIRALCEL OJ-H
®
, Hexane – 
Isopropanol 9 : 1, Flow rate 0.8 mL/min, P= 30 bar, t1 = 20.4 min].  
1
H NMR (300MHz, CDCl3) δ 7.34-7.32 (m, 1H), 5.84 (d, 1H, J = 7.8 Hz), 4.35-4.25 (m, 
1H),3.67 (s, 3H), 1.49 (d, 3H, J = 7.2 Hz); 
19
F NMR (282 MHz, CDCl3) δ -134.2 (m, 2F), -135.7 
(m, 2F);
 13
C NMR (75 MHz, CDCl3)  173.7, 147.5 (dd, J = 247.5, 6.0 Hz), 145.1 (dd, J = 261.7, 
15.1 Hz), 144.2, 141.6,121.2 (t, J = 15.0 Hz), 109.9 (t, J = 22.5 Hz), 61.9, 54.7, 18.8;IR (nujol) 
3227, 1745, 153, 1485, 1327, 1059,989 cm
-1
.Anal. Calcd. for  C10H9F4NO4S: C, 38.10; H, 2.88; 
N, 4.44. Found: C, 39.23; H, 2.92; N, 4.52. 
 
 
 (S)-methyl 2-(4-bromo-2,3,5,6-tetrafluorophenylsulfonamido)-4-
methylpentanoate (S-23c) (4 h, 388.7 mg, 89%). wax,  FCC - 
AcOEt/hexane (1 : 9); []D
20
 -36.6 (c 0.5 CHCl3). [CHIRALCEL 
OJ-H
®
, Hexane – Isopropanol 9 : 1, Flow rate 0.8 mL/min, P= 30 
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bar, t1 = 9.2 min].  
1H NMR (300MHz, CDCl3) δ 5.49 (d, 1H, J = 9.3 Hz), 4.30-4.22 (m, 1H),3.61 
(s, 3H), 1.84-1.77 (m, 1H), 1.63-1.55 (m, 2H), 0.97-0.93 (m, 6H); 
19F NMR (282 MHz, CDCl3) δ 
-130.7 (m, 2F), -136.3 (m, 2F);
 13
C NMR (75 MHz, CDCl3)  171.5, 146.3 (dd, J = 248.2, 18.7 
Hz), 145.0 (dd, J = 262.5, 16.5 Hz), 143.1, 141.5, 119.6, 104.8 (t, J = 22.5 Hz), 54.5, 52.0, 41.4, 
23.8, 22.1, 20.7;IR (nujol) 3220, 1755, 147, 1460, 1318, 1042,982 cm
-1
.Anal. Calcd. for   
C13H14BrF4NO4S: C, 35.79; H, 3.23; N, 3.21. Found: C, 35.84; H, 3.50; N, 3.40. 
 
 
 
 (S)-methyl 4-methyl-2-(2,3,5,6-
tetrafluorophenylsulfonamido)pentanoate (S-23d) (4,5 h, 310.8 
mg, 87%). Brown wax,  FCC - AcOEt/hexane (1 : 7); []D
20
 +17.6 
(c1 CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 9 : 1, Flow 
rate 0.8 mL/min, P= 30 bar, t1 = 11.1 min]. 
1
H NMR (300MHz, 
CDCl3) δ 7.28-7.25 (m, 1H), 5.52 (d, 1H, J = 9 Hz), 4.26-4.23 (m, 1H),3.59 (s, 3H), 1.81-1.79 
(m, 1H), 1.62-1.56 (m, 2H), 0.93 (d, 6H, J = 6 Hz); 
19F NMR (282 MHz, CDCl3) δ -136.7 (m, 
2F), -137.5 (m, 2F);
 13
C NMR (75 MHz, CDCl3)  172.0, 147.7 (dm, J = 255.7 Hz), 145.3 (dm, J 
= 254.2  Hz), 144.3, 141.9, 121.3 (t, J = 15.0 Hz), 110.1 (t, J = 22.5 Hz), 54.9, 52.4, 41.7, 24.3, 
22.5, 21.1;IR (nujol) 3214, 1752, 157, 1475, 1314, 1038,970 cm
-1
.Anal. Calcd. for  
C13H15F4NO4S: C, 43.70; H, 4.23; N, 3.92. Found: C, 43.77; H, 4.30; N, 3.87. 
 
 
 
 (S)-methyl 2-(4-bromo-2,3,5,6-tetrafluorophenylsulfonamido)-4-
(methylthio)butanoate (S-23e) (4h, 336.1 mg, 74%). Wax,  FCC - 
AcOEt/hexane (1 : 5).  [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 
7 : 3, Flow rate 0.5 mL/min, P= 27 bar, t1 = 11.2 min]. 
1
H NMR 
(300MHz, CDCl3) δ 5.95 (d, 1H, J = 10.8 Hz), 4.43-4.39 (m, 1H),3.69 (s, 3H), 2.60-2.53 (m, 
2H), 2.19-2.02 (m, 5H); 
19F NMR (282 MHz, CDCl3) δ -130.8 (m, 2F), -136.7 (m, 2F); 13C NMR 
(75 MHz, CDCl3)  171.1, 146.8 (dd, J = 248.2, 21.7 Hz), 145.5 (dd, J = 258.0, 15.7 Hz), 143.5, 
142.0, 119.6 (t, J = 13.5 Hz), 105.4 (t, J = 22.5 Hz), 55.2, 52.8, 31.8, 29.5,15.2;IR (nujol) 3234, 
1740, 148, 1465, 1308, 1027,967 cm
-1
.Anal. Calcd. for  C12H12BrF4NO4S2: C, 31.73; H, 2.66; N, 
3.08;. Found: C, 31.82; H, 2.70; N, 3.13. 
113 
 
 
 (S)-methyl 4-(methylthio)-2-(2,3,5,6-
tetrafluorophenylsulfonamido)butanoate (S-23f) (4h, 292.5 mg, 
78%). Wax,  FCC - AcOEt/hexane (1 : 3). [CHIRALCEL OJ-H
®
, 
Hexane – Isopropanol 7 : 3, Flow rate 0.8 mL/min, P= 48 bar, t1 = 
13.2 min]. 
1H NMR (300MHz, CDCl3) δ 7.31-7.26 (m, 1H), 6.24 (d, 1H, J = 9 Hz), 4.39-4.32 (m, 
1H),3.62 (s, 3H), 2.60-2.54 (m, 2H), 2.13-1.98 (m, 5H); 
19F NMR (282 MHz, CDCl3) δ -134.1 
(m, 2F), -135.3 (m, 2F);
 13
C NMR (75 MHz, CDCl3)  171.2, 147.8 (dd, J = 255, 7.5 Hz), 145.4 
(dd, J = 255.0, 13.5 Hz), 144.4, 142.0, 121.1, 110.1 (t, J = 22.5 Hz), 55.2, 52.8, 31.9, 
29.5,15.1;IR (nujol) 3272, 1735, 139, 1454, 1312, 1015,953 cm
-1
.Anal. Calcd. for  
C12H13F4NO4S2: C, 38.40; H, 3.49; N, 3.73. Found: C, 38.50; H, 3.53; N, 3.82. 
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7.6 SL-PTC N-Alkylation of Sulfonamides 7a-b, S-19a-d, S-24a-j: General 
Procedure. 
 
 
 
 
 
To a solution of sulfonamide (1 mmol) and TEBA (23 mg, 0.1 mmol) in dry MeCN (2 mL) at 25 
°C, anhydrous K2CO3 (276 mg, 2 mmol) was added. This suspension was stirred for 10 min,then 
a solution of the alkylating agent (1.5 mmol) in MeCN (1 mL) was added under vigorousstirring, 
and the reaction was monitored by TLC (AcOEt : hexane – 1 : 9) until completion. Themixture 
was then diluted with AcOEt (5 mL), washed with brine (2 × 2 mL), dried over MgSO4and 
filtered. The solvent was removed under vacuum, the crude was purified by column 
chromatography ; alkylating agent, product, yield, chromatographic eluant, physical andanalytical 
data are as follows. 
 
 
 
Methyl 2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)-2-
phenylacetate (7a)  (24 h, 368 mg, 90%);white solid, mp 67-69 °C 
(EtOH/water – 9 : 1).1H NMR (300 MHz, CDCl3) δ7.42-7.23 (m, 
5H), 6.04 (s,1H), 3.72 (s, 3H), 2.84 (s, 3H).
19
F NMR (282 MHz, 
CDCl3) δ-135.3 (m, 2F), -146.4 (m,1F), -159.7 (m, 2F).IR (nujol) 
1744, 1644, 1541, 1296, 1271, 1222, 1173, 1098,1025, 699, 678 cm
-1
.Anal. Calcd. for 
C16H12F5NO4S: C, 46.95; H, 2.95; N,3.42. Found: C, 47.02; H, 3.00; N, 3.37. 
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Methyl 2-(N-allyl-2,3,4,5,6-pentafluorophenylsulfonamido)-2-
phenylacetate (7b)  (40 h, 122 mg, 48%);FCC - AcOEt/hexane (1 : 
12), white wax.
1
H NMR (300 MHz, CDCl3) δ 7.42-7.35 (m, 3H), 
7.28-7.26 (m, 2H), 6.06 (s, 1H), 5.42-5.28 (m, 1H), 4.82 (d, 1H, J= 
17.0 Hz), 4.77 (d, 1H, J = 9.9 Hz), 3.98 (dd, 1H, J = 16.4,4.7 Hz), 
3.82 (dd, 1H, J = 16.4, 6.9 Hz), 3.74 (s, 3H).
19
F NMR (282 MHz, CDCl3)δ-135.0 (m, 2F), -146.4 
(m,1F), -159.6 (m, 2F).Anal. Calcd. for C18H14F5NO4S: C, 49.66; H, 3.24; N,3.22. Found: C, 
49.63; H, 3.24; N, 3.20. 
 
 
 (S)-methyl 2-(2,3,4,5,6-pentafluoro-N-
methylphenylsulfonamido)-3-phenylpropanoate (S-19a) (12 h, 
410.8 mg, 96%). Wax,  FCC - AcOEt/hexane (1 : 3). [CHIRALCEL 
OD
®
, Hexane – Isopropanol 9 : 1, Flow rate 1 mL/min, P= 13 bar, t1 
= 15.5 min]. 
1H NMR (300MHz, CDCl3) δ 7.27-7.14 (m, 5H), 4.97-
4.89 (m, 1H), 3.74 (s, 3H), 3.36 (dd, 1H, J = 21.0, 6 Hz), 3.09 (s, 3H), 2.93 (dd, 1H, J= 21.0, 18 
Hz); 
19F NMR (282 MHz, CDCl3) δ -137.0 (m, 2F), -147.1 (m, 1F), -159.8 (m, 2F);13C NMR (75 
MHz, CDCl3) 169.9, 145.9 (dm, J = 263.2 Hz), 145.2 (dm, J = 262.5 Hz), 139.6 (dm, J = 252.7 
Hz),135.9, 128.7, 128.4, 127.0, 61.5, 52.6, 35.1, 30.6;IR (nujol) 3268, 1742, 128, 1446, 1316, 
1012,946 cm
-1
.Anal. Calcd. for  C17H14F5NO4S: C, 48.23; H, 3.33; N, 3.31. Found: C, 48.50; H, 
3.52; N, 3.53. 
 
 
 (S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)-3-phenylpropanoate(S-19b) (12 h, 
409.5 mg, 85%).FCC - AcOEt/hexane (1 : 8); []D
20
 -24.9 (c 0.3 
CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow 
rate 0.8 mL/min, P= 48 bar, t1 = 20.3 min]. 
1
H NMR (300MHz, 
CDCl3) δ 7.16-7.15 (m, 5H), 4.94-4.89 (m, 1H),3.30 (s, 3H), 3.34 (dd, 1H, J = 15.0, 6.0 Hz), 3.11 
(s, 3H), 2.92 (dd, 1H, J= 15, 12 Hz); 
19
F NMR (282 MHz, CDCl3)  -130.9 (m, 2F), -136.2 
(m,2F);
 13
C NMR (75 MHz, CDCl3)  169.5, 146.6 (dd, J = 251.2, 15 Hz), 144.9 (dd, J = 264.0, 
16.9 Hz), 143.1, 141.4, 135,5, 128.2, 128.0, 126.6, 109.1, 104.6, 61.2, 52.3, 34.8, 30.4;IR (nujol) 
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3218, 1720, 157’, 1514, 1334, 1157, 1105, 1083,970 cm-1.Anal. Calcd. for C17H14BrF4NO4S: C, 
42.16; H, 2.91; N, 2.89. Found: C, 42.20; H, 2.98; N, 2.97. 
 
 
 
 (S)-methyl 3-phenyl-2-(2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)propanoate (S-19c) (12 h, 376.9 mg, 
93%). White wax, FCC - AcOEt/hexane (1 : 8); []D
20
 -24.4 (c1 
CHCl3). [CHIRALCEL OJ
 ®
, Hexane – Isopropanol 8 : 2, Flow rate 
0.8 mL/min, P= 33 bar, t1 = 19.4 min]. 
1H NMR (300MHz, CDCl3) δ 
7.23-7.15 (m, 5H), 4.56-4.49 (m, 1H),3.68 (s, 3H), 3.19 (dd, 1H, J = 15.0, 6.0 Hz), 3.07 (s, 3H), 
2.92 (dd, 1H, J= 15, 12 Hz); 
19
F NMR (282 MHz, CDCl3)  -136.0 (m, 2F), -136.8 (m,2F); 13C 
NMR (75 MHz, CDCl3)  169.5, 147.1 (dm, J = 243.7 Hz), 144.8 (dm, J = 255.0 Hz), 143.9, 
141.4, 135,3, 128.2, 127.9, 126.7, 109.3 (t, J = 22.5 Hz), 60.9, 51.9, 34.8, 30.1;IR (nujol) 3222, 
1718, 149, 1508, 1329, 1148, 1117, 1076,968 cm
-1
.Anal. Calcd. for C17H15F4NO4S: C, 50.37; H, 
3.73; N, 3.46. Found: C, 50.42; H, 3.80; N, 3.53. 
 
 
 
 (S)-methyl 2-(N-allyl-2,3,4,5,6-pentafluorophenylsulfonamido)-3-
phenylpropanoate (S-19d) (24 h, 359.2 mg, 80%);FCC - 
AcOEt/hexane (1 : 9), white wax. 
1
H NMR (300 MHz, CDCl3) δ 
7.24-7.21 (m, 5H), 5.86-5.75 (m, 1H), 5.26 (d, 1H, J= 17.0 Hz), 5.17 
(d, 1H, J = 9.0 Hz),  4.94-4.89 (m, 1H), 4.81-4.08 (m, 2H), 3.69 (s, 
3H), 3.36 (dd, 1H, J = 15.0, 6.0 Hz), 3.04 (dd, 1H, J = 15.0, 9.0 Hz).
19
F NMR (282 MHz, 
CDCl3)δ-134.8 (m, 2F), -147.0 (m,1F), -159.8 (m, 2F).13C NMR (75 MHz, CDCl3)  169.7, 145.7 
(dm, J = 255.0 Hz), 144.8 (dm, J = 245.0 Hz), 142.3, 139.0, 135,6, 135.4, 133.0, 128.5, 128.0, 
126.5, 118.6, 61.2, 51.9, 48.6, 35.7.Anal. Calcd. for C19H16F5NO4S: C, 50.78; H, 3.59; N, 3.12. 
Found: C, 50.85; H, 3.62; N, 3.23. 
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 (S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)propanoate (S-24a) (12 h, 370.2 mg, 
91%) Brown wax,  FCC - AcOEt/hexane (1 : 5); []D
20
 -12.2 (c2 
CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow 
rate 0.8 mL/min, P= 48 bar, t1 = 11.0 min]. 
1H NMR (300MHz, CDCl3) δ 4.87-4.80 (m, 1H),3.60 
(s, 3H), 2.94 (s, 3H), 1.48 (d, 3H, J = 9.0 Hz); 
19F NMR (282 MHz, CDCl3) δ -131.1 (m, 2F), -
135.0 (m, 2F);
 13
C NMR (75 MHz, CDCl3)  170.7, 147.0 (dd, J = 247.5, 15.0 Hz), 145.8 (dd, J = 
262.5, 15.0 Hz), 143.6, 142.3, 105.0 (t, J = 21.9 Hz), 55.4, 52.41, 29.9, 15.7;IR (nujol) 3218, 
1720, 156, 1329, 1053,985 cm
-1
.Anal. Calcd. for  C11H10BrF4NO4S: C, 32.37; H, 2.47; N, 3.43. 
Found: C, 32.52; H, 2.60; N, 3.57. 
 
 
 
 (S)-methyl 2-(2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)propanoate (S-24b)(6 h, 292.9 mg, 
89%) White wax,  FCC - AcOEt/hexane (1 : 5); []D
20
 -20.2 (c1 
CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow rate 
0.8 mL/min, P= 48 bar, t1 = 13.6 min]. 
1H NMR (300MHz, CDCl3) δ 7.31-7.25 (m, 1H), 4.82 (q, 
1H, J = 12.0, 6.0 Hz),3.58 (s, 3H), 2.93 (s, 3H), 1.46 (d, 3H, J = 9.0 Hz); 
19
F NMR (282 MHz, 
CDCl3) δ -136.3 (m, 2F), -136.6 (m, 2F); 13C NMR (75 MHz, CDCl3)  170.7, 147.8 (dd, J = 
247.5, 15.0 Hz), 145.5 (dd, J = 240.0, 15.0 Hz), 144.5, 142.3, 121.8, 109.9 (t, J = 22.5 Hz), 55.3, 
52.3, 29.9, 15.6;IR (nujol) 3224, 1718, 158, 1320, 1047,978 cm
-1
.Anal. Calcd. for  
C11H11F4NO4S: C, 40.12; H, 3.37; N, 4.25. Found: C, 40.30; H, 3.42; N, 4.32. 
 
 
 
(S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)-4-methylpentanoate (S-24c) (12 h, 
414.9 mg, 92%). wax,  FCC - AcOEt/hexane (1 : 9); []D
20
 -30.8 
(c1.3 CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, 
Flow rate 0.5 mL/min, P= 27 bar, t1 = 11.2 min]. 
1
H NMR 
(300MHz, CDCl3) δ 4.84-4.78 (m, 1H),3.60 (s, 3H), 2.95 (s, 3H)1.72-1.69 (m, 3H), 1.02-0.98 
(m, 6H); 
19F NMR (282 MHz, CDCl3) δ -129.2 (m, 2F), -132.6 (m, 2F); 13C NMR (75 MHz, 
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CDCl3)  170.5, 145.4 (dd, J = 248.2, 18.7 Hz), 145.0 (dd, J = 262.5, 16.5 Hz), 143.1, 141.7, 
126.5, 104.8 (t, J = 22.5 Hz), 57.6, 51.7, 37.3, 29.4, 23.9, 22.5, 20.2;IR (nujol) 3240, 1747, 138, 
1452, 1309, 1037,975 cm
-1
.Anal. Calcd. for   C14H16BrF4NO4S: C, 37.35; H, 3.58; N, 3.11. 
Found: 37.42; H, 3.70; N, 3.35. 
 
 
 
 (S)-methyl 4-methyl-2-(2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)pentanoate(S-24d)(12 h, 330.2 mg, 
89%). Brown wax,  FCC - AcOEt/hexane (1 : 7); []D
20
 +23.6 (c1 
CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow rate 
0.8 mL/min, P= 48 bar, t1 = 6.9 min]. 
1H NMR (300MHz, CDCl3) δ 
7.30-7.24 (m, 1H), 4.82-4.77(m, 1H),3.57 (s, 3H), 2.96 (s, 3H), 1.71-1.68 (m, 3H), 1.01-0.97 (m, 
6H);
19F NMR (282 MHz, CDCl3) δ -133.8 (m, 2F), -134.8 (m, 2F);IR (nujol) 3220, 1748, 1489, 
1318, 1030,960 cm
-1
.Anal. Calcd. for  C14H17F4NO4S: C, 45.28; H, 4.61; N, 3.77. Found: C, 
45.38; H, 4.75; N, 3.82. 
 
 
 
(S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)-4-(methylthio)butanoate (S-24e) (12 
h, 331.6 mg, 73%). Wax,  FCC - AcOEt/hexane (1 : 5), []D
20
 +2.5 
(c1 CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 9 : 1, 
Flow rate 0.8 mL/min, P= 29 bar, t1 = 24.1 min]. 
1H NMR (300MHz, CDCl3) δ 4.92-4.87 (m, 
1H),3.63 (s, 3H), 2.97 (s, 3H), 2.63-2.52 (m, 2H), 2.28-2.25 (m, 1H), 2.13 (s, 3H), 2.04-1.97 (m, 
1H); 
19F NMR (282 MHz, CDCl3) δ -131.7 (m, 2F), -135.0 (m, 2F); 13C NMR (75 MHz, CDCl3) 
 169.9, 146.6 (dd, J = 247.5, 15.0 Hz), 145.5 (dd, J = 262.5, 12.5 Hz), 143.5, 142.3, 118.8, 
105.1, 58.8, 52.4, 30.1, 29.5, 28.4,15.2;IR (nujol) 3223, 1736, 136, 1452, 1312, 1016,952 cm
-
1
.Anal. Calcd. for   C13H14BrF4NO4S2: C, 33.34; H, 3.01; N, 2.99. Found: C, 33.52; H, 3.35; N, 
3.16. 
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 (S)-methyl 4-(methylthio)-2-(2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)butanoate (S-24e) (12 h, 291.7 mg, 
75%). Brown wax,  FCC - AcOEt/hexane (1 : 5); []D
20
 +19.4 (c1.3 
CHCl3). [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 9 : 1, Flow rate 
0.8 mL/min, P= 28 bar, t1 = 30.5 min]. 
1H NMR (300MHz, CDCl3) δ 7.34-7.26 (m, 1H), 4.92-
4.87 (m, 1H),3.62 (s, 3H), 2.97 (s, 3H), 2.63-2.53 (m, 2H), 2.28-2.25 (m, 1H), 2.14 (s, 3H), 2.04-
1.97 (m, 1H); 
19F NMR (282 MHz, CDCl3) δ -135.8 (m, 2F), -136.3 (m, 2F); 13C NMR (75 MHz, 
CDCl3)  170.0, 147.7 (dm, J = 238.5 Hz), 145.6 (dm, J = 255.0  Hz), 144.6, 142.2, 109.9 (t, J = 
22.5 Hz), 58.8, 52.3, 30.2, 28.5, 15.4;IR (nujol) 3220, 1762, 163, 1482, 1320, 1041,969 cm
-
1
.Anal. Calcd. for   C13H15F4NO4S2: C, 40.10; H, 3.88; N, 3.60. Found: C, 40.35; H, 3.90; N, 
3.80. 
 
 
 
(S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)-3-(4-(4-bromo-
2,3,5,6-tetrafluorophenylsulfonyloxy)phenyl) 
propanoate (S-24i) (24 h, 654,7 mg, 83%).FCC - 
AcOEt/hexane (1 : 7); []D
20
 -8.6 (c1.2 CHCl3). 
[CHIRALCEL OD-H
®
, Hexane – Isopropanol 8 : 
2, Flow rate 0.8 mL/min, P= 38 bar, t1 = 30.7 
min]. 
1H NMR (300MHz, CDCl3) δ 7.26-7.15 (m, 4H),4.87 (q, 1H, J = 9.0, 6.0 Hz), 3.65 (s, 3H),  
3.34 (dd, 1H, J = 15.0, 6.0 Hz), 2.98 (dd, 1H, J= 15.0, 9.0 Hz), 2.94 (s, 3H9; 
19
F NMR (282 MHz, 
CDCl3)  -129.5 (m, 2F), -131.3 (m, 2F), -135.1 (m, 2F), -135.2 (m, 2F); 13C NMR (75 MHz, 
CDCl3)  169.3, 148.7, 147.0 (dm, J = 255.0 Hz), 145.7 (dm, J = 247.5 Hz), 143.6 (dm, J = 255.0 
Hz), 142.4 (dm, J = 246.5 Hz), 136,0, 130.8, 128.7, 121.5, 118.8, 114.6 (d, J = 15.0 Hz), 108.2 (t, 
J = 22.5 Hz),  105.3 (t, J = 22.5 Hz), 61.3, 52.6, 34.6, 30.4, 29.6;IR (nujol) 3230, 1735, 158, 
1514, 1356, 1158, 1106, 1085,980 cm
-1
.Anal. Calcd. for C23H13Br2F8NO7S2: C, 34.91; H, 1.66; 
N, 1.77. Found: C, 35.02; H, 1.86; N, 1.81. 
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(S)-methyl 2-(2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)-3-(4-(2,3,5,6-
tetrafluorophenylsulfonyloxy)phenyl)propanoate 
(S-24j) (12 h, 519.0 mg, 82%). White wax, FCC - 
AcOEt/hexane (1 : 5); []D
20
 -10.6 (c1.2 CHCl3). 
1H NMR (300MHz, CDCl3) δ 7.26-7.15 (m, 6H), 
4.93 (q, J= 9.0, 6 Hz 1H),3.65 (s, 3H), 3.64 (dd, 1H, 
J = 15.0, 6.0 Hz), 2.99 (dd, 1H, J= 15, 12 Hz),2.97 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -134.3 
(m, 2F), -134.9 (m,2F)-135.9 (m, 2F), -136.5 (m,2F);
 13
C NMR (75 MHz, CDCl3)  169.4, 147.8 
(dm, J = 195.0 Hz), 146.1 (dm, J = 262.5 Hz), 145.3, 144.3, 142,4, 142.1, 136.1, 130.7, 121.5, 
120.2(t, J = 15.0 Hz), 116.1 (t, J = 7.5 Hz), 112.5 (t, J = 22.5 Hz), 109.9 (t, J = 22.5 Hz), 61.0, 
52.4, 34.6, 30.4;IR (nujol) 3242, 1725, 132, 1523, 1328, 1145, 1114, 1079,971 cm
-1
.Anal. Calcd. 
for C23H15F8NO7S2: C, 43.61; H, 2.39; N, 2.21. Found: C, 43.83; H, 2.45; N, 2.48. 
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7.7 Synthesis of (S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)-4-(methylsulfonyl)butanoate (27) 
 
 
 
 
(S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-methylphenylsulfonamido)-4-(methylthio)butanoate 
(S-24e)(93.3 mg, 0.2 mmol) was addedto a round bottom flask and dissolved in DCM (1 mL). 
The stirred solutionwas cooled to 0 ºC and 3-chloroperoxybenzoic acid (70%, 103.5mg, 0.42 
mmol) wasadded as a suspension in 0.3 mL of DCM by pipette over a period of 5 min. 
Anadditional 0.3 mL of DCM was used to complete the transfer of oxidant. The reactionwas 
stirred for 1.5 hours at room temperature at which time it was diluted with diethylether (10 mL) 
and sodium hydrogen carbonate (5 mL of a saturated aqueoussolution). The layers were separated 
and the organic fraction was washedsuccessively with sodium hydrogen carbonate (2 x 10 mL of 
a saturated aqueoussolution) and brine (15 mL). The organics were dried (MgSO4), filtered, 
andconcentrated under reduced pressure. The product was purified by flash 
columnchromatography (ethyl acetate/hexane, 1:1) to afford the corresponding sulfone 27 
 
 
(S)-methyl 2-(4-bromo-2,3,5,6-tetrafluoro-N-
methylphenylsulfonamido)-4-(methylsulfonyl)butanoate (27) 
(12 h, 331.6 mg, 73%). White solid, p.f. 130°C,FCC - 
AcOEt/hexane (1 : 1), []D
20
 +2.7 (c1 CHCl3). [CHIRALPAK 
AD
®
, Hexane – Isopropanol 9 : 1, Flow rate 1 mL/min, P= 17 bar, t1 = 52.8 min]. 
1
H NMR 
(300MHz, CDCl3) δ 4.82-4.77 (m, 1H),3.63 (s, 3H), 3.21-3.12 (m, 2H), 2.98 (s, 3H), 2.93 (s, 
3H), 2.62-2.50 (m, 1H), 2.31-2.20 (m, 1H); 
19F NMR (282 MHz, CDCl3) δ -131.1 (m, 2F), -
135.1 (m, 2F);
 13
C NMR (75 MHz, CDCl3)  168.5, 146.8 (dd, J = 247.5, 15.0 Hz), 145.7 (dd, J = 
255.0, 15.0 Hz), 143.5, 142.3, 118.2, 105.6 (t, J =22.5 Hz), 58.8, 52.7, 50.9, 41.1, 30.1, 20.9;IR 
(nujol) 3240, 1742, 141, 1457, 1317, 1022,948 cm
-1
.Anal. Calcd. for  C13H14BrF4NO6S2: C, 
31.21; H, 2.82; N, 2.80. Found: C, 31.48; H, 2.93; N, 2.97. 
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7.8 Synthesis of methionine sulfoxide sulfonamide 26e,f: General 
procedure. 
 
 
 
 
 
 
 
 
 
In a round-bottomed flask equipped with a magnetic stirrer are placed 34.1 mg. (0.159 mmole) of 
powdered sodium metaperiodate and 2 ml. of water. The mixture is stirred and cooled in an ice 
bath, and 600 mg. (1.59 mmole) of sulphonamide S-24e,f is added. The reaction mixture is stirred 
for 15 hours at ice-bath temperature and is then filtered through a Büchner funnel. The filter cake 
of sodium iodate is washed with three 3 ml portions of methylene chloride. The water-methylene 
chloride filtrate is transferred to a separatory funnel, the lower methylene chloride layer is 
removed, and the water layer is extracted with three 10 ml portions of methylene chloride. The 
combined methylene chloride extracts are treated with activated carbon and dried over anhydrous 
sodium sulfate. The solvent is removed at reduced pressure to yield 98% of sulfoxide derivatives 
as a thick clear wax, and as a mixture of diastereomers.Starting sulfonamides, reaction time, 
product, yield, physical and analytical data are as follows. 
 
 
 
 Methionine sulfoxide sulfonamide 26a (20 h, 100.6 mg, 98%, 
mixture of diastereomers 1:1). wax, FCC - AcOEt/hexane (1 : 
1), []D
20
 +1.5 (c 1 CHCl3). [CHIRALCEL OJ-H
®
, Hexane – 
Isopropanol 7 : 3, Flow rate 0.5 mL/min, P= 27 bar, t1 = 17.9 
min, t2 = 21.5 min]. 
1
H NMR (300MHz, CDCl3) δ 4.85-4.77 
(m, 1H),3.59 (s, 3H), 2.92 (s, 3H), 2.82-2.71 (m, 2H), 2.61 (s, 3H), 2.59-2.49 (m, 1H), 2.25-2.16 
(m, 1H); 
19
F NMR (282 MHz, CDCl3) δ -131.2 (m, 2F), -135.1 (m, 2F); 13C NMR (75 MHz, 
CDCl3)  168.9, 147.0 (dd, J = 255.0, 7.5 Hz), 145.8 (dd, J = 265.5, 16.5 Hz), 143.6, 142.3, 
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118.2, 105.6 (t, J = 22.5 Hz), 58.8, 52.7, 50.3, 38.8, 30.1, 21.9;IR (nujol) 3238, 1738, 145, 1448, 
1306, 1018,952 cm
-1
.Anal. Calcd. for  C13H14BrF4NO5S2: C, 32.24; H, 2.91; N, 2.89. Found: C, 
32.52; H, 3.23; N, 2.97. 
 
 
 
 
 Methionine sulfoxide sulfonamide 26b (12 h, 399.6 mg, 94%, 
mixture of diastereomers 2:1). wax, FCC - AcOEt/MeOH(13 : 1), 
[]D
20 
- 27.8 (c 1.1 CHCl3). [CHIRALCEL OJ-H
®
, Hexane – 
Isopropanol 7 : 3, Flow rate 0.8 mL/min, P= 48 bar, t1 = 21.3 min, 
t2 = 28.0 min]. 
1
H NMR (300MHz, CDCl3) δ7.33-7.27 (m, 1H), 
4.88-4.83 (m, 1H),3.62 (s, 3H), 2.96 (s, 3H), 2.85-2.69 (m, 2H), 2.64 (s, 3H), 2.59-2.51 (m, 1H), 
2.27-2.22 (m, 1H); 
19
F NMR (282 MHz, CDCl3) δ -133.6 (m, 2F), -134.4 (m, 2F); 13C NMR (75 
MHz, CDCl3)  168.9, 147.7 (dd, J = 247.5, 7.5 Hz), 145.6 (dd, J = 247.5, 15.0 Hz), 144.4, 142.2, 
118.2, 110.2 (t, J = 22.5 Hz), 59.3, 52.5, 50.2, 38.7, 30.0, 21.8;IR (nujol) 3248, 1758, 136, 1457, 
1316, 1025,964 cm
-1
.Anal. Calcd. for  C13H15F4NO5S2: C, 38.52; H, 3.73; N, 3.46. Found: C, 
38.65; H, 3.89; N, 3.72. 
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7.9 Synthesis of Benzo[d]sultams 8a-d: General Procedure. 
 
 
 
 
To a solution of sulfonamide (1 mmol) in dry DME (4 mL), base (4 mmol) in DME(1mL) was 
added and the mixture was stirred at  25°C until completion (TLC control).The solution was then 
diluted with AcOEt (10 mL), washed with aqueous 5% citric acid(3×10 mL), saturated NaHCO3 
solution (2×10 mL), and brine (10 mL). The organic phasewas dried over MgSO4, filtered, and 
concentrated under reduced pressure (RV), givingthe sultams, in some case without any further 
purification. Starting sulfonamides,reaction time, product, yield, physical and analytical data are 
as follows. 
 
 
 
Methyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (8a).4 h, 3.60 g, 96%;white solid; mp 98-
99°C.
1
H NMR (300 MHz, CDCl3) δ 7.42-7.34 (m, 5H), 6.38 (s,1H), 3.93 
(s, 3H).
19
F NMR (282 MHz, CDCl3) δ -132.5 (m, 1F), -140.1 (m,1F), -144 
(m, 1F), -147.9 (m, 1F).
13
C NMR (75 MHz, CDCl3) δ 168.0, 144.6 (dt, J = 
262.2,14.3 Hz), 143.6 (ddd, J = 261.8, 12.4, 3.3 Hz), 141.6 (dt, J =262.1, 14.2 Hz), 140.9 (dd, J = 
261.6, 12.5 Hz), 135.4, 129.6,129.0, 126.2, 121.8 (d, J = 14.3 Hz), 119.6 (d, J = 17.8 Hz),69.9, 
54.3.IR (nujol) 3280, 1748, 1637, 1512, 1376, 1319, 1257, 1173,1035, 914 cm
-1
.Anal. Calcd. for 
C15H9F4NO4S: C, 48.01; H, 2.42; N, 3.73.Found: C, 47.96; H, 2.44; N, 3.73. 
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Ethyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (8b).16 h, 366 mg, 94%;white solid; mp 83.5-
84.5°C.
1
H NMR (300 MHz, CDCl3) δ 7.43-7.37 (m, 5H), 5.98 (s,1H), 
4.50-4.08 (m, 2H), 3.93 (t, 3H, J = 6.3 Hz).
19
F NMR (282 MHz, CDCl3) δ-
132.1 (m, 1F), -139.6 (m,1F), -143.8 (m, 1F), -147.5 (m, 1F).IR (nujol) 
3245, 1742, 1643, 1518, 1369, 1314, 1252, 1173,1033, 909 cm
-1
.Anal. Calcd. for C16H11F4NO4S: 
C, 49.36; H, 2.85; N,3.60. Found: C, 49.34; H, 2.82; N, 3.59. 
 
 
 
 Isopropyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate1,1-dioxide (8c).20 h, 379,1 
mg, 94%;white solid; mp 95.5-96.5°C.
1
H NMR (300 MHz, CDCl3) δ7.41-
7.36 (m, 5H), 6.09 (s,1H), 5.27-5.18 (m, 1H), 1.34 (d, 3H, J = 6.3 Hz), 1.29 
(d,3H, J = 6.3 Hz).
19
F NMR (282 MHz, CDCl3) δ -131.9 (m, 1F), -139.8 
(m,1F), -144.0 (m, 1F), -147.7 (m, 1F).
13
C NMR (75 MHz, CDCl3) δ167.5, 145.2 (dt, J = 
261.1,14.4 Hz), 144.2 (dd, J = 257.6, 11.6 Hz), 142.1 (dt, J =260.7, 14.4 Hz), 141.4 (dd, J = 
260.6, 11.7 Hz), 136.2, 129.9,129.5, 126.8, 122.5 (d, J = 15.2 Hz), 120.4 (d, J = 17.6 Hz),73.5, 
70.5, 21.8.IR (nujol) 3229, 1746, 1644, 1523, 1362, 1315, 1256, 1171,1033, 920 cm
-1
.Anal. 
Calcd. for C17H13F4NO4S: C, 50.62; H, 3.25; N,3.47. Found: C, 50.60; H, 3.26; N, 3.45. 
 
 
 
tert-Butyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate1,1-dioxide (8d). 16 h, 379,8 
mg, 91%;white solid; mp 108-109°C.
1
H NMR (300 MHz, CDCl3) δ 7.41-
7.39 (m, 5H), 6.16 (s,1H), 1.52 (s, 9H).
19
F NMR (282 MHz, CDCl3) δ -
132.0 (m, 1F), -140.1 (m,1F), -144.4 (m, 1F), -148.1 (m, 1F).
13
C NMR 
(75 MHz, CDCl3) δ 166.4, 146.5-139.1 (4 C-FAr), 136.1, 129.5, 129.1, 125.9, 120.5, 119.5, 86.6, 
70.5, 27.9.IR (nujol) 3233, 1745, 1641, 1523, 1363, 1315, 1257, 1171,1040, 903 cm
-1
.Anal. 
Calcd. for C18H15F4NO4S: C, 51.80; H, 3.62; N,3.36. Found: C, 51.81; H, 3.63; N, 3.39. 
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7.10  N-Alkylation of Racemic Benzo[d]sultams 8a: General Procedure. 
 
 
 
 
To a solution of sultam (0,25 mmol) and TEBA (5,7 mg, 0,025 mmol) in dryacetonitrile (1 mL) 
at 25 °C, anhydrous potassium carbonate (51,8 mg, 0,375 mmol)was added. The resulting 
heterogeneous mixture was stirred for 10 min, then thealkylating agent RX (0,375 mmol) was 
added and the reaction was monitored byTLC until completion. The mixture was filtered through 
a celite pad and, afterevaporation of the solvent (RV), the crude was purified by FCC. Starting 
sulfonamideand alkylating agent (RX), reaction time, product, yield and eluant are as follows. 
 
 
 
 Methyl 4,5,6,7-tetrafluoro-2-ethyl-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4b). 
Starting sultam 8a, 93,8 mg; EtI, 58,5 mg; 
sultam 4b, 87,2 mg, 95%, 
MPLC (AcOEt : esano – 1 : 12). 
 
 
 
Methyl 4,5,6,7-tetrafluoro-2-n-propyl-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (4c). 
Starting sultam 8a, 93,8 mg; n-PrI, 63,7 mg; 
sultam 4c, 83,9 mg, 88%, 
MPLC (AcOEt : esano – 1 : 12). 
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7.11 SL-PTC Ring Closing Reactions of N-Alkylsulfonamide 7a. 
 
 
 
To a solution of N-alkyl-sulfonamide (0.2 mmol) and TEBA (5 mg, 0.02 mmol) in dry DMSO 
(1mL) at 25 °C, anhydrous Cs2CO3 (130 mg, 0.4 mmol) was added. This suspension 
wasvigorously stirred for 15 min, monitoring by TLC (AcOEt : hexane – 1 : 9), then diluted 
withwater (2 mL), extracted with DCM (3×10 mL). The solvent was removed under vacuum 
(RV).The residue was diluted with AcOEt (10 mL), washed with brine (5×2mL), dried over 
Mg2SO4filtered and, after evaporation of the solvent (RV), purified by MPLC (AcOEt : hexane – 
1 : 12) togive the desired N-alkyl benzosultam. Starting sulfonamides, product, yield 
andchromatographic eluants are as follows. 
 
 
 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carbossilate 1,1-dioxide (4a). 
Starting sultam 8a, 93,8 mg; MeI, 53,2 mg; 
sultam 4a, 142 mg, 91%, 
MPLC (AcOEt : hexane – 1 : 12). 
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7.12 Synthesis of Benzo[d]sultams (+)8a,d, (+)18a-e: General Procedure  
 
 
 
 
 
To a solution of sulfonamide S-3a,d(1 mmol) in dry DME (3 mL), was added BTMG(609 mg, 4 
mmol)in dry DME (3 mL) at 0°C. The solution was stirred at 25 °C until completion (TLC 
control). The crude was then diluted with AcOEt (10 mL), washed with aqueous 5% citric acid 
(2×10 mL), saturated NaHCO3 solution (2×10 mL), and brine (10 mL). The organic phase was 
dried over MgSO4, filtered, and concentrated under reduced pressure (RV), giving the sultam 
(+)8a,d and (+)18a-6. Starting sulfonamide S-3a,d, reaction time, product, yield, physical and 
analytical data are as follows. 
 
 
 
 
(R)-Methyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(+)8a]. 
SulfonamideS-3a 395 mg. (+)8a (4d, 360 mg, 96%). White solid; mp 
98-99°C; FCC - AcOEt/hexane (1 : 4); []D
20.
+ 61.2 (c 1.1, CHCl3) ee 
80% [CHIRALCEL OD
®
, Hexane – Isopropanol 8 : 2+ 0.2% TFA, 
Flow rate 0.7 mL/min, P= 10 bar, t1 = 9.9 min, t2 = 10.7 min]. 
1
H NMR (300 MHz, CDCl3)  
7.42-7.34 (m, 5H), 6.38 (s, 1H), 3.93 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -132.5 (m, 1F), -
140.1 (m, 1F), -144 (m, 1F), -147.9 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  168.0, 144.6 (dt, J = 
262.2, 14.3 Hz), 143.6 (ddd, J = 261.8, 12.4, 3.3 Hz), 141.6 (dt, J = 262.1, 14.2 Hz), 140.9 (dd, J 
= 261.6, 12.5 Hz), 135.4, 129.6, 129.0, 126.2, 121.8 (d, J = 14.3 Hz), 119.6 (d, J = 17.8 Hz), 
69.9, 54.3; IR (nujol) 3280, 1748, 1637, 1512, 1376, 1319, 1257, 1173, 1035, 914 cm
-1
. Anal. 
Calcd. for C15H9F4NO4S: C, 48.01; H, 2.42; N, 3.73. Found: C50.13; H, 2.68; N, 3.92. 
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(R)-tert-butyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(+)8d]. 
SulfonamideS-3d 437 mg. (+)8d(6d, 146 mg, 35%). White solid; mp 
108-109°C; FCC - AcOEt/hexane (1 : 4); []D
20 
+90.7 (c 0.8, CHCl3) 
ee 87% [CHIRALCEL OD
®
, Hexane – Isopropanol 9 : 1+ 0.2% TFA, 
Flow rate 1 mL/min, P= 13 bar, t1 = 6.2 min, t2 = 7.0 min]. 
1
H NMR (300 MHz, CDCl3)  7.41-
7.39 (m, 5H), 6.16 (s, 1H), 1.52 (s, 9H); 
19
F NMR (282 MHz, CDCl3)  -132.0 (m, 1F), -140.1 
(m, 1F), -144.4 (m, 1F), -148.1 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  166.4, 144.7 (dd, J = 
261.5, 14.9 Hz), 143.7 (ddd, J = 257.5, 13.1, 4.2 Hz), 141.3 (dd, J = 260.3, 13.7 Hz), 140.9 (dd, J 
= 260.4, 14.6 Hz), 136.1, 129.6, 129.1, 126.4, 128.5, 126.4, 126.0, 86.6, 70.5, 27.7; IR (nujol) 
3233, 1745, 1641, 1523, 1363, 1315, 1257, 1171, 1040, 903 cm
-1
.Anal. Calcd. for C18H15F4NO4S: 
C, 51.80; H, 3.62; N, 3.36. Found: C, 51.87; H, 3.75; N, 3.45. 
 
 
 
 
(R)-Methyl 4,5,6,7-tetrafluoro-3-(4-nitrophenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(18a)]. 
Sulfonamide9a, 440 mg. 18a (16h, 189 mg, 45%). Yellow wax; FCC - 
AcOEt/hexane (1 : 2); ee 0% [CHIRALCEL OD ®, Hexane – 
Isopropanol 9 : 1+ 0.2% TFA, Flow rate 1 mL/min, P= 13 bar, t1 = 13.7 
min, t2 = 23.0 min]. 
1
H NMR (300 MHz, CDCl3)  7.28-7.24 (m, 2H), 
7.66-7.63 (m, 2H), 6.2 (s, 1H), 3.99 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -133.2 (m, 1F), -
138.7, -142.9 (m, 1F), -146.1 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.2, 148.6, 144.9 (dd, J = 
262.1, 13.1 Hz), 143.7 (dd, J = 256.9, 11.3 Hz), 142.1(dm, J = 264.0 Hz), 142.0, 141.4 (dd, J = 
260.9, 10.7 Hz), 127.9, 124.2, 120.4, 119.9 (d, J = 10.8 Hz), 69.7, 55.2. Anal. Calcd. for 
C15H8F4N2O6S: C, 42.87; H, 1.92; N, 6.67. Found: C, 42.97; H, 2.13; N, 6.84. 
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(R)-Methyl 4,5,6,7-tetrafluoro-3-(4-chlorophenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(+)18b]. 
Sulfonamide9b, 429 mg. (+)18b (7d, 135 mg, 33%). White wax; FCC - 
AcOEt/hexane (1 : 4); ee<10% [CHIRALCEL OD
®
, Hexane – 
Isopropanol 9 : 1, Flow rate 1 mL/min, P= 13 bar, t1 = 11.7 min, t2 = 15.0 
min]. 
1
H NMR (300 MHz, CDCl3)  7.50 (dd, 1H, J = 7.8, 1.2 Hz), 7.39 
(dt, 1H, J = 7.8, 1.5 Hz), 7.25 (dt, 1H, J = 7.5, 1.2 Hz), 6.84 (dd, 1H, J = 8.1, 1.8 Hz), 6.5 (s, 1H), 
3.92 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -131.6 (m, 1F), -138.4 (m, 1F), -143.8 (m, 1F), -
146.3 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  168.5, 144.6 (dm, J = 261.2 Hz), 143.5 (dm, J = 
259.2 Hz), 142.1(dm, J = 264.0 Hz), 142.0, 141.3 (dm, J = 258.1 Hz), 131.5, 131.1, 128.3, 127.2, 
120.3, 115.0, 69.3, 55.2; IR (nujol) 3274, 1731, 1634, 1288, 1160, 911 cm
-1
.Anal. Calcd. for 
C15H8ClF4NO4S: C, 43.97; H, 1.97; N, 3.42. Found: 44.20; H, 2.35; N, 3.76.  
 
 
 
 
R-Methyl 4,5,6,7-tetrafluoro-3-(4-phenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide ((+)18c)  
sulfonamide 49c, 501 mg, (+)18c (4d, 169 mg, 98%), white wax; 
FCC - AcOEt/hexane (1 : 4); []D
20
= +35.2 (c 0.8 CHCl3) ee64% 
[.CHIRALCEL OD
®
, Hexane – Isopropanol 9 : 1 + 0.2% TFA, 
Flow rate 1 mL/min, P= 15 bar, t1 = 18.7 min, t2 = 34.0 min.].
1
H 
NMR (300 MHz, CDCl3)  7.63-7.55 (m, 4H), 7.47-7.38 (m, 5H), 7.20 (bs, 1H), 3.98 (s, 
3H).
19
F NMR (282 MHz, CDCl3)  -132.6 (m, 1F), -139.9 (m, 1F), -144.0 (m, 1F), -147.8 (m, 
1F). Anal. Calcd. for C21H13F4NO4S: C, 55.88; H, 2.90; N, 3.10. Found: C, 56.12; H, 3.06; N, 
3.25.  
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(R)-Methyl 4,5,6,7-tetrafluoro-3-(4-benzyloxyphenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(+)18d]. 
Sulfonamide9d, 501 mg. (+)18d (4d, 169 mg, 35%). White wax; FCC 
- AcOEt/hexane (1 : 4); []D
20
 +59.2 (c 0.8 CHCl3) ee 96% 
[CHIRALCEL OD
®
, Hexane – Isopropanol 8 : 2 + 0.2% TFA, Flow 
rate 1 mL/min, P= 15 bar, t1 = 9.5 min, t2 = 14.0 min]. 
1
H NMR (300 
MHz, CDCl3)  7.42-7.33 (m, 5H), 7.31-7.25 (m, 2H), 7.00-6.96 (m, 2H), 6.13 (s, 1H), 5.06 (s, 
2H), 3.93 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -132.5 (m, 1F), -140.0 (m, 1F), -143.9 (m, 1F), 
-147.9 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.8, 159.3, 144.4 (dt, J = 274.4, 13.9 Hz), 143.3 
(dd, J = 259.9, 11.4 Hz), 141.4 (dt, J = 260.8, 13.4 Hz), 140.7 (dd, J = 261.6, 10.8 Hz), 135.9, 
129.9, 128.2, 127.7, 127.4, 127.0, 121.7 (d, J = 13.6 Hz), 119.4 (d, J = 17.4 Hz), 115.0, 69.8, 
69.3, 54.1; IR (nujol) 3284, 1739, 1645, 1508, 1371, 1304, 1255, 1170, 1022, 906 cm
-1
. Anal. 
Calcd. for C22H15F4NO5S: C, 54.89; H, 3.14; N, 2.91. Found: C, 54.92; H, 3.23; N, 3.20. 
 
 
 
 
(R)-Methyl 4,5,6,7-tetrafluoro-3-(4-methoxyphenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(+)18e]. 
Sulfonamide9e, 425 mg. (+)18e (4d, 385 mg, 95%). White wax; FCC 
- AcOEt/hexane (1 : 4); []D
20
 +39.5 (c 1 CHCl3) ee 94% 
[CHIRALCEL OD
®
, Hexane – Isopropanol 9 : 1, Flow rate 1 mL/min, 
P= 13 bar, t1 = 12.2 min, t2 = 18.4 min].
 1
H NMR (300 MHz, CDCl3)  
7.26-7.23 (m, 2H), 6.88-6.85 (m, 2H), 5.9 (s, 1H), 3.91 (s, 3H), 3.78 (s, 3H); 
19
F NMR (282 
MHz, CDCl3)  -132.7 (m, 1F), -140.2 (m, 1F), -144.1 (m, 1F), -148.1 (m, 1F); 
13
C NMR (75 
MHz, CDCl3)  168.2, 160.5, 144.7 (dt, J = 264.2, 14.3 Hz), 143.7 (dd, J = 261.9, 12.1 Hz), 
141.6 (dt, J = 264.2, 14.4 Hz), 140.9 (dd, J = 261.9, 12.1 Hz), 127.7, 127.2, 122.2 (d, J = 13.6 
Hz), 119.8 (d, J = 17.4 Hz), 114.1, 69.7, 55.3, 54.4; IR (nujol) 3270, 1750, 1600, 1458, 1436, 
1352, 1326, 1258, 1170, 1050, 912 cm
-1
. Anal. Calcd. for C16H11F4NO5S: C, 47.41; H, 2.74; N, 
3.46. Found: C, 47.64; H, 2.83; N, 3.68. 
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7.13 Synthesis of Benzo[d]sultams (-)8a,d, (-)18a-e: General Procedure 
BTMG/DBU 
 
 
 
 
To a solution of sulfonamide S-3a,d (1 mmol) in dry DME (3 mL), was added a solution of DBU 
(46 mg, 0.3 mmol) and BTMG (291 mg, 1.7 mmol)in dry DME (3 mL) at 0°C. The solution was 
stirred at 25 °C until completion (TLC control). The crude was then diluted with AcOEt (10 mL), 
washed with aqueous 5% citric acid (3×10 mL), saturated NaHCO3 solution (2×10 mL), and 
brine (10 mL). The organic phase was dried over MgSO4, filtered, and concentrated under 
reduced pressure (RV), giving the sultam (-)8a,d and (-)18a-e. 
 
 
 
 
(S)-Methyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(-)8a]. 
SulfonamideS-3a 395 mg. (-)8a (16h, 364 mg, 97%). White wax; 
[]D
20
 -52.8 (c 1 CHCl3) ee 68% [CHIRALCEL OD
®
, Hexane – 
Isopropanol 8 : 2+ 0.2% TFA, Flow rate 0.7 mL/min, P= 10 bar, t1 = 
9.9 min, t2 = 10.7 min]. NMR spectra match those of (+)8a.  
 
 
 
(S)-tert-butyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(-)8d)]. 
SulfonamideS-3d 437 mg. (-)8d(24h, 379.8 mg, 91%). Clare wax; 
[]D
20
 +90.7 (c 0.8 CHCl3) ee 82% [CHIRALCEL OD
®
, Hexane – 
Isopropanol 9 : 1+ 0.2% TFA, Flow rate 1 mL/min, P= 13 bar, t1 = 
6.2 min, t2 = 7.0 min]. NMR spectra match those of (+)8d.  
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(S)-Methyl 4,5,6,7-tetrafluoro-3-(4-methoxyphenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(-)18e]. 
Sulfonamide9e, 425 mg. (-)18e (4d, 401 mg, 99%). White wax; FCC - 
AcOEt/hexane (1 : 4); []D
20
 -37.1 (c 0.7 CHCl3) ee 94% 
[CHIRALCEL OD
®
, Hexane – Isopropanol 9 : 1, Flow rate 1 mL/min, 
P= 13 bar, t1 = 12.2 min, t2 = 18.4 min]. NMR spectra match those of 
(+)18e.  
 
 
 
(S)-Methyl 4,5,6,7-tetrafluoro-3-(4-benzyloxyphenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(-)18d]. 
Sulfonamide9d, 501 mg. (-)18d (4d, 390 mg, 81%). White wax; FCC - 
AcOEt/hexane (1 : 4); []D
20
 -59.2 (c 1.1 CHCl3) ee 94% 
[CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2 + 0.2% TFA, Flow 
rate 1 mL/min, P= 15 bar, t1 = 9.53 min, t2 = 13.94 min.]. NMR spectra 
match those of (+)18d.  
 
 
 
(S)-Methyl 4,5,6,7-tetrafluoro-3-(4-phenyl)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(-)18c]. 
Sulfonamide9c, 471 mg. (-)18c (16h, 424 mg, 94%). White wax; FCC - 
AcOEt/hexane (1 : 4); []D
20
 -27.7 (c 0.7 CHCl3) ee 56% 
[CHIRALCEL OD
®
, Hexane – Isopropanol 9 : 1 + 0.2% TFA, Flow 
rate 1 mL/min, P= 15 bar, t1 = 18.7 min, t2 = 34.0 min.]. NMR spectra 
match those of (+)18c. 
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7.14 N-Alkylation of enantiopure Benzo[d]sultams 8a,d: General Procedure.  
 
 
 
 
 
To a solution of sultam 8a,d (1 mmol) and TEBA (23 mg, 0.1 mmol) in dry acetonitrile (4 mL) at 
25 °C, anhydrous potassium carbonate (208 mg, 1.5 mmol) was added. The resulting 
heterogeneous mixture was stirred for 10 min, then the alkylating agent R
2
X (1.5 mmol) was 
added and the reaction was monitored by TLC until completion. The mixture was filtered through 
a celite pad and, after evaporation of the solvent (RV), the crude was purified by FCC and 
recrystallized giving the enantiomerically pure sultams 4c,f,g. Starting sulphonamide and 
alkylating agent (RX), reaction time, product, yield and eluant are as follows. 
 
 
 
(S)-Methyl 4,5,6,7-tetrafluoro-1-methyl-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(+)4g]. MeI, 
213 mg; sultam (+)8d, 375 mg. (+)4g (8h, 3702 mg, 95%). White solid, 
mp 165-166°C (iPrOH. Solution: 86%, ee>99%; crystallized: 14%, ee 
0%); FCC - AcOEt/hexane (1 : 7); []D
20
 -119.8 (c 1 CHCl3) ee>99% 
[CHIRALCEL OD
®
, Hexane – Isopropanol 8 : 2, Flow rate 1 mL/min, P= 15 bar, t1 = 5.4 min, 
t2 = 6.7 min.]. 
1
H NMR (300 MHz, CDCl3)  7.42- 7.26 (m, 5H), 2.84 (s, 3H), 1.53(s, 9H); 
19
F 
NMR (282, MHz, CDCl3)  135 (m, 1F), -140.3 (m, 1F), -145.3 (m, 1F), -149 (m, 1F); 
13
C 
NMR (125 MHz, CDCl3)  165.1, 144.1 (dt, J = 259.4, 14.3 Hz), 143.3 (ddd, J = 259.0, 13.5, 
2.8 Hz), 141.3 (dt, J = 259.3, 14.3 Hz), 140.8 (dd, J = 259.2, 13.7 Hz), 133.1, 129.6, 129.1, 
127.4, 123.0 (d, J = 13.7 Hz), 120.3 (d, J = 16.1 Hz), 85.5, 72.2, 27.7, 25.4; IR (nujol) 1748, 
1638, 1516, 1495, 1296, 1256, 1230, 1170, 1077, 977, 916, 880, 693, 629, 614 cm
-1
. Anal. 
Calcd. for C19H17F4NO4S: C, 52.90; H, 3.97; F, N, 3.25. Found: C, 53.01; H, 3.95; N, 3.64. 
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(R)-Methyl 4,5,6,7-tetrafluoro-2-propyl-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(-)4a]. nPrI, 
255 mg; sultam (-)8a,375 mg. (-)4a (8h, 363 mg, 87%). White solid, mp 
56-57°C (iPrOH. Solution: 30%, ee 0; crystallized: 68%, ee>99%); FCC 
- AcOEt/hexane (1 : 4); []D
20
 +122.6 (c 1 CHCl3) ee>99% 
[CHIRALCEL OD
®
, Hexane – Isopropanol 9 : 1, Flow rate 0.6 mL/min, P= 7 bar, t1 = 8.7 min, t2 
= 10.6 min]. 
1
H NMR (300 MHz, CDCl3)  7.41-7.25 (m, 5H), 3.90 (s, 3H), 3.34-3.10 (m, 2H), 
1.71-1.56 (m, 2H), 0.79 (t, 3H, J = 7.5 Hz); 
19
F NMR (282 MHz, CDCl3)  -135.4 (m, 1F), -140.5 
(m, 1F), -145.3 (m, 1F), -149.1 (m, 1F); 
13
C NMR (125 MHz, CDCl3)  167.0, 144.2 (dt, J = 
258.7, 16.1 Hz), 143.0 (dd, J = 257.9, 9.4 Hz), 141.4 (dt, J = 260.0, 13.4 Hz), 140.9 (dd, J = 
258.6, 11.2 Hz), 133.7, 129.7, 129.0, 127.6, 122.3 (d, J = 16.1 Hz), 118.3, 72.4, 53.7, 44.7, 22.4, 
11.2; IR (nujol) 1748, 1639, 1510, 1497, 1300, 1232, 1209, 1167, 1078, 993, 876, 699 cm
-1
. 
Anal. Calcd. for C18H15F4NO4S: C, 51.80; H, 3.62; N, 3.36. Found: C, 51.75; H, 3.60; N, 3.41.  
 
 
 
(S)-Methyl 4,5,6,7-tetrafluoro-2-allyl-3-phenyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [(-)4f]. AllBr, 
181 mg; sultam (-)8a, 375 mg. (-)4f (8h, 142 mg, 91%). White solid, mp 
111-112°C (iPr2O/hexane – 1 : 1. Solution: 67%, ee>99%; crystallized: 
30%, ee 0%); FCC - AcOEt/hexane (1 : 6); []D
20
 +122.6 (c 1 CHCl3) 
ee>99% [CHIRALCEL OD
®
, Hexane – Isopropanol 9 : 1, Flow rate 0.7 mL/min, P= 8 bar, t1 = 
8.3 min, t2 = 9.5 min]. 
1
H NMR (300 MHz, CDCl3)  7.41-7.38 (m, 3H), 7.31-7.27 (m, 2H), 5.88-
5.75 (m, 1H), 5.20-5.08 (m, 2H), 4.03-3.78 (m, 2H), 3.89 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  
-135.2 (m, 1F), -140.5 (m, 1F), -145.2 (m, 1F), -149.1 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  
167.0, 144.3 (dt, J = 260.0, 13.6 Hz), 143.2 (dd, J = 257.7, 11.9 Hz), 141.4 (dt, J = 259.7, 14.0 
Hz), 140.7 (dd, J = 259.1, 10.8 Hz), 133.5, 132.3, 129.8, 129.1, 127.6, 122.3 (d, J = 13.7 Hz), 
118.8, 118.3, 72.2, 53.8, 44.9; IR (nujol) 1748, 1643, 1516, 1498, 1302, 1262, 1230, 1171, 1077, 
977, 916, 880, 691 cm
-1
. Anal. Calcd. for C18H13F4NO4S: C, 52.05; H, 3.15; N, 3.37. Found: C, 
52.00; H, 3.19; N, 3.34. 
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7.15 Synthesis of Benzo[d]sultams R-20a-d, R-25a-j, 28e,f, R-29: General 
Procedure (DBU) 
 
 
 
 
To a solution of sulfonamide S-19a-d, 24a-j,26e,f or 27 (0.2 mmol) in dry DME (0.5 mL), was 
added a solution of DBU (121.7 mg, 0.8 mmol) in dry DME (0.3 mL) at -20°C. The solution was 
stirred at -20 °C until completion (TLC control). The crude was then diluted with AcOEt (10 
mL), washed with aqueous 5% citric acid (3×3 mL), saturated NaHCO3 solution (2×5 mL), and 
brine (5 mL). The organic phase was dried over MgSO4, filtered, and concentrated under reduced 
pressure (RV), giving the sultam. 
 
 
 
 
(S)-Methyl 4,5,6,7-tetrafluoro-2-methyl-3-benzyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-20a. sultam 
R-20a  (2h, 50.7 mg, 63%). Wax; FCC - AcOEt/hexane (1 : 4); []D
20
 
+78.5 (c 1 CHCl3) ee>95% [CHIRALCEL OD
®
, Hexane – Isopropanol 
9 : 1, Flow rate 1 mL/min, P= 13 bar, t1 = 10.8 min, t2 = 16.2 min]. 
1
H 
NMR (300 MHz, CDCl3)  7.26-7.17 (m, 3H), 7.01-7.00 (m, 2H), 3.81 
(s, 3H), 3.58-3.56 (m, 2H), 3.01 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -137.5 (m, 1F), -139.5 
(m, 1F), -146.2 (m, 1F), -148.7 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.1, 144.3 (dt, J = 
262.5, 15.0 Hz), 144.1 (dd, J = 255.7, 14.2 Hz), 142.8 (dd, J = 262.5, 18.7 Hz), 142.1 (dt, J = 
262.5, 15.0 Hz), 140.8 (dd, J = 255.7, 14.2 Hz), 139.5 (dd, J = 262.5, 18.7 Hz), 132.5, 129.5, 
128.5, 127.9, 70.1, 53.9, 36.6, 24.9; IR (nujol) 1753, 1635, 1522, 1483, 1314, 1254, 1227, 1163, 
1068, 967, 878, 685 cm
-1
. Anal. Calcd. for C17H13F4NO4S: C, 50.62; H, 3.25; N, 3.47. Found: C, 
50.75; H, 3.34; N, 3.52. 
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(S)-Methyl 4,5,6,7-tetrafluoro-2-allyl-3-benzyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-20d. sultam 
R-20d(2h, 40.7 mg, 650%). Wax; FCC - AcOEt/hexane (1 : 6); []D
20
 
+78.5 (c 1 CHCl3) ee>96% [CHIRALCEL OD
®
, Hexane – Isopropanol 
9 : 1, Flow rate 1 mL/min, P= 13 bar, t1 = 11.6 min, t2 = 17.9 min]. 
1
H 
NMR (300 MHz, CDCl3)  7.20-7.18 (m, 3H), 7.04-7.03 (m, 2H), 6.12-
5.99 (m, 1H), 5.45-5.32 (m, 2H), 4.08-4.05 (m, 2H), 3.77 (s, 3H), 3.60 (s, 3H); 
19
F NMR (282 
MHz, CDCl3)  -138.1 (m, 1F), -139.3 (m, 1F), -145.9 (m, 1F), -148.4 (m, 1F); 
13
C NMR (75 
MHz, CDCl3)  167.4, 143.8 (dd, J = 255.0, 15.0 Hz), 143.0 (dt, J = 262.5, 19.5 Hz), 140.4(dd, J 
= 255.0, 15.0 Hz), 139.4 (dt, J = 262.5, 15.0 Hz), 132.5, 131.2, 129.6, 128.4, 127.8, 120.5, 69.4, 
53.1, 45.5, 43.5, 36.7; IR (nujol) 1748, 1642, 1505, 1467, 1308, 1247, 1236, 1153, 1054, 956, 
868, 675 cm
-1
. Anal. Calcd. for C19H15F4NO4S: C, 53.15; H, 3.52; N, 3.26. Found: C, 53.27; H, 
3.64; N, 3.31. 
 
 
 
(S)-Methyl 6-bromo-4,5, 7-trifluoro-2-methyl-3-benzyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-20b. 
sultam R-20b  (8h, 80.7 mg, 87%). Wax; FCC - AcOEt/hexane (1 : 1); 
[]D
20
 +149.2 (c 1.2 CHCl3) ee>95% [CHIRALCEL OJ-H
®
, Hexane – 
Isopropanol 8 : 2, Flow rate 0.8 mL/min, P= 33 bar, t1 = 17.8 min, t2 = 
24.4 min]. 
1
H NMR (300 MHz, CDCl3)  7.17-7.16 (m, 3H), 7.01-
6.97 (m, 2H), 3.82 (s, 3H), 3.59-3.50 (m, 2H), 3.00 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -
106.2 (m, 1F), -117.5 (m, 1F), -138.6 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.2, 151.8, 150.5 
(dd, J = 255.0, 15.0 Hz), 148.5, 147.1 (dd, J = 255.0, 15.0 Hz), 142.5 (dd, J = 265.5, 15.0 Hz), 
139.0 (dd, J = 265.5, 15.0 Hz), 132.6,129.6, 128.4, 127.8, 132.6 (d, J = 15.0 Hz), 119,0 (d, J = 
15.0 Hz), 105.6 (t, J = 22.5Hz), 70.1, 53.8, 36.5, 24.9; IR (nujol) 1747, 1625, 1518, 1476, 1306, 
1248, 1216, 1154, 1052, 957, 868, 682 cm
-1
. Anal. Calcd. for C17H13BrF3NO4S: C, 43.98; H, 
2.82; N, 3.02. Found: C, 44.02; H, 2.94; N, 3.16. 
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(S)-Methyl 4,5, 7-trifluoro-2-methyl-3-benzyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-20c. sultam 
R-20c  (12h, 63.0 mg, 82%). Wax; FCC - AcOEt/hexane (1 : 1); []D
20
 
+64.2 (c 1 CHCl3) ee>95% [CHIRALCEL OJ-H
®
, Hexane – 
Isopropanol 7 : 3, Flow rate 0.8 mL/min, P= 46 bar, t1 = 18.1 min, t2 = 
20.8 min]. 
1
H NMR (300 MHz, CDCl3)  7.17-7.12 (m, 3H), 6.99-6.98 
(m, 2H), 3.79 (s, 3H), 3.63-3.48 (m, 2H), 3.99 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -114.4 (m, 
1F), -128.1 (m, 1F), -143.9 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.1, 153.3 (dd, J = 250.5, 
7.5 Hz), 151.7 (dt, J = 255.0, 11.2 Hz), 149.9 (dd, J = 250.5, 15.0 Hz), 142.5 (dt, J = 255.0, 15.0 
Hz), 142.1 (dd, J = 255.0, 15.0 Hz), 138.7 (dd, J = 255.0, 22.5 Hz), 132.2, 129.1, 127.8, 127.2, 
118.8 (d, J = 15.0 Hz), 109.9 (t, J = 24.7Hz), 69.3, 53.2, 35.9, 29.2, 24.3; IR (nujol) 1752, 1631, 
1515, 1464, 1306, 1236, 1214, 1148, 1042, 953, 875, 679 cm
-1
. Anal. Calcd. for  C17H14F3NO4S: 
C, 52.99; H, 3.66; N, 3.63. Found: C, 53.09; H, 3.78; N, 3.71. 
 
 
 
(S)-Methyl 6-bromo-4,5, 7-trifluoro-2-methyl-3-methyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-25a. sultam 
R-25a  (24h, 64.1 mg, 83%). Wax; FCC - AcOEt/hexane (1 : 6); []D
20
 - 
5.2 (c 1.0 CHCl3) ee>35% [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 
8 : 2, Flow rate 0.8 mL/min, P= 32 bar, t1 = 15.2 min, t2 = 16.6 min]. 
1
H 
NMR (300 MHz, CDCl3) 3.76 (s, 3H), 2.87 (s, 3H), 1.82 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  
-108.6 (m, 1F), -118.4 (m, 1F), -138.8 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.4, 152.1, 
150.7, 150.5, 148.8, 142.7, 139.2, 109.8, 106.3, 65.4, 53.7, 24.4, 19.3; IR (nujol) 1762, 1311, 
1253, 1217, 1162, 1047, 943, 675 cm
-1
. Anal. Calcd. for C11H9BrF3NO4S: C, 34.04; H, 2.34;  N, 
3.61. Found: C, 34.11; H, 2.42;  N, 3.59. 
 
 
 
(S)-Methyl 4,5, 7-trifluoro-2-methyl-3-methyl-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-25b. sultam 
R-25b  (5 day, 46.7 mg, 75%). Wax; FCC - AcOEt/hexane (1 : 6); []D
20
 
+4.2 (c 1 CHCl3) ee>27% [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 
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: 3, Flow rate 0.8 mL/min, P= 46 bar, t1 = 15.6 min, t2 = 16.2 min]. 
1
H NMR (300 MHz, CDCl3) 
 7.26-7.19 (m, 1H), 3.75 (s, 3H), 2.88 (s, 3H), 1.81 (s, 3H); 19F NMR (282 MHz, CDCl3)  -
108.4 (m, 1F), -118.1 (m, 1F), -123.9 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.3, 153.5 (dd, J 
= 255.0, 7.5 Hz), 151.8 (dt, J = 256.5, 16.5 Hz), 150.2 (dd, J = 255.0, 7.5 Hz), 148.4 (dt, J = 
256.5, 15.0 Hz), 142.2 (d, J = 15.0 Hz), 138.8 (d, J = 15 Hz), 130.7 (d, J = 15 Hz), 128.5 (t, J = 
15 Hz), 121.2 (d, J = 22.5 Hz), 110.3 (t, J = 22.5 Hz), 64.8, 53.1, 23.9, 18.9; IR (nujol) 1748, 
1628, 1512, 1457, 1137, 1035, 947, 867, 682 cm
-1
. Anal. Calcd. for  C11H10F3NO4S: C, 42.72; H, 
3.26; N, 4.53. Found: C, 42.81; H, 3.32; N, 4.64. 
 
 
 
(S)-Methyl 6-bromo-4,5, 7-trifluoro-2-methyl-3-(2-methyl, propyl)-
2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-25c. 
sultam R-25c(5 day, 35.3 mg, 42%). Wax; FCC - AcOEt/hexane (1 : 6); 
[]D
20
+15.2 (c 1.0 CHCl3) ee>95% [CHIRALCEL OJ-H
®
, Hexane – 
Isopropanol 9 : 1, Flow rate 0.8 mL/min, P= 27 bar, t1 = 9.5 min, t2 = 
12.1 min]. 
1
H NMR (300 MHz, CDCl3) 3.74 (s, 3H), 2.86 (s, 3H), 2.31-
2.17 (m, 2H), 0.94 (d, J = 6.0 Hz, 3H), 0.65 (d, J = 9.0 Hz, 3H); 
19
F NMR (282 MHz, CDCl3)  -
109.0 (m, 1F), -120.1 (m, 1F), -140.6 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  167.2, 153.8, 151.7, 
150.3, 148.4, 145.8, 142.4, 138.8, 129.3, 126.7, 110.2 (t, J = 22.5, Hz),53.1, 37.7, 29.2, 23.2; IR 
(nujol) 1771, 1308, 1248, 1215, 1158, 1056, 936, 681 cm
-1
. Anal. Calcd. for C14H15BrF3NO4S: C, 
39.08; H, 3.51; N, 3.26. Found: C, 39.11; H, 3.59; N, 3.31. 
 
 
 
(S)-Methyl 6-bromo-4,5, 7-trifluoro-2-methyl-3-
(methyl(propyl)sulfane)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide R-25e. sultam R-25e(18h, 61.8 mg, 70%). 
Wax; FCC - AcOEt/hexane (1 : 4); []D
20
 + 15.2 (c 1.0 CHCl3) 
ee>57% [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow rate 
0.8 mL/min, P= 46 bar, t1 = 15.5 min, t2 = 19.1 min]. 
1
H NMR (300 
MHz, CDCl3) 3.78 (s, 3H), 2.87 (s, 3H), 2.75-2.65 (m, 1H), 2.59-2.48 (m, 1H), 2.39-2.31 (m, 
1H), 2.10-1.99 (m, 4H); 
19
F NMR (282 MHz, CDCl3)  -110.2 (m, 1F), -120.0 (m, 1F), -140.9 
140 
 
 
(m, 1F); 
13
C NMR (75 MHz, CDCl3)  166.9, 152.1, 150.7 (dd,J =255.0, 7.5 Hz), 148.7, 147.4 
(dd, J = 255.0, 7.5 Hz), 142.7 (dd, J = 262.5, 15.0 Hz), 139.2(dd, J = 262.5, 15.0 Hz), 128.2, 
118.2 (d, J = 22.5, Hz),  106.0 (t, J = 22.5, Hz), 68.6, 53.7, 30.4, 27.2, 24.3, 15.6; IR (nujol) 1764, 
1305, 1236, 1211, 1149, 1051, 929, 674 cm
-1
. Anal. Calcd. for C14H15BrF3NO4S: C, 39.08; H, 
3.51; N, 3.26. Found: C, 39.11; H, 3.64; N, 3.29. 
 
 
 
(S)-Methyl 4,5, 7-trifluoro-2-methyl-3-(methyl(propyl)sulfane)-2,3-
dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-25f. sultam 
R-25f  (24 h, 38.4 mg, 52%). Wax; FCC - AcOEt/hexane (1 : 2); 
ee>37% [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow rate 
0.8 mL/min, P= 46 bar, t1 = 18.1 min, t2 = 20.8 min]. 
1
H NMR (300 
MHz, CDCl3) 7.28-7.18 (m, 1H), 3.75 (s, 3H), 2.86 (s, 3H), 2.78-2.64 
(m, 1H), 2.56-2.50 (m, 1H), 2.38-2.28 (m, 1H), 2.15-1.99 (m, 4H); 
19
F NMR (282 MHz, CDCl3) 
 -115.2 (m, 1F), -127.4 (m, 1F), -143.2 (m, 1F); 13C NMR (75 MHz, CDCl3)  167.5, 154.2 (dd, 
J = 255.0, 7.5 Hz), 152.5 (dm, J = 265.2 Hz), 150.7 (dd, J = 255.0, 7.5 Hz), 142.9 (d, J = 15.0 
Hz), 139.4 (d, J = 15.0 Hz),  110.8 (t, J = 22.5, Hz), 69.5, 53.7, 30.6, 27.3, 24.3, 15.7; IR (nujol) 
1756, 1309, 1228, 1209, 1147, 1049, 917, 669 cm
-1
. Anal. Calcd. for C13H14F3NO4S2: C, 42.27; 
H, 3.82; N, 3.79. Found: C, 42.31; H, 3.93; N, 3.83. 
 
 
(S)-Methyl 6-bromo-4,5, 7-trifluoro-2-methyl-3-(1-
(methylsulfinyl)propane)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide 28e. sultam 28e  (28 h, 40.8 mg, 54%, mixture 
of diastereomers 1:1). Wax; FCC - AcOEt/MeOH(9 : 1); []D
20
 + 10.5 (c 
1.1 CHCl3) [CHIRALPAK AB
®
, Hexane – Isopropanol 9 : 1, Flow rate 
0.8 mL/min, P= 18 bar, t1 = 34.2 min, t2 = 39.7 min, t3 = 47.5 min]. 
1
H NMR (300 MHz, CDCl3) 
3.80 (s, 3H), 2.89-2.83 (m, 5H), 2.54-2.47 (m, 4H), 2.26-2.16 (m, 1H); 19F NMR (282 MHz, 
CDCl3)  -109.9 (m, 1F), -119.0 (m, 1F), -140.3 (m, 1F); 
13
C NMR (75 MHz, CDCl3)  166.5, 
152.2 (dd, J = 255.0, 7.5 Hz), 151.1(dd, J = 255.0, 15 Hz), 148.8, (dd, J = 255.0, 7.5 Hz), 147.7 
(dd, J = 255.0, 15 Hz), 142.8 (dd, J = 262.5, 15.0 Hz), 139.3 (dd, J = 262.5, 15.0 Hz), 123.9 (d, J 
= 15.0 Hz), 117.9 (d, J = 22.5 Hz), 106.5 (t, J = 22.5, Hz), 68.1, 54.0, 47.8, 47.0, 39.2, 38.5, 29.6, 
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24.6, 24.3, 23.6; IR (nujol) 1757, 1308, 1228, 1209, 1145, 1049, 926, 679 cm
-1
. Anal. Calcd. for 
C13H13BrF3NO5S2: C, 33.63; H, 2.82; N, 3.02. Found: C, 33.69; H, 2.88; N, 3.06. 
 
 
 
(S)-Methyl 4,5, 7-trifluoro-2-methyl-3-(1-(methylsulfinyl)propane)-
2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide 28f. sultam 
28f  (48 h, 63.4 mg, 82%, mixture of diastereomers 1:1). Wax; FCC - 
AcOEt/MeOH(9 : 1); []D
20
 + 10.5 (c 1.1 CHCl3) [CHIRALCELOJ-H
®
, 
Hexane – Isopropanol 7 : 3, Flow rate 0.8 mL/min, P= 48 bar, t1 = 21.3 
min, t2 = 25.9 min, t3 = 29.2 min]. 
1
H NMR (300 MHz, CDCl3) 7.29-
7.23 (m, 1H), 3.78 (s, 3H), 2.89-2.67 (m, 5H), 2.59-2.43 (m, 4H), 2.27-2.14 (m, 1H); 
19
F NMR 
(282 MHz, CDCl3)  -115.3 (m, 1F), -126.8 (m, 1F), -143.1 (m, 1F); 
13
C NMR (75 MHz, CDCl3) 
 166.8, 154.0 (dt, J = 255.0, 7.5 Hz), 152.7 (dt, J = 255.0, 7.5 Hz), 150.6, (dt, J = 255.0, 7.5 Hz), 
149.3 (dt, J = 255.0, 15 Hz), 142.9 (dd, J = 262.5, 15.0 Hz), 139.4 (dd, J = 262.5, 15.0 Hz), 125.5 
(d, J = 15.0 Hz), 118.1 (d, J = 22.5 Hz), 111.3 (t, J = 7.5, Hz), 68.3, 67.9, 53.8, 47.9, 47.2, 39.1, 
38.6, 24.4, 24.3, 24.1, 23.7; IR (nujol) 1762, 1306, 1231, 1205, 1144, 1051, 928, 680 cm
-1
. Anal. 
Calcd. for C13H14F3NO5S2: C, 40.52; H, 3.66; N, 3.63. Found: C, 40.59; H, 3.71; N, 3.69. 
 
 
 
(S)-Methyl 6-bromo-4,5, 7-trifluoro-2-methyl-3-(1-(methylsulfonyl) 
propane)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide 
28e. sultam 28e  (48 h, 37.7 mg, 59%). Wax; FCC - AcOEt/Hexane (1 : 
1); []D
20
 + 7.6 (c 1.0 CHCl3) [CHIRALPAK AB
®
, Hexane – 
Isopropanol 85 : 15, Flow rate 0.8 mL/min, P= 18 bar, t1 = 18.5 min, t2 = 
22.7 min]. 
1
H NMR (300 MHz, CDCl3) 3.81 (s, 3H), 2.92-2.98 (m, 
6H), 2.61-2.49 (m, 1H); 
19
F NMR (282 MHz, CDCl3)  -110.1 (m, 1F), -118.4 (m, 1F), -139.8 
(m, 1F); IR (nujol) 1757, 1308, 1217, 1209, 1145, 1049, 926, 679 cm
-1
. Anal. Calcd. for 
C13H13BrF3NO6S2: C, 32.51; H, 2.73; N, 2.92. Found: C, 32.57; H, 2.70; N, 2.98. 
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(S)-Methyl 6-bromo-4,5, 7-trifluoro-2-methyl-3-(4-
ethylphenyl 4-bromo-2,3,5,6-tetrafluorobenzenesulfonate)-
2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide R-
25i. sultam R-25i (7 h, 668.8 mg, 87%). Wax; FCC - 
AcOEt/Hexane(1 : 3); []D
20
 + 121.3 (c 1.0 CHCl3) 
[CHIRALCELOD-H
®
, Hexane – Isopropanol 8 : 2, Flow rate 0.8 
mL/min, P= 38 bar, t1 = 21.5 min, t2 = 25.1 min]. 
1
H NMR (300 
MHz, CDCl3) 7.03-6.96 (m, 4H),3.81 (s, 3H), 3.62-3.46 (m, 
2H), 2.92 (s, 3H); 
19
F NMR (282 MHz, CDCl3)  -109.5 (m, 1F), 
-119.0 (m, 1F), -129.4 (m, 2F), -134.4 (m, 2F), -140.6 (m, 1F); 
13
C NMR (75 MHz, CDCl3) 166.9, 151.6, 150.7 (dd, J = 255.0, 15 Hz), 148.3, 147.2 (dm, J = 
255.0 Hz), 145.9, (dd, J = 255.0, 22.5 Hz), 143.8 (dm, J = 255.0 Hz), 142.5 (dm, J = 255.0 Hz), 
139.1 (d, J = 15.0 Hz), 133.0, 131.4, 121.5, 118.4 (d, J = 22.5 Hz), 108.3 (t, J = 22.5 Hz), 105.8 
(t, J = 22.5, Hz), 69.8, 54.0, 35.9, 29.6, 24.9; IR (nujol) 1761, 1309, 1226, 1204, 1139, 1053, 928, 
680 cm
-1
. Anal. Calcd. for C23H12Br2F7NO7S2: C, 35.82; H, 1.57; N, 1.82. Found: C, 35.87; H, 
1.61; N, 1.85. 
 
 
(S)-Methyl 4,5, 7-trifluoro-2-methyl-3-(4-ethylphenyl -2,3,5,6-
tetrafluorobenzenesulfonate)-2,3-dihydrobenzo[d]isothiazole-
3-carboxylate 1,1-dioxide R-25j. sultam R-25j (50 h, 460.0 mg, 
75%). Wax; FCC - AcOEt/Hexane(1 : 3); []D
20
 + 19.2 (c 1.0 
CHCl3) [CHIRALCEL OJ-H
®
, Hexane – Isopropanol 7 : 3, Flow 
rate 0.8 mL/min, P= 48 bar, t1 = 23.9 min]. 
1
H NMR (300 MHz, 
CDCl3)  7.40-7.34 (m, 1H), 7.16-7.12 (m, 1H), 7.08-6.95 (m, 
4H), 3.79 (s, 3H), 3.62-3.43 (m, 2H), 2.93 (s, 3H); 
19
F NMR (282 
MHz, CDCl3)  -114.6 (m, 1F), -126.9 (m, 1F), -134.8 (m, 4F), -
134.4 (m, 1F); 
13
C NMR (75 MHz, CDCl3) 167.1, 153.5 (dd, J = 
255.0, 7.5 Hz), 152.3 (dm, J = 247.5 Hz), 150.1 (dd, J = 255.0, 7.5 Hz), 148.3, 147.8 (dm, J = 
247.5 Hz), 145.9 (dm, J = 247.5 Hz), 144.5 (dm, J = 247.5 Hz), 142.5 (dm, J = 262.5 Hz), 239.1 
(d, J = 15.0 Hz), 133.0, 131.4, 130.8, 121.3, 115.2, 112.2 (t, J = 22.5 Hz), 110.5 (t, J = 22.5, Hz), 
69.6, 53.7, 35.7, 35.7, 29.6, 24.7; IR (nujol) 1767, 1305, 1218, 1207, 1141, 1057, 926, 683 cm
-1
. 
Anal. Calcd. for  C23H14F7NO7S2: C, 45.03; H, 2.30; N, 2.28. Found: C, 45.09; H, 2.37; N, 2.31. 
